  
 
 
Protocol  
 
Study ID:  209668 
 Official Title of Study : Phase IIb Multi-Center, Randomised, Partial- Blind Parallel 
Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in 
Participants with Chronic Hepatitis B Virus (B -Clear) 
 
IND Identifier:
 122685 
 
EudraCT : 2020‐001083‐29 
 
 
Approval Date of Document : 23-SEP-2021  
 
 
TMF-13956480  CONFIDENTIAL   
GlaxoSmithKline group of companies   209668  
  Protocol Amd 02  
 1 
 TITLE PAGE  
Protocol Title: Phase IIb Multi -Center, Randomised, Partial -Blind Parallel Cohort Study 
to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants  with 
Chronic Hepatitis B Virus  (B-Clear)  
Protocol Number : 209668  / Amendment 02 
Compound Number 
or Name:  GSK3228836  
Study Phase:  PHASE 2B  
Short Title : Phase 2b Study of GSK3228836  in Participants with Chronic Hepatitis B 
(B-Clear)  
Sponsor Name and Legal Registered Address:  
GlaxoSmithKline Research & Development Limited  
980 Great West Road  
Brentford  
Middlesex, TW8 9GS  
UK 
Regulatory Agency Identifying Number(s):  
IND: IND 122685  
EudraCT number: 2020‐001083‐29  
Approval Date: 23-Sep-2021  
 
 
 
 
 
Copyright  2021 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copying or use of this information is prohibited.  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 2 
 SPONSOR SIGNATORY  
Protocol Title: Phase IIb Multi -Center, Randomised, Partial -Blind Parallel Cohort Study 
to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with 
Chronic Hepatitis B Virus (B-Clear)  
Protocol Number : 209668 / Amendment 02 
Compound Number or Name:  GSK3228836  
 
 
 
 
Dickens Theodore, MD , MPH  
Senior Director, Clinical Development  
Immunology and Fibrosis  
GlaxoSmithKline   Date  
The signed page is a separate document.  
 
 
 
 
Medical Monitor Name and Contact Information  can be found in the Study Reference 
Manual.  
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 3 
 PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
DOCUMENT HISTORY  
Document  Date  Document Number  
Amendment 02  23-SEP-2021  TMF-1395648 0 
Amendment 01  10-MAY -2021  TMF-11803132  
Original Protocol  09-APR-2020  2019N420582_00  
Amendment 02: 23-Sep-2021  
This amendment is considered to be substantial  based on the criteria set forth in Article 
10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union.  
Overall Rationale for the Amendment:   
The primary driver for this amendment was a request from a regulatory agency to include 
nucleos(t)ide analogue (NA) therapy initiation until hepatitis B flare could be ruled out 
(specifically for the patients who are not receiving NA therapy at baseline).  
Text has also been included to allow additional interim analyses prior to the end of study 
(after all participants  have completed treatment) to support asset development planning 
and decision making.  
In addition, minor typographical errors and inconsistencies have been corrected and 
minor editorial changes have been made. Changes made to the text body have been made 
concurrently in the synopsis.  
Section # and 
Name  Description of Change  Brief Rationale  
Section 6.5.1  
NA Treatment 
during and 
after the End of 
the Study ; 
Section 7.1.1  
Liver 
Chemistry 
Monitoring and 
Stopping 
Criteria  
Table 6  Added text:  
For participants who are not receiving NA therapy at 
baseline, initiate NA therapy if ALT ≥3x ULN and 
bilirubin >1.5x ULN, as per Section  7.1.1 (Liver 
Chemistry Monitoring and Stopping Criteria). NA therapy 
may be subsequently discontinued if other tests (e.g., 
HBV DNA, HB sAg) rule out hepatitis B flare.  As per regulatory request in 
consideration of participant safety.  
Section 9.5 
Interim 
Analyses  Added text:  
Additional interim analyses may be conducted after the 
third interim (at which time all participants will have 
completed treatment and sponsor staff [as specified in 
the blinding plan] will be unblinded), to support 
development planning and decision making. If 
conducted, these analyses will be unblinded to the 
sponsor staff (as specified in the blinding plan) and 
referenced in the clinical study report.  To allow further review of the data 
prior to end of study (after all 
participants  have completed 
treatment ). 
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 4 
 TABLE OF CONTENTS  
PAGE  
1. PROTOCOL SUMMARY  ................................ ................................ ..........................  8 
1.1. Synopsis  ................................ ................................ ................................ ....... 8 
1.2. Schema  ................................ ................................ ................................ ...... 13 
1.3. Schedule of Activities (SoA)  ................................ ................................ ........  14 
2. INTRODUCTION  ................................ ................................ ................................ .... 21 
2.1. Study Rationa le ................................ ................................ ..........................  21 
2.2. Background  ................................ ................................ ................................  21 
2.3. Benefit/Risk Assessment  ................................ ................................ ............  23 
2.3.1. Risk Assessment  ................................ ................................ .........  23 
2.3.1.1.  Regarding Coronavirus Disease 2019 (COVID -
19) ................................ ................................ ..............  26 
2.3.2.  Benefit Assessment  ................................ ................................ ..... 26 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ..................  26 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ...........  27 
4. STUDY DESIGN  ................................ ................................ ................................ .... 31 
4.1. Overall Design  ................................ ................................ ............................  31 
4.2. Scientifi c Rationale for Study Design  ................................ ..........................  31 
4.2.1.  Rationale for Study Blinding  ................................ .........................  32 
4.2.2.  Rationale for Placebo -First Arm  ................................ ...................  33 
4.2.3.  Participant Input into Design  ................................ ........................  33 
4.3. Justification for Dose  ................................ ................................ ..................  34 
4.4. End of Study Definition  ................................ ................................ ...............  36 
5. STUDY POPULATION  ................................ ................................ ...........................  36 
5.1. Inclusion  Criteria  ................................ ................................ .........................  36 
5.2. Exclusion Criteria  ................................ ................................ ........................  39 
5.3. Lifestyle Considerations  ................................ ................................ ..............  41 
5.3.1. Alcohol and Tobacco  ................................ ................................ ... 41 
5.3.2.  Activity  ................................ ................................ .........................  41 
5.4. Screen Failures ................................ ................................ ...........................  41 
5.5. Additional Participant Enrollment  ................................ ................................  42 
6. STUDY INTERVENTION  ................................ ................................ ........................  42 
6.1. Study Intervention(s) Administered  ................................ .............................  42 
6.2. Preparation/Handling/Storage/Accountability  ................................ ..............  43 
6.3. Measures to Minimize Bias: Randomization and Blinding  ...........................  43 
6.4. Study Intervention Compliance  ................................ ................................ ... 44 
6.5. Concomitant Therapy ................................ ................................ ..................  44 
6.5.1.  Nucleos(t)ide Treatment during and after the End of the 
Study  ................................ ................................ ...........................  45 
6.5.2.  Initiation of Nucleos(t)Ides During GSK3228836 Treatment  .........  45 
6.5.3.  Initiation of Nucleos(t )ide Therapy Post GSK3228836 
Treatment  ................................ ................................ ....................  46 
6.5.4.  Prohibited Medications and Non -Drug Therapies  .........................  46 
6.6. Dose Modification  ................................ ................................ .......................  46 
6.7. Intervention after the End of the Study  ................................ ........................  46 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 5 
 7. DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..... 47 
7.1. Discontinuation of Study Intervention  ................................ ..........................  47 
7.1.1.  Liver Chemistry Monitoring and Stopping Criteria  ........................  47 
7.1.2.  Drug Induced Vascular Injur y and Complement Stopping 
Criteria  ................................ ................................ .........................  50 
7.1.3.  Haematological Stopping Criteria  ................................ .................  52 
7.1.4.  Drug Induced Kidney Injury (Renal) Stopping Criteria  ..................  52 
7.1.5.  Study Intervention Restart or Rechallenge after stopping 
criteria met  ................................ ................................ ...................  53 
7.2. Participant Discontin uation/Withdrawal from the Study  ...............................  54 
7.3. Lost to Follow Up  ................................ ................................ ........................  55 
8. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  55 
8.1. Efficacy Assessments  ................................ ................................ .................  56 
8.2. Safety Assessments  ................................ ................................ ...................  57 
8.2.1.  Physical Examinations  ................................ ................................ . 57 
8.2.2. Injection Site Reactions  ................................ ...............................  57 
8.2.3.  Vital Signs  ................................ ................................ ....................  57 
8.2.4.  Electrocardiograms  ................................ ................................ ...... 58 
8.2.5.  Clinical Safety Laboratory Assessments  ................................ ...... 58 
8.3. Adverse Events and Serious Adverse Events  ................................ .............  58 
8.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ...................  59 
8.3.2.  Method of Detecting AEs and SAEs  ................................ .............  59 
8.3.3.  Follow -up of AEs and SAEs  ................................ .........................  59 
8.3.4.  Regulatory Reporting Requirements for SAEs  .............................  59 
8.3.5.  Pregnancy  ................................ ................................ ...................  60 
8.3.6.  Cardiovascular and Death Events  ................................ ................  60 
8.3.7.  Adverse Events of Special Interest  ................................ ..............  61 
8.3.7.1.  ALT Increases  ................................ ............................  61 
8.3.7.2.  Vascular Inflammation and Complement 
Activation  ................................ ................................ .... 61 
8.3.7.3.  Thrombocytopenia  ................................ ......................  61 
8.3.7.4.  Renal Injury  ................................ ................................  61 
8.3.7.5.  Injection Site Reactions  ................................ ..............  62 
8.4. Treatment of Overdose  ................................ ................................ ...............  62 
8.5. Pharmacokinetics  ................................ ................................ .......................  62 
8.6. Pharmacodynamics  ................................ ................................ ....................  63 
8.7. Genetic s ................................ ................................ ................................ ..... 64 
8.8. Biomarkers  ................................ ................................ ................................ . 64 
8.9. HBV Resistance Monitoring  ................................ ................................ ........  65 
8.9.1.  Resistance Analysis based upon HBV DNA Criteria  ....................  65 
8.9.2.  Resistance Analysis based upon HBsAg Criteria  .........................  65 
8.10.  Patient Reported Outcomes (PROs)  ................................ ...........................  66 
8.10.1.  Hepatitis B Quality of Life (HBQOL)  ................................ .............  66 
8.10.2.  EQ-5D-3L ................................ ................................ ....................  66 
8.11.  Survey Questionnaires  ................................ ................................ ................  66 
9. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  67 
9.1. Statistical Hypotheses ................................ ................................ .................  67 
9.2. Sample Size Determination  ................................ ................................ ........  67 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 6 
 9.3. Populations for Analyses  ................................ ................................ ............  69 
9.4. Statistical Analyses  ................................ ................................ .....................  69 
9.4.1.  General Considerations  ................................ ...............................  69 
9.4.2. Primary Endpoint(s)  ................................ ................................ ..... 69 
9.4.2.1.  Primary Estimands  ................................ .....................  70 
9.4.2.2.  Supplementary Estimands  ................................ ..........  71 
9.4.2.3.  Handling of Withdrawal from Study and 
Missing HBsAg and HBV DNA Data  ...........................  71 
9.4.3.  Primary Analyses  ................................ ................................ .........  71 
9.4.4.  Secondary Endpoint(s)  ................................ ................................  73 
9.4.4.1.  Estimands for Secondary Objectives:  .........................  73 
9.4.4.2.  Secondary Efficacy Analyses  ................................ ..... 74 
9.4.4.3.  Historical placebo:  ................................ ......................  75 
9.4.5.  Safety Endpoints  ................................ ................................ ..........  75 
9.4.6.  Exploratory Objectives  ................................ ................................ . 76 
9.4.6.1.  Estimand for Exploratory Objectives  ...........................  76 
9.4.6.2.  Participant Population Analyses  ................................ . 76 
9.4.6.3.  PK and PK -PD Analyses  ................................ ............  77 
9.5. Interim Analyses  ................................ ................................ .........................  77 
9.6. Independent Data Monitoring Committee (IDMC)  ................................ ....... 78 
9.7. Internal Safety Review Team (SRT)  ................................ ............................  78 
10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ...............................  79 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ............................  79 
10.1.1.  Regulatory and Ethical Considerations  ................................ ........  79 
10.1.2.  Financial Disclosure  ................................ ................................ ..... 79 
10.1.3.  Informed Consent Process  ................................ ..........................  80 
10.1.4.  Data Protection  ................................ ................................ ............  80 
10.1.5.  Committees Structure  ................................ ................................ .. 81 
10.1.6.  Dissemination of Clinical Study Data  ................................ ...........  81 
10.1.7.  Data Quality Assurance  ................................ ...............................  82 
10.1.8.  Source Documents  ................................ ................................ ...... 83 
10.1.9.  Study and Site Start and Closure  ................................ .................  83 
10.1.10.  Publication Policy  ................................ ................................ .........  84 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ .........................  85 
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ....... 89 
10.3.1.  Definition of AE  ................................ ................................ ............  89 
10.3.2.  Definition of SA E ................................ ................................ ..........  90 
10.3.3.  Definition of Cardiovascular Events  ................................ .............  91 
10.3.4.  Recording and Follow -Up of AE and SAE  ................................ .... 91 
10.3.5.  Division of AIDS (DAIDS) Table for Grading Severity of 
Adult and Pediatric Adverse Events  ................................ .............  92 
10.3.6.  Reporting of  SAE to GSK  ................................ .............................  93 
10.4.  Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  ................................ ................................ ................................ .. 95 
10.4.1.  Definitions:  ................................ ................................ ...................  95 
10.4.2.  Contracept ion Guidance:  ................................ .............................  96 
10.4.3.  Collection of Pregnancy Information:  ................................ ...........  97 
10.5.  Appendix 5: Genetics  ................................ ................................ ..................  98 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 7 
 10.6.  Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Restart/Rechallenge 
Guidelines  ................................ ................................ ................................ ... 99 
10.7.  Appendix 7: Country -specific requirements  ................................ ...............  102 
10.7.1.  China  ................................ ................................ .........................  102 
10.7.1.1.  China Schedule of Activities  ................................ ..... 102 
10.7.1.2.  China Biomarkers and Archived Samples  .................  109 
10.8.  Appendix 8: Abbreviations and Trademarks  ................................ ..............  110 
10.9.  Appendix 9: Protocol Amendment History  ................................ .................  112 
11. REFERENCES  ................................ ................................ ................................ ..... 116 
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 8 
 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  Phase IIb Multi -Center, Randomised, Partial -Blind , Parallel Cohort Study 
to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants  with 
Chronic Hepatitis B Virus  (B-Clear)  
Short Title:  Phase IIb study of GSK3228836 in Participants with  Chronic Hepatitis B  
(B-Clear)  
Rationale:  
Study 209668 is intended to evaluate if treatment with GSK3228836 can achieve 
sustained virologic response (SVR, HBsAg < lower limit of quantitation  [LLOQ] and 
HBV DNA <LLOQ sustained for 24 weeks post -GSK3228836 tr eatment end) with a 
finite course of GSK3228836.  In addition, the study will evaluate the safety, tolerability, 
pharmacokinetic and pharmacodynamic properties of GSK3228836 in the four dosing 
regimens.  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 9 
 Key Objectives and Estimand/ Endpoints:  
Objectives  Estimand/Endpoints  
Primary  
Efficacy:  To assess the efficacy 
of the three dosing regimens of 
GSK3228836 in participants with 
CHB  Primary estimands supporting the primary objective are defined as:  
- Population : separate assessment for the following:  
• participants with CHB on stable nucleos(t)ide therapy  
• participants with CHB not currently on nucleos(t)ide therapy  
- Variable : Participants achieving s ustained virologic response (SVR, 
described in Section 9.4.2 ) for 24 weeks after the planned end of 
GSK3228836 treatment in the absence of rescue medication.  
- Treatments : arms 1, 2, and 3. Estimation of the within -arm response 
rate. 
- Intercurrent events : use of rescue medication, and discontinuation 
of/interruption of/adherence to IP. The use of rescue medication has 
been incorporated into the definition of variable (composite strategy). 
Discontinuation of, interruption of, and adherence to IP will be ignored 
(treatment  policy) . Wide disruptive events (such as COV ID-19 
pandemic) leading to discontinuation of, interruption in, and non -
adherance to GSK3228836 will be handled assuming they had not 
happened (hypothetical strategy) . 
- Population summary : proportion of partici pants who achieve SVR for 
each treatment arm.  
 
The primary estimands for each sub -population is  the proportion of 
participants in each treatment arm 1, 2, and 3 who achieve SVR for 24 
weeks after the planned end of GSK3228836 treatment in the absence 
of rescue medication regardless of completing IP, interruptions in IP or 
adherence to IP  had they not been affected by wide disruptive events.  
A supplementary estimand is defined to support the primary objective:  
- the supplementary estimand is defined in the same way as the main 
estimand, except the assessment time frame for participants achieving 
SVR will be 24 weeks after the actual end of treatment. Therefore, the 
strategy for intercurrent events of treatment discontinuation will be 
while -on-treatment. This  supplementary estimand supporting the 
primary objective in participants with CHB on stable nucloes(t)ide 
therapy and participants with CHB not currently on nucleos(t)ide therapy 
is the proportion of participants in each treatment arm 1, 2, and 3 who 
achie ve SVR for 24 weeks after the actual end of GSK3228836 
treatment in the absence of rescue medication, regardless of 
completing IP, interruptions in IP or adherence to IP, had they not been 
affected by wide disruptive events.  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 10 
 Objectives  Estimand/Endpoints  
Secondary  
Efficacy:  To assess the efficacy 
of GSK3228836 on biomarkers 
and virus -specific antibody 
responses  The estimands supporting this secondary objective are defined as 
follows:  
 
- Population : separate assessment for the following:  
• participants with CHB on stable nucl eos(t)ide therapy  
• participants with CHB not currently on nucleos(t)ide therapy.  
- Treatments : arms 1 -4. Estimation within each arm.  
- Intercurrent events : use of rescue medication, and discontinuation 
of/interruption of/adherence to IP. The use of rescue  medication will be 
ignored (treatment policy strategy). Discontinuation of, interruption of, 
and adherence to IP will be ignored (treatment policy)  
 
1) Categorical Variables : 
-  Achieving HBsAg <LLOQ and HBV DNA <LLOQ at the end of 
treatment.  
- Categorical changes from baseline in HBsAg (e.g. <0.5, ≥0.5, ≥1, 
≥1.5, ≥3 log 10 IU/mL) and in HBV DNA (e.g. , <1, ≥1, ≥2, ≥3 log 
IU/mL)  
- ALT normalization (ALT≤ULN) over time in absence of rescue 
medication  in participants with baseline ALT>ULN  
- HBe antibody (anti -HBeAg)  levels  
- Population summary:  proportion of participants in each category for 
each treatment arm.  
2)  Continuous Variables : Actual values and change from baseline 
over time of HBsAg and HBV DNA and actual values and change from 
baseline  of HBeAg levels; HBs antibody (anti -HBsAg) levels  
- Population summary : mean values and mean changes from 
baseline for each variable in each treatment arm  
3) Time to Event Variable : Time to ALT normalization in absence of 
rescue medication in participants with baseline ALT>ULN  
- Population summary : Turnbull’s estimate for non-paramet ric 
estimation of t ime to ALT normalization in each treatment arm  
The group of estimands supporting this objective for each sub -
population is the population summary for each variable in each 
treatment arm 1 -4 regardless of completing IP, interruptions in IP or 
adherence to IP and regardless of rescue medication (except for ALT 
normalization which can only be achieved in the absence of rescue 
medication)  
Efficacy: To compare the 
efficacy between 12 weeks, 12 
weeks + 12 weeks step -down, 
and 24 weeks of GSK3228836 
treatment  The same definition as the primary estimand except treatments and 
population summary are defined as:  
-Treatments : arms 1, 2, and 3. Three treatment comparisons between: 
arms 1 & 2, arms 1 & 3, and arms 2 & 3  
- Population summary : difference in proportion of participants who 
achieve SVR between treatment arms  
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 11 
 Objectives  Estimand/Endpoints  
The group of estimands supporting this objective for each sub -
population are the difference in each treatment compa risons in the 
proportion of participants who achieve SVR for 24 weeks after the 
planned end of GSK3228836 treatment in the absence of rescue 
medication regardless of completing IP,  interruptions in IP or adherence 
to IP had they not been affected by wide disruptive events . 
Pharmacokinetics (PK):  To 
characterize GSK3228836 and 
nucleos(t)ide  PK in participants 
with CHB  • In a subset of participants with intensive PK sampling: Derived 
GSK3228836 and nucleos(t)ide plasma PK parameters including , 
but not limited  to, area under the concentration -time curve (AUC), 
concentration at the end of the dosing interval  (C), maximum 
observed concentration (C max), time of maximum observed 
concentration (t max). 
• In all participants: C  and terminal half -life (t ½) of GSK3228836.  
Overall Design:  
The study is a Phase  2b, multi -center, randomized, partial -blind , parallel cohort study to 
assess the efficacy and safety of treatment with GSK3228836 in two populations of 
patients with CHB (1) participants on stable nucleos(t)ide treatment and (2) participants 
not currently on nucleos(t)ide therapy.  
For each  population  (participants on stable nucleos[t]ide therapy and participants not 
currently on nucleos(t)ide therapy), participants will be randomized into one of 4 parallel 
arms:  
• 300 mg GSK3228836 once/week for 24 weeks  (plus loading doses on Day 4 and 
Day 11); 
• 300 mg GSK3228836 once/week for 12 weeks (plus loading doses on Day 4 and 
Day 11) followed by step-down in dose of 150 mg GSK3228836 once/week (plus 
placebo to match to maintain participant blinding) for 12 weeks;  
• 300 mg GSK3228836 once/week for 12 weeks (plus loading doses on Day 4 and 
Day 11) followed by placebo  once/week  for 12 weeks;  
• Placebo once/week for 12 weeks followed by 300 mg  GSK3228836  once/week  for 
12 weeks  (plus placebo loading doses to match on Day 4 and Day 11,  no loading dose 
for GSK3228836 treatment ) 
 
Disclosure Statement :  
This is a parallel group treatment study with 8 arms that is sponsor and participant 
blinded . 
Num ber of Participants : 
The study will plan to enrol approximately 440 participants.   
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 12 
 In the case of a disruptive event impacting study treatment dosing, participation, and/or 
withdrawal, the study team may enroll additional participants to within 10% of the 
planned 440 . 
Note : "Enrolled" means a participant's , or their legally acceptable representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process  and after study personnel have confirmed that all eligibility criteria have been 
met.  Potential participants who are screened for the purpose of determining eligibility for 
the study, but do not participate in the study, are not considered enrolled, unle ss 
otherwise specified by the protocol.  
Intervention Groups and Duration:  
The total duration of the study, including screening, treatment, and post -treatment follow -
up, is not expected to exceed 55  weeks for each participant .  
• 45-day screening window. Eligible participant s who fall out of the 45 -day window 
may be re -screened at the discretion of the Investigator/site  
• 24 weeks treatment with either GSK3228836 and/or placebo  
• 24 weeks post treatment follow -up 
There are no plans for  group dose adjustments.  Individual dose adjustments for safety 
are outlined in the monitoring/stopping criteria.  
Data Monitoring or Oth er Committee:  Yes 
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 13 
 1.2. Schema  

TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 14 
 1.3. Schedule of Activities (SoA)  
[China specific Schedule of Activities can be found in Appendix 7]. 
Table 1 Screening  
ASSESSMENTS   
Informed Consent  X 
Inclusion and exclusion criteria  X 
Demography  X 
Medical history (includes substance usage) and current medical conditions  X 
Medication history and concomitant medication review  X 
Full physical exam including height and weight  X 
Vital signs  X 
12-lead ECG  X 
LABORATORY  
Serum hCG pregnancy test (women of child -bearing potential)  X 
FSH/Estradiol ( to confirm status of women of non -child-bearing potential)1 X 
Hematology/Chemistry/Urinalysis  X 
Urine ACR  X 
PT, INR, aPTT  X 
HIV, hepatitis D, and hepatitis C screen  X 
Hepatitis B profile (HBsAg, HBV  DNA, HBeAg)  X 
Alpha -fetoprotein  X 
APRI/Fibrosure X 
ANCA2 X 
Total bile acid profile  (as available)  X 
Complement C3 , C4, C5a, hsCRP, MCP -1, complement Bb, Ang -2 X 
1. As appropriate to confirm menopause  
2. With MPO -ANCA, PR3 -ANCA if results are positive or border -line positive  
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 15 
 Table 2 On Treatment Day 1 to Day 50  
ASSESSMENTS1 Day 1  D4 D8 D11 D15 D22 D29 D36 D43 D50 
Window   1 day  3 days  
 Week 1 W1 W2 W2 W3 W4 W5 W6 W7 W8 
Randomization  X          
Study treatment dosing  X X X X X X X X X X 
Safety Assessments   
AE/SAE review  X X X X X X X X X X 
Concomitant medication review  X X X X X X X X X X 
Symptom directed  exam  X      X    
Vital signs X X X X X X X X X X 
Injection site reactions X X X X X X X X X X 
Questionnaire (cell phone app, optional)  X          
Questionnaire (patient feedback on dosing regimen)  X          
Patient Reported Outcomes Questionnaires: HBQOL, 
EQ-5D X          
Laboratory   
Pregnancy test (women of child bearing potential)2 X2      X    
Hematology3 [includes platelet  count   and WBC] X  X  X X X X X X 
PT, INR, aPTT  X      X    
Chemistry  X  X  X X X X X X 
Urinalysis  X  X  X X X X X X 
Urine ACR X    X  X  X  
HBsAg and HBV DNA  X  X  X X X X X X 
Anti- HBsA g X      X    
Anti-HBeAg  X      X    
HBeAg  (only for participants HBeAg positive at 
screening)  X  X  X X X X X X 
HBV RNA , HBcrAg , and Sequencing (HBV 
Genotype /phenotype ; HBV DNA and/or RNA)  X     X    X 
Complement C3, Complement C4, hs -CRP, MCP -1 X    X  X  X  
Complement C5a, Complement factor Bb  X    X  X  X  
ANCA, Ang II  X      X    
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 16 
 ASSESSMENTS1 Day 1  D4 D8 D11 D15 D22 D29 D36 D43 D50 
Window   1 day  3 days  
 Week 1 W1 W2 W2 W3 W4 W5 W6 W7 W8 
PK X  X  X X X X X X 
PBMC Collection for immunophenotyping4 X          
Soluble Protein (immunology)  X     X    X 
PAXGene RNA for expression analysis in whole blood  X    X      
OPTIONAL: Genetics  X          
Archived Samples [serum; plasma]  X    X  X  X  
1. In selected countries /sites , participant s will have the option to use a centralised home nursing provider. Only selected visits will have the option to be performed as a home 
visit, these will include drug administration, blood draws, participant  assessments and data collection. The full specifi cations of the home nursing services will be outlined in 
the SRM  
2. A WOCBP must have both:  
a. A confirmed menstrual period prior to the first dose of study intervention ; additional evaluation (e.g., amenorrhea in athletes, birth control) should also be 
consider ed 
b. AND a negative highly sensitive pregnancy test [urine or serum] within  24 hours before the first dose of study treatment   
3. Hematology - platelet count to be analyzed at local laboratory  prior to dose ; hematology samples to be collected for central laboratory assessments in parallel  
4. Only for selected sites able to transport to the analysis lab as specified in the SRM . 
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 17 
 Table 3 On-Treatment: Day 57 to Day 162  
Assessments1 D57 D64 D71 D78 D85 D92 D99 D106  D113  D120  D127  D134  D141  D148  D155  D162  
Window   3 days  
 W9 W10 W11 W12 W13 W14 W15 W16 W17 W18 W19 W20 W21 W22 W23 W24 
Study treatment dosing  X X X X X X X X X X X X X X X X 
Safety Assessments   
AE/SAE review  X X X X X X X X X X X X X X X X 
Concomitant medication review  X X X X X X X X X X X X X X X X 
Symptom directed  exam  X    X    X    X    
Vital signs  X X X X X X X X X X X X X X X X 
Injection site reactions  X X X X X X X X X X X X X X X X 
Questionnaire (cell phone app, 
optional)                 X 
Questionnaire (patient feedback 
on dosing regimen)                 X 
Laboratory   
Pregnancy test (women of child 
bearing potential)  X    X    X    X    
Hematology2 [includes platelet  
count  and WBC]  X X X X X X X X X X X X X X X X 
PT, INR, aPTT  X    X    X    X    
Chemistry  X X X X X X X X X X X X X X X X 
Urinalysis  X X X X X X X X X X X X X X X X 
Urine ACR  X  X  X  X  X  X  X  X  
HBsAg and HBV DNA  X X X X X X X X X X X X X X X X 
Anti- HBsA g  X    X    X    X    
Anti- HBeAg   X    X    X    X    
HBeAg  (only for participants 
HBeAg positive at screening)  X X X X X X X X X X X X X X X X 
HBV RNA , HBcrAg , and 
Sequencing (HBV 
Genotype /phenotype ; HBV DNA 
and/or RNA)     X    X    X    X 
Complement C3, Complement 
C4, hs -CRP, MCP -1 X  X  X  X  X  X  X  X  
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 18 
 Assessments1 D57 D64 D71 D78 D85 D92 D99 D106  D113  D120  D127  D134  D141  D148  D155  D162  
Window   3 days  
 W9 W10 W11 W12 W13 W14 W15 W16 W17 W18 W19 W20 W21 W22 W23 W24 
Complement C5a, Complement 
factor Bb  X  X  X  X  X  X  X  X  
ANCA, Ang II  X    X    X    X    
PK3 X X X X X X X X X X X X X X X X 
PBMC Collection for 
immunophenotyping4    X            X 
Soluble protein (immunology)     X    X    X    X 
PAXGene RNA for  expression 
analysis in whole blood      X            
Archived Samples [serum; 
plasma]  X  X  X  X  X  X  X  X  
1. In selected countries /sites , participant s will have the option to use a centralised home nursing provider. Only selected visits will have the option to be performed as a home 
visit, these will include drug administration, blood draws, participant  assessments and data collection. The full specifi cations of the home nursing services will be outlined in 
the SRM  
2. Hematology - platelet count to be analyzed at local laboratory  prior to dose ; hematology samples to be collected for central laboratory assessments in parallel  
3. In addition to the pre -dose PK s ample, in tensive PK may be collected  for China , Japan , and  country(ies) with participants of non -Asian heritage (TBD)  see Table 8 for details 
of intensive PK sample collection  
a.  Intensive PK (GSK3228836  and nucleos[t]ide ) will be collected at 1 visit between Week 14 (inclusive) and Week 24 (inclusive), selected between th e site and participant : 
post dose  at 0.5 hr, 1 hr, 1.5 hr,  2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 12 hr, 24 hr, 72 hr, and 168 hr [the site should make all attempts to align the 168 hr post -dose PK with the 
next scheduled visit’s pre -dose PK, see Table 8 for more details] ]  
4. Only for selected sites able to transport to the analysis lab as specified in the SRM.  
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 19 
 Table 4 Off-Treatment Follow -Up  
Assessments1  OT-Day 1  OT-Day 8  OT-Day 22  OT-Day 50  OT-Day 78  OT-Day 106  OT-Day 134  OT-Day 162  Early 
Termination  
Window   3 Days  10 Days   
  OT- W1 OT-W2 OT-W4 OT-W8 OT-W12 OT-W16 OT-W20 OT-W24  
Questionnaire    
Patient Reported  Outcomes 
Questionnaire: HBQOL, EQ -5D        X X 
Safety Assessments   
AE/SAE review  X X X X X X X X X 
Concomitant medication review  X X X X X X X X X 
Symptom directed  exam  X X  X X X X X X 
Vital signs X X X X X X X X X 
Laboratory   
Pregnancy test (women of child bearing 
potential)  X  X X X X X X X 
Hematology2 [includes platelet  count  
and WBC] X X X X X X X X X 
PT, INR, aPTT  X  X  X X X X X 
Chemistry  X X X X X X X X X 
Urinalysis  X X X X X X X X X 
Urine ACR X X X X X X X X X 
HBsAg and HBV DNA  X X X X X X X X X 
Anti- HBsA g X X X X X X X X X 
Anti- HBeAg X X X X X X X X X 
HBeAg (only for participants HBeAg 
positive at screening)  X X X X X X X X X 
HBV RNA , HBcrAg , and Sequencing 
(HBV Genotype /phenotype ; HBV DNA 
and/or RNA)  X  X  X  X X X 
Complement C3, Complement C4, hs -
CRP, MCP -1  X X X X X X X X 
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 20 
 Assessments1  OT-Day 1  OT-Day 8  OT-Day 22  OT-Day 50  OT-Day 78  OT-Day 106  OT-Day 134  OT-Day 162  Early 
Termination  
Window   3 Days  10 Days   
  OT- W1 OT-W2 OT-W4 OT-W8 OT-W12 OT-W16 OT-W20 OT-W24  
Complement C5a, Complement factor 
Bb  X X X X X X X X 
ANCA, Ang II  X  X X X X X X X 
PK X X X X X X X X X 
PBMC Collection for 
immunophenotyping3 X    X   X X 
Soluble  Protein (immunology)  X  X  X  X X X 
PAXGene RNA for expression analysis 
in whole blood  X    X   X X 
APRI/Fibrosure         X X 
Archived Samples [serum; plasma]  X X X X X X X X X 
1. In selected countries /sites , participant s will have the option to use a centralised home nursing provider. Only selected visits will have the option to be performed as a home 
visit, these will include drug administration, blood draws, participant  assessments and data collection. The full specifi cations of the home nursing services will be outlined in 
the SRM . 
2. Hematology - platelet count analyzed  at local laboratory  is optional  during the off -treatment period ; hematology samples to be collected for central laboratory assessments  
(required; if local  lab is being drawn, in parallel with local lab sample ) . 
3. Only for selected sites able to transport to the analysis lab as specified in the SRM.  
 
OT: off-treatment; the first off -treatment visit occurs 7 days after the last study treatment dose received, whether planned or last dose given after particip ant is withdrawn from study 
treatment (e.g., the planned first off -treatment visit occurs on Day 169, 7 days after the Day 162 visit; if participant is withdrawn from study treatment on Day 50, the first off -treatment 
visit occurs on Day 57)
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 21 
 2. INTRODUCTION  
2.1. Study Rationale  
This is a Phase 2b study examining multiple dose administration of GSK3228836 in 
partic ipants with CHB. This study will evaluate the efficacy, safety, and PK profile of 
GSK3228836 and provide a first look at differences between efficacy and/or durability of 
HBsAg suppression when GSK3228836 is given as 24 weeks treatment at 300 mg 
GSK3228836  with loading doses , 12 weeks treatment at 300 mg GSK3228836  with 
loading doses  followed by 12 weeks treatment at a step -down dose of 150 mg 
GSK3228836, 12 weeks treatment at 300 mg GSK3228836  with loading doses , and 
12 weeks placebo followed by 12 weeks t reatment at 300 mg GSK3228836 without 
loading doses . 
Data from this study will provide an assessment of the safety, tolerability, 
pharmacokinetic and pharmacodynamic outcomes of the different dosing regimens and 
identification of the optimal treatment regi men(s), thus supporting subsequent clinical 
studies.  
2.2. Background  
HBV infection, especially chronic infection, is a significant worldwide medical problem.  
Globally, in 2015, an estimated 257 million people were living with chronic Hepatitis B, 
with only 9% of patients with Hepatitis B being treated. Viral hepatitis led to 1.34 million 
deaths and of these deaths, 66% were the results of complications of CHB infection 
[WHO , 2015].  
The goal of therapy for CHB is to improve quality of life and survival by preventing 
progression of the disease to cirrhosis, decompensated liver disease, end -stage liver 
disease, hepatocellular carcinoma (HCC), or death. This goal can be achi eved if HBV 
replication is suppressed in a sustained manner thereby decreasing the histological 
activity of CHB and reducing the risk of cirrhosis and HCC [ Liaw , 2004; Feld, 2009]. In 
both HBeAg -positive and HBeAg negative CHB, the ultimate treatment endpoint is loss 
of detectable serum hepatitis B surface antigen (HBsAg) [ Lok, 2009; EASL , 2012]. Loss 
of HBsAg is preceded by a robust immunological response to HBV infection resulting in 
susta ined suppression of serum HBV deoxyribonucleic acid (DNA) and disease 
resolution.  
First-line therapy for CHB is treatment with a nucleoside or nucleotide (nucleos(t)ide) 
analogue (NA). While these antiviral agents are effective in suppressing HBV replicati on 
in both HBeAg -positive and HBeAg -negative CHB, patients frequently relapse after 
treatment is discontinued, particularly if HBsAg loss was not achieved. Treatment with a 
pegylated interferon (PEG -interferon), of which 2 are available, is also approved f or CHB 
[Lok, 2009; EASL , 2012] for a defined treatment duration (usually up to 48 weeks). 
Because of  their frequent and sometimes severe side effects and high cost versus a small 
gain in treatment response, PEG -interferons are less frequently used than NAs. 
Unfortunately, with both the NAs and PEG -interferon, HBsAg loss and the subsequent 
development of antibodies to HBsAg is rarely achieved. Rates of HBsAg loss following 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 22 
 12 months of treatment with either a NA or PEG -interferon generally range from 0 to 3% 
in most studies [ Lok, 2009; EASL , 2012]. Loss of HBeAg occurs more frequently 
following treatment with either the NAs or PEG -interferon, approximately 15 to 30% 
after 1 to 2 years of therapy, but off  treatment durability is variable and questions remain 
as to whether virologic responses can be maintained over an extended follow -up period. 
Thus, most patients on treatment fail to achieve a sustained off -treatment virological 
response and require extend ed and often life -long therapy to suppress HBV DNA.  
It has been proposed that the continued production of viral antigens by infected 
hepatocytes interferes with immune clearance of both the infected cells and circulating 
virus particles [ Vanlandschoot , 2003]. In vitro studies with human peripheral blood 
mononuclear cells (PBMCs) have shown HBsAg impairs the functioning of dendritic 
cells and inhibits the activ ation of monocytes [ Vanlandschoot , 2002; Op den Brouw , 
2009]. Further, data suggest the production of vast excess of non -replication competent 
HBsAg (so called “sub -viral particles”) likely functions as a decoy for host antibody 
responses. Most  chronically infected patients produce antibody to HBsAg, but these can 
only be detected as immune complexes due to the vast excess of circulating antigen 
[Maruyama , 199 3]. HBeAg is also thought to have a role in immune response evasion 
through down regulation of the innate immune system [ Milich , 1998; Wu, 2009; Walsh , 
2012]. As noted above, since loss of HBsAg expression is rarely achieved while loss of 
HBeAg expression occurs in a higher  proportion of the patient population, HBsAg 
appears to be the main antagonist of immune clearance.  
Should the viral antigens be instrumental in preventing clearance of persistent infection 
by the immune system, reducing the expression of these antigens, especially HBsAg, 
would be expected to permit reconstitution of an immune response against HBV [ Boni , 
2007; Boni , 2012; Bertoletti , 2013]. Support for this hypothesis is the observation that 
spontaneous seroconversion and resolution of chronic infection is most  likely in patients 
that have lower serum HBsAg levels [ Chen , 2012; Höner Zu S iederdissen , 2014].  
Similarly, during treatment with NAs, patients with low HBsAg levels are mor e likely to 
lose HBsAg and seroconvert to anti -HBs antibody positive than patients with high 
HBsAg levels [ Wursthorn , 201 0; Jaroszewicz , 2011; Boni , 2012; Höner Zu S iederdissen , 
2014].  A study to examine whether inhibition of HBsAg production for a finite duration 
would lead to sustained suppression of HBV has not been possible up to the present due 
to the lack of specific inhibitors of HBsAg.  
GSK3228836, an antisense oligonucleotide, was designed to inhibit the synthesis of 
HBsAg without having a direct effect on covalently closed circular DNA or integrated 
HBV DNA. GSK3228836 directly targets all HBV mRNAs via Ribonuclease H (RNase 
H) m ediated degradation, resulting in the reduction of viral proteins including HBsAg. 
GSK32288336 treatment permits examination of whether reduction of HBsAg allows 
resumption of a host immune response against HBV and infected cells and can induce 
HBsAg seroc learance.  
Recently, a functional cure of CHB infection has been endorsed as the endpoint for new 
HBV therapies. Functional cure of CHB infection is defined as sustained seroclearance of 
HBsAg from serum (with or without anti -HBsAg seroconversion,) and unde tectable HBV 
DNA in serum, after completion of a finite course of treatment [ Lok, 2017].  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02  
 23 
 Functional cure occurs in only a very small percentage of patients on NA therapy alone 
(approx. 3% per annum), meaning that patients frequently relapse once they are taken off 
treatment [ Lok, 2017].  The high rate of relapse in these patients is hypothesised to be 
due to their inability to raise an effective immune response to the virus in the presence of 
high circulating levels of HBsAg, which continues to be produced by infected 
hepatocytes, even in the absence of ongoing viral replication. The present study will 
investigate whether pharmacological suppression of HBV antigens up to 24 weeks of 
treatment by GSK3228836 will allow patients to achieve functional cure.  
2.3. Benefit/Risk Asses sment  
More detailed information about the identified and potential  benefits and risks and 
expected adverse events of GSK322 8836 may be found in the Investigator’s Brochure.  
2.3.1.  Risk Assessment  
Risks are summarized in Table 5.  Additional w ithdrawal/stopping criteria for liver 
chemistry  monitoring, drug induced vascular injury (DIVI),  hematology, renal function, 
and PK are discussed in Section 7.  Planned dose adjustments for individuals for safety 
are outlined in Section 6.6. 
 
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
24 
 Table 5 Summary of Potential Risks of Clinical Significance  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Investigational Product (IP) [e.g., GSK3228836]  
Nonclinical Risks :  
Drug Induced Vascular Inflammation and Complement 
Activatio n Inflammatory and immune changes are recognized as a 
class effect of antisense oligonucleotide (ASOs ). Vasculitis 
and/or perivascular inflammation has been described in 
monkey studies with many if not most ASOs . 
 
This effect has not been observed in clinical studies with 
GSK3228836 to date . Laboratory Evaluations : Inclusion of biomarker panels to 
look for inflammatory and immune activation that would be 
expected to accompany vascular injury  
 
Stopping Criteria:  Proposed Monitoring Schedule and 
Stopping Rules for Drug Induced Vascular Injury and 
Complement Activation  (see Section 7.1.2 ) 
Clinical Risks : 
Drug induced liver injury / ALT Flares  The liver is a site of accumulation of antisense 
oligonucleotides. Liver findings in nonclinical  studies of 
GSK3228836  were generally limited to mild hepatic 
enzyme elevations associated with hepatic vacuolation 
without concomitant histologic evidence of degeneration in 
mice , consistent with findings  noted with other 2' -
methoxyethyl ( MOE ) ASOs . Review of the available cli nical 
data indicates liver enzymes are increased on treatment 
with ASOs in a low percentage of patients compared to 
placebo.  
ALT elevation s (defined as ALT ≥ 2X ULN) associated with 
HBsAg reductions were observed in 8 out of 18 treatment -
naïve participant s in the ISIS 505358 -CS3 study (150 mg 
GSK3228836, N=6; 300 mg GSK3228836, N=12).  Among 
the 8 participant s with ALT flares, 6 achieved >1 log 
HBsAg reduction, another 2 had >0.5 log HBsAg reduction.  Laboratory Evaluations: hepatic enzyme monitoring as 
presented in Table 6 
 
Stopping Criteria: ALT flares are expected in the study 
population. Monitoring and stopping criteria are presented 
in Section 7.1.1  
TMF-1395648 0 CONFIDENTIAL   
  209668  
 Protocol Amd 02  
25 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Thrombocytopenia  leading to clinically significant bleeding 
events  Two types of thrombocytopenia have been described for 
the 2' -MOE ASOs [ Chi, 2017 ; Crooke , 2017 ].  One type is 
a rapid onset, unpredictable thrombocytopenia.  The other 
more common type is characterised by a gradual decline in 
platelets leading to mild to severe thrombocytopenia and 
can be asymptomatic or associated with mild to severe 
bleeding.   In monkeys given GSK3228836 , there were 
incidences of both types in a 39 -week study.  
Thrombocytopenia was not reported in the clinical studies 
with GSK3228836 ( ISIS 505358 -CS1 and ISIS 505358 -
CS3)  Laboratory Evaluations: platelet  count  
 
Stopping Criteria: monitoring and stopping criteria are 
presented in Section 7.1.3  
Drug -Induced Kidney Injury  Glomerulonephritis has been reported with ASOs and is 
thought to be a result of the proinflammatory effect of 
ASOs.  
No adverse events related to renal function were  reported 
in Study ISIS 505358 -CS3 Laboratory Evaluations: Serum creatinine, eGFR, 
urinalysis with microscopy and ACR assessed per the SoA 
tables  
 
Stopping Criteria: Monitoring Schedule and Stopping 
Rules are presented in Section 7.1.4  
Injection site reactions  Injection site reactions have been reported with ASOs, and 
reported in clinical studies with GSK3228836 (ISIS 
505358 -CS1 and ISIS 505358 -CS3).  
Injection site re actions were the most common study 
treatment -related AEs reported and were Grade 1 (mild) 
and Grade 2 (moderate) in severity.  Evaluations: Participants are assessed for injection site 
reactions at all visits during the on -treatment period.  
 
In order to minimize the risk of injection site reaction ( ISR), 
injections should be rotated within each anatomical site or 
site(s) of injection should be changed administration -to-
administration. Injection into areas with ongoing injection 
site reactions should be avoided.  
 
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
26 
 2.3.1.1.  Regarding Coronavirus Disease 2019 (COVID -19) 
In addition to the study related risks listed in Table 5, it should be noted that COVID -19 
is a risk for everyone. The magnitude of the risk depends on the prevalence in the 
population, frequency, dura tion and closeness of contact with other people, use of 
protective measures, age, ethnicity, sex and co -morbidities including medications.  
Currently, there is no evidence that patients with chronic HBV have increased 
susceptibility to severe acute respirat ory syndrome coronavirus 2 virus strain 
(SARS -CoV -2) infection.  Patients with uncomplicated viral hepatitis (i.e., without 
cirrhosis, or history of transplantation or current immunosuppressant use) don’t appear to 
be over -represented in hospitalized or in tensive care unit cases of COVID -19, and 
therefore viral hepatitis isn’t considered a risk factor for a more severe course of COVID -
19 [Fix, 2020; Boettler , 2020].  
The actual risk of COVID -19 will vary by country and region, so study participants 
should follow any national or local hospital restrictions, as well as specific 
recommendations from t heir healthcare providers.  
2.3.2.  Benefit Assessment  
Treatment of CHB with nucleos(t)ide analogues has been effective in reducing the long -
term complications of CHB, but evidence is emerging that HBsAg loss is associated with 
lower rates of hepatocellular carcino ma [ Kim, 2014; Yip, 2016] . Even patients who 
achieve complete viral suppression experience significantly lower rates of hepatocellular 
carcinoma if they are able to achieve HBsAg loss.  Thus, there is a need in patients with 
CHB for a finite treatment that allows them to achieve im mune control of their infection 
(functional cure, defined as HBsAg loss with HBV DNA suppression), removing the 
need for lifelong therapy and to improve long term disease outcomes, particularly 
development of hepatocellular carcinoma.  
GSK3228836 demonstrat ed target engagement in CHB patients who were not on 
treatment and in CHB patients on stable NA therapy. Overall, continued clinical 
development of GSK3228836 is supported by the results from the completed study ISIS 
505358 -CS3.   It is not known if there w ill be any direct therapeutic benefit to the CHB 
population that will be included in this study. However, their participation could 
potentially contribute to the development of an improved treatment for patient s with 
CHB.  
2.3.3.  Overall Benefit:  Risk Conclusion  
Considering  the measures taken to minimiz e risk to participants in this study, the 
potential risks identified in association with GSK3228836 and from COVID -19 are 
balanced  by the anticipated benefits that may be afforded to participants with CHB . 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
27 
 3. OBJECTIVES  AND ENDPOINTS  
Objectives  Estimand/Endpoints  
Primary  
Efficacy:  To assess the efficacy of the 
three dosing regimens of GSK3228836 
in participants with CHB  Primary estimands supporting the primary objective are defined 
as: 
- Population : separate assessment for the following:  
• participants with CHB on stable nucleos(t)ide therapy  
• participants with CHB not currently on nucleos(t)ide 
therapy  
- Variable : Participants achieving s ustained virologic response 
(SVR, described in Section 9.4.2 ) for 24 weeks after the planned 
end of GSK3228836 treatment in the absence of rescue 
medication.  
- Treatments : arms 1, 2, and 3. Estimation of the within -arm 
response rate.  
- Intercurr ent events : use of rescue medication, and 
discontinuation of/interruption of/adherence to IP. The use of 
rescue medication has been incorporated into the definition of 
variable (composite strategy). Discontinuation of, interruption of, 
and adherence to IP will be ignored (treatment policy) . Wide 
disruptive events (such as COV ID-19 pandemic) leading to 
discontinuation of, interruption in, and non -adherance to 
GSK3228836 will be handled assuming they had not happened 
(hypothetical strategy) . 
- Population summary : proportion of participants who achieve 
SVR for each treatment arm.  
 
The primary estimands for each sub -population is  the proportion 
of participants in each treatment arm 1, 2, and 3 who achieve 
SVR for 24 weeks after the planned end of GSK3228836  
treatment in the absence of rescue medication regardless of 
completing IP, interruptions in IP or adherence to IP  had they not 
been affected by wide disruptive events.  
A supplementary estimand is defined to support the primary 
objective:  
- the supplementa ry estimand is defined in the same way as the 
main estimand, except the assessment time frame for 
participants achieving SVR will be 24 weeks after the actual end 
of treatment. Therefore, the strategy for intercurrent events of 
treatment discontinuation wi ll be while -on-treatment. This 
supplementary estimand supporting the primary objective in 
participants with CHB on stable nucloes(t)ide therapy and 
participants with CHB not currently on nucleos(t)ide therapy is the 
proportion of participants in each treat ment arm 1, 2, and 3 who 
achieve SVR for 24 weeks after the actual end of GSK3228836 
treatment in the absence of rescue medication, regardless of 
completing IP, interruptions in IP or adherence to IP, had they not 
been affected by wide disruptive events.   
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
28 
 Objectives  Estimand/Endpoints  
Secondary  
Efficacy:  To assess the efficacy of 
GSK3228836 on biomarkers and virus -
specific antibody responses  The estimands supporting this secondary objective are defined as 
follows:  
 
- Population : separate assessment for the following:  
• participants with CHB on stable nucleos(t)ide therapy  
• participants with CHB not currently on nucleos(t)ide 
therapy.  
- Treatments : arms 1 -4. Estimation within each arm.  
- Intercurrent events : use of rescue medication, and 
discontinuation of/interruption o f/adherence to IP. The use of 
rescue medication will be ignored (treatment policy strategy). 
Discontinuation of, interruption of, and adherence to IP will be 
ignored (treatment policy)  
 
2) Categorical Variables : 
-  Achieving HBsAg <LLOQ and HBV DNA <LLOQ at the  end 
of treatment.  
- Categorical changes from baseline in HBsAg (e.g. <0.5, 
≥0.5, ≥1, ≥1.5, ≥3 log 10 IU/mL) and in HBV DNA (e.g. , <1, 
≥1, ≥2, ≥3 log IU/mL)  
- ALT normalization (ALT≤ULN) over time in absence of 
rescue medication  in participants with baseline ALT>ULN  
- HBe antibody (anti -HBeAg) levels  
- Population summary:  proportion of participants in each 
category for each treatment arm.  
2)  Continuous Variables : Actual values and change from 
baseline over time of HBsAg and HBV DNA and actual values 
and change from baseline  of HBeAg levels; HBs antibody (anti -
HBsAg) levels  
- Population summary : mean values and mean changes from 
baseline for each variable in each treatment arm  
3) Time to Event Variable : Time to ALT normalization in 
absence of rescue medication in  participants with baseline 
ALT>ULN  
- Population summary : Turnbull’s estimate for non-paramet ric 
estimation of t ime to ALT normalization in each treatment arm  
The group of estimands supporting this objective for each sub -
population is the population summary for each variable in each 
treatment arm 1 -4 regardless of completing IP, interruptions in IP 
or adherence to IP and regardless of rescue medication (except 
for ALT normalization which can only be achieved in the 
absence of rescue medication)  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
29 
 Objectives  Estimand/Endpoints  
Effic acy: To compare the efficacy 
between 12 weeks, 12 weeks + 12 
weeks step -down, and 24 weeks of 
GSK3228836 treatment  The same definition as the primary estimand except treatments 
and population summary are defined as:  
-Treatments : arms 1, 2, and 3. Three tre atment comparisons 
between: arms 1 & 2, arms 1 & 3, and arms 2 & 3  
- Population summary : difference in proportion of participants 
who achieve SVR between treatment arms  
 
The group of estimands supporting this objective for each sub -
population are the diffe rence in each treatment comparisons in 
the proportion of participants who achieve SVR for 24 weeks after 
the planned end of GSK3228836 treatment in the absence of 
rescue medication regardless of completing IP,  interruptions in IP 
or adherence to IP  had the y not been affected by wide disruptive 
events . 
Pharmacokinetics (PK):  To 
characterize GSK3228836 and 
nucleos(t)ide  PK in participants with 
CHB  • In a subset of participants with intensive PK sampling: 
Derived GSK3228836 and nucleos(t)ide plasma PK 
parameters including , but not limited to , area under the 
concentration -time curve (AUC), concentration at the end of 
the dosing interval  (C), maximum observed concentration 
(Cmax), time of maximum observed concentration (t max). 
• In all participants: C  and terminal half -life (t ½) of 
GSK3228836.  
Safety  
Safety: To assess the safety and 
tolerability of GSK3228836 when dosed 
for 12 weeks, 12 weeks + 12 weeks 
step-down, and 24 weeks duration in 
participants with CHB  Clinical assessments including, but not limited to vital signs, 
laboratory measurements and adverse events  
Exploratory  
PK-PD relationships:  To evaluate PK -
efficacy relationship and PK -safety 
relationship  Exploratory graphical analyses will be initially performed for 
efficacy (e.g. , HBsAg) and safety endpoints. If a relationship 
between exposure and efficacy and/or safety endpoints is 
present, population PK -PD modelling will be conducted using 
nonlinear mixed effect methods.  
 
The model will assess the effect of various factors (covar iates) of 
the modelled efficacy or safety endpoints. Relevant PK -PD model 
endpoints for example:  
• apparent clearance  
• apparent volume of distribution  
• IC50  
• random variability  
Efficacy: To compare the efficacy 
between 12 weeks of GSK3228836 
treatment with a loading dose or 
without a loading dose  The same definition as the primary Estimand except treatments 
and population summary are defined as:  
- Treatments : arm 3 & 4. Treatment comparison between arms 
3&4.  
- Population summary : difference in proportion of p articipants 
who achieve SVR between treatment arms 3 & 4.  
 
The group of estimands supporting this objective  for each sub -
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
30 
 Objectives  Estimand/Endpoints  
population are the differences between arms 3  & 4 in the 
proportion of participants  who achieve SVR for 24 weeks after the 
planned end of GSK3228836 treatment in the absence of rescue 
medication regardless of completing IP, interruptions in IP or 
adherence to IP  had they not been affected by wide disruptive 
events . 
Efficacy:  To assess the 
pharmacodynamic effect of 
GSK3228836 on explorato ry viral 
biomarkers  HBV core related antigen (HBcrAg), HBV RNA  
Virology:  To assess the effect of 
genotype /phenotype  and presence of 
baseline polymorphisms within the 
GSK3228836 binding site to assess the 
effect on treatment response.  
To assess the emergence of mutations 
within the GSK binding site, and 
elsewhere in the hepatitis B genome, 
during and after treatment.  Sequencing of the viral HBV DNA and/or HBV RNA prior to 
treatment, during treatment and post treatment visits  
Immunology:  To assess t he effect of 
12 weeks, 12 weeks + 12 weeks step -
down  or 24 weeks treatment with 
GSK3228836 on immunological 
biomarkers . 
To describe the relationship (s) between 
virology biomarkers, including but not 
limited to HBsAg,  and immunologic al 
biomarker s.  Laborato ry measurements of and correlation between the 
following  
• Virological biomarkers, as determined by (but not limited 
to) specific viral parameters (HBeAg, HBV DNA, HBV 
RNA, HBcrAg).  
• Soluble immunological biomarkers, as determined by 
(but not limited to) levels of circulating cytokines and 
chemokines.  
• Markers of immune cell function, as measured by (but 
not limited to) relative frequencies of immune cell 
subsets among PBMCs, activation status as determined 
by phenotyping and gene expression patterns, and 
functional assays including HBV -specific cytokine and/or 
antibody production  
Patient Reported Outcomes:  To 
assess changes  from baseline in 
patient reported outcomes following 12  
weeks, 12 weeks + 12 weeks step -
down,  and 24 weeks of treatment with 
GSK3228 836. Change from baseline of HBQOL and EQ -5D. 
 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
31 
 4. STUDY DESIGN  
4.1. Overall Design  
This is a Phase  2b, multi -center, randomized, partial -blind [Sponsor and Participant 
blinded], study to assess efficacy and safety of treatment with GSK3228836 in two 
populations of patients with CHB (1) participants on stable nucleos(t)ide treatment and 
(2) participants not currently on nucleos(t)ide therapy.  
Both populations of patients with CHB will be randomized into one of 4 par allel arms:  
• 300 mg GSK3228836 once/week for 24 weeks  (plus loading dose of 300  mg 
GSK3228836 on Day 4 and Day 11) ; 
• 300 mg GSK3228836 once/week for 12 weeks (plus loading dose of 300 mg 
GSK3228836 on Day 4 and Day 11) followed by step-down in dose of 150 mg  (plus 
placebo to match to maintain participant blinding) GSK3228836 once/week for 12 
weeks;  
• 300 mg GSK3228836 once/week for 12 weeks (plus loading dose of 300 mg 
GSK3228836 on Day  4 and Day 11) followed by placebo once/week for 12 weeks;  
• Placebo once/week  for 12 weeks followed by 300 mg GSK3228836 once/week for 12 
weeks  (plus placebo loading doses  to match on Day 4 and Day 11 , no loading dose 
for GSK3228836 treatment)  
After the 24 weeks of dosing with GSK3228836 or placebo, there will be a post -
treatment f ollow -up period of 24 weeks.  
Populations will be stratified based on HBsAg level (HBsAg 3 log IU/mL and >3 log 
IU/mL) and whether participants are HBeAg positive or negative.  
The study is a partially blinded study where participants will be blinded to the  study 
treatment.  The investigators, site staffs and pharmacist will be unblinded.  GSK and 
contract research organization (CRO) team members will be blinded to participants’ 
study treatment and any potentially unblinding information, unless specified oth erwise  in 
the study blinding management plan (e.g., unblinded site monitors) . 
4.2. Scientific Rationale for Study Design  
In a previous clinical study ( ISIS 505358 -CS3), 7 of 12 (58%) of treatment -naïve 
participants dosed with 300 mg GSK3228836 over 4 weeks expe rienced a ≥0.5 log 10 
reduction in HBsAg by Day 29 .  Two treatment -naïve participants dosed with 300 mg 
GSK3228836 experienced HBsAg loss  that persisted for 102 and 28 days, respectively, 
before the HBsAg became detectable again.   
In participants on stable  nucleos(t)ide analogue therapy, 3 of 5 (60%) participants treated 
with 300 mg GSK3228836 achieved HBsAg reductions >3 log10 IU/mL.  Two of five 
participant s (40%) treated with 300 mg GSK3228836 achieved HBsAg <LLOQ 
(0.05  IU/mL). One participant  reached HB sAg levels <LLOQ on Day 23, but this was not 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
32 
 sustained.  HBsAg was detectable on the Day 85 and Day 113 visits.  One participant  had 
HBsAg <LLOQ on Day 36 and remained <LLOQ as of the Day 85 visit.   
The proposed Phase 2b study (209668) will evaluate whethe r up to 24 weeks treatment 
with GSK3228836 results in a clinically meaningful rate of sustained virologic response 
(SVR, HBsAg <LLOQ and HBV DNA <LLOQ) with a finite course of GSK3228836.  
The study will evaluate the efficacy, safety, tolerability, pharmac okinetic and 
pharmacodynamic properties of GSK3228836 when dosed as part of four different dosing 
regimens.  
4.2.1.  Rationale for Study Blinding  
A partial blind study (participant and sponsor blinded, site staff unblinded) was chosen 
because there is a high probab ility that the PI and site staff could infer treatment 
assignment due to:  
 
• Differences in the injection force due to the viscosity of GSK3228836 versus placebo 
saline.  
a. GSK3228836 is much more viscous than placebo saline and the 
administrating site staff may be able to infer treatment based on the 
differences in pressure exerted to administer the dose.  
• Color difference of GSK3228836 versus placebo  
• Syringes will be wrappe d in a colored transparent tape to prevent 
unblinding of the participant.  
• Laboratory results (e.g., platelets, ALT, HBV DNA and HBsAg) needed in the course 
of participant treatment and/or safety management  
a. Platelet decreases and thrombocytopenia have been  reported with ASOs. 
In this study thrombocytopenia is an AE of special interest. For safety 
management of the participants, the platelet counts cannot be blinded.  
b. ALT increases are expected to be seen during the course of treatment with 
GSK3228836. In the  previous ISIS 505358 -CS3 study, where participants 
received up to 4 weeks of 300 mg GSK3228836 treatment, 33% of 
treatment -naïve participants had increase in ALT ≥3x ULN, not associated 
with other chemistry changes (e.g., bilirubin, INR). In order for the  
investigator to better ascertain the etiology of an ALT increase (e.g., drug -
induced liver injury vs therapeutic flare vs nucleos(t)ide treatment failure 
ALT increase), virology data are required.  
c. HBV DNA results are needed to evaluate whether to initiate  nucleos(t)ide 
treatment in the event of a sub -optimal response or virological failure in 
response to GSK3228836. Initiation of nucleos(t)ides should reduce the 
risk of development of resistance to GSK3228836.  
Participants will be kept blinded to decrease reporting bias and to decrease risk of missed 
visits during the placebo part of the study.  The Sponsor will remain blinded to minimize 
bias ( unless specified otherwise in the study blinding management plan (e.g., unblinded 
site monitors ).  The primary end point assessments (HBsAg , HBV DNA ) are objective 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
33 
 laboratory measurement s and therefore the unblinding of the site staff will not 
compromise the assessment of the primary endpoint of the study.  
4.2.2.  Rationale for Placebo -First Arm  
Inflammatory and immune changes  are recognized as a class effect of ASOs. Vasculitis 
and/or perivascular inflammation has been described in pre -clinical monkey studies with 
many ASOs, including pre -clinical monkey studies with GSK3228836. However, this 
effect has not been observed in cl inical studies with GSK3228836 to date.  
As part of the safety monitoring, inclusion of biomarker panels to look for inflammatory 
and immune activation that would be expected to accompany vascular injury have been 
included. The biomarkers being utilized to monitor for inflammatory and immune 
activation (e.g., complement factors C3, C4, C5a, Bb; ANCA; MCP -1) are exploratory in 
nature with little to no literature around normal values/behaviors in chronic hepatitis B 
patients.  The placebo -first arm (placebo tr eatment for 12 weeks, 300 mg GSK3228836, 
then off -treatment follow -up for 24 weeks) will be used as a comparator for these 
exploratory safety analyses.  
The placebo -first arm (placebo treatment for 12 weeks, 300 mg GSK3228836 for 12 
weeks, then off -treatme nt follow -up for 24 weeks) will also provide an assessment for 
loading versus non -loading dose.  Participants in the placebo -first arm will not be 
receiving loading dose when starting their 12 weeks 300 mg GSK3228836 treatment, and 
efficacy results (Week 1 3-24) may be compared with participants being treated for 12 
weeks of 300 mg GSK3228836 with loading dose (Week 1 -12). 
The comparisons/assessments for the placebo -first arm are not statistically powered.  
4.2.3.  Participant Input into Design  
A small group of patie nts with CHB were asked to review an example informed consent 
form for the 209668 study.  The patients provided feedback for more clarity in the 
informed consent form regarding the purpose of the study and optional assessments (e.g. 
biomarkers), mode of ad ministration of GSK3228836, the study burden in both terms of 
visit schedule and duration of visit.  Efforts to reduce the burden of visits were 
encouraged. The input from the patients will be incorporated into the Informed Consent 
Form.  The study team re viewed the blood collection timepoints and made changes to 
balance participant burden with the data/timepoints needed for safety and efficacy 
analyses.  
Due to the feedback from patients that the number of visits may be challenging (weekly 
visits to the cli nic/hospital), the study team are working with countries/sites to provide an 
option where participants may use a centralised home nursing provider.  The home 
nursing providers will go to the participant, decreasing the number of times the 
participant must travel to/from the clinic/hospital.  Only selected visits will have the 
option to be performed as a home visit, these will include drug administration, blood 
draws, participant  assessments and data collection.  The full specifications of the home 
nursing s ervices will be outlined in the SRM.  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
34 
 4.3. Justification for Dose  
Dose Levels, Frequency and Duration  
Weekly dosing of GSK3228836 has been evaluated over a four -week dosing duration in 
both healthy volunteers (ISIS 505358 -CS1 study) and in participant s with CHB (ISIS 
505358 -CS3 study).  In both studies, GSK3228836 was administered subcutaneously on 
Study Day 1, 4, 8, 11, 15, and 22.  The loading schedule  (i.e., loading doses ) in Week 1 
(Day 4) and Week 2 (Day 11) were included in order to accelerate the achievement of 
steady state concentration in the liver to increase the likelihood of observing anti -HBV 
activity during a short treatment duration.  In study 209668, a study arm will be included 
to explore  placebo for 12 weeks followed by weekly dosing of GSK3228836 300 mg for 
12 weeks without the loading doses  (see below).  
To date, the highest dose of GSK3228836 evaluated was 2700 mg over 4 weeks (450 mg 
per injection including loading doses ; n=3) in healt hy volunteers, and 1800 mg over 
4 weeks (300 mg per injection including loading doses ; n=18) in participant s with CHB. 
In treatment -naïve participant s with CHB dosed with 300 mg per injection in ISIS 
505358 -CS3 study, continuous HBsAg declines were observe d in many participant s 
during GSK3228836 treatment, with two participants achieving HBsAg seroclearance 
that persisted for 102 and 28 days, respectively. In participants  who achieved HBsAg 
<LLOQ , HBsAg subsequently became detectable after discontinuation o f GSK3228836 
dosing .  Moreover , many participants had declining HBsAg levels that hadn’t plateaued 
by the end of treatment.   
Similar responses were observed in participants in Study ISIS 505358 -CS3 on stable NA 
therapy.  Three of 5 GSK3228836 -treated participants (60%) achieved HBsAg reductions 
>3 log10 IU/mL.  Two of five participant s (40%) treated with 300 mg GSK3228836 
achieved HBsAg <LLOQ (0.05 IU/ mL).  One participant  reached HBsAg levels <LLOQ 
on Day 23, but this was not s ustained.  HBsAg was detectable on the Day 85 and Day 
113 visits.  One participant  had HBsAg <LLOQ on Day 36 and remained <LLOQ as of 
the Day 85 visit.   Taken together, the data suggest that a longer duration of GSK3228836 
therapy may be required to both i ncrease the rate of seroclearance and to achieve 
sustained seroclearance.  
In study 209668, 2 different treatment durations (12 weeks and 24 weeks) will be studied 
to assess differences in the efficacy endpoints (e.g., proportion of participant s achieving 
seroclearance, durability of response ) with GSK3228836 in two populations of patients 
with CHB :  
(1) participant s receiving  stable nucleos(t)ide treatment and  
(2) participant s not currently receiving  nucleos(t)ide therapy.  
Study 209668 will also explore the impact on efficacy and safety of decreasing overall 
exposure to GSK3228836 by administrating a step -down dose of 150 mg GSK3228836 
for 12 weeks after an initial 12  weeks of 300 mg GSK3228836 dose.  In each population 
of patients with CHB (participants receiving stable nucleos[t]ide treatment and 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
35 
 participants not currently receiving nucleos[t]ide therapy), f our different treatment 
regimens of GSK3228836 will be studied in study 209668:  
• 300 mg GSK3228836 once/week for 24 weeks ( plus loading doses  on Day 4  and 
Day 11);  
• 300 mg GSK3228836 once/week for 12 weeks weeks ( plus loading doses  on Day 
4 and Day 11)  followed by a step -down dose of 150  mg GSK3228836 once/week 
(plus placebo to match to maintain participant blinding) for 12;  
• 300 mg GSK3228836 once/week for 12 weeks ( plus loading doses  on Day 4 and 
Day 11)  followed by placebo once/week for 12 weeks;  
• Placebo once/week for 12 weeks followed by 300 mg GSK3228836 once/week 
for 12 weeks ( placebo loading doses  to match on Day 4 and Day 11 , no loading 
dose for GSK3228836 treatment ) 
Co-administration of GSK3228836 and Nucleos(t)ide Analogues  
GSK3228836 is unlikely to be a victim or perpetrator of drug -drug interactions when 
administered with nucleos(t)ide analogues due to their divergent absorption, distribution,  
metabolism, and excretion pathways.  
Drug -drug interactions with GSK3228836 as victim:  
Upon entry into the system circulation, GSK3228836 rapidly becomes highly bound 
(approximately 95%) to serum proteins and is then rapidly distributed to tissues.  
GSK3228 836 enters hepatic cells through target -mediated endocytosis and enters renal 
cells through micropinocytosis [ Geary , 2008; Bennett , 2010]. GSK3228836 is eliminated 
primarily via nucleolytic degradation by endogenous endonucleases [ Geary , 2008]. None 
of these proce sses is inhibited or induced by small -molecule drugs including 
nucleos(t)ide analogues (e.g. tenofovir, entecavir, lamivudine, adefovir and telbivudine).  
In Cohorts 1 -3 of the ISIS 505358 -CS3 study , treatment -naïve participant s were started 
on tenofovir after treatment ended; in Cohort 4, where participant s were nuc leos(t)ide  
experienced, the majority of participant s entered the study  on entecavir.   Clinical data 
from this study suggest that co -administration of entecavir  is un likely to impact plasma 
PK of GSK3228836.  GSK3228836 was co -administered with entecavir  throughout the 
treatment period in 4 participant s in Cohort 4 while administered alone in 18 participant s 
in Cohorts 1 to 3.   GSK3228836 plasma concentration was compa rable with entecavir  
(n=4) and without entecavir  (n=18).  Dose normalization was applied to Cohort 1 as 
150 mg of GSK3228836 was administered in Cohort 1 as compared to 300 mg in 
Cohorts  2 to 4.   
Drug -drug interactions with GSK3228836 as perpetrator:  
Tenof ovir, entecavir, and other nucleos(t)ide analogues circulated in the blood stream 
with little binding to serum proteins [ Bristol -Myers Squibb , 2018; Gilead , 2018]. 
Tenofovir, entecavir, lamivudine, adefovir and telbivudine are predominantly renally 
eliminated from systemic circulation [ Epivir , 2002; Kearney , 2004; Hepsera , 2012; 
Tyzeka , 2013; Entecavir , 2015 ; Bristol -Myers Squibb , 2018; Gilead , 2018]. These 5 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
36 
 drugs undergo a combination of glomerular filtration and tubular secretion, which have 
been reported to be mediated by one or more of the following transporters: the organic 
anion transporter (OAT) 1, OAT3, the organic cation transporter (OCT) 1, and OCT2 
[Cihlar , 2001; Cihlar , 2004; Servais , 2006; Uwai , 2007; Minuesa , 2009; Yanxiao , 2011; 
Xu, 2013]. It has been shown that 2' -MOE ASO is neither a substrate nor an inhibitor of 
OAT1, OAT3, OCT1 and OCT2 [ Yu, 2016; Shemesh , 2017]. Therefore, although 
GSK3228836 was shown to be extensively distributed into the kidney in non -clinical 
studies, it is unlikely to interact with tenofovir, entecavir, lamivudine, adefovi r, 
telbivudine, or other nucleos(t)ide analogues.  
Clinical data from ISIS 505358 -CS3 suggest that co -administration of GSK3228836 is 
unlikely to impact efficacy and safety profiles.  Given the long plasma and tissue half -life 
of GSK3228836 (approximately 3 weeks), there is a period of at least several weeks 
during which there was a substantial presence of both drugs in the plasma, liver and other 
tissues.  Potent reduction of HBV DNA w as observed following initiation of tenofovir in 
all participant s.  There were no obvious differences in tenofovir potency and efficacy in 
participant s who received 150 mg of GSK3228836 (Cohort 1), 300 mg of GSK3228836 
(Cohorts 2 and 3), and placebo (no GS K3228836).   There were no adverse event or 
clinical laboratory results that may indicate a change in tenofovir safety profile due to 
drug-drug interaction with GSK3228836.  
4.4. End of Study Definition  
A participant is considered to have completed the study if h e/she has completed all 
phases of the study including the last visit.  
The end of the study is defined as the date of the last visit of the last participant in the 
study.  
5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
AGE  
1. At least 18 years  of age at the time of signing the informed consent  [if country/sit e 
age requirements for consent differ, the more stringent (e.g.,  higher age) 
restriction will be required for that country/site] . 
TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS  
2. Participant s who have d ocumented chronic HBV infection ≥6 months prior to 
screening AND  
a. Not currently on nucleos(t)ide analogue therapy population defined as 
participants who never received HBV treatment ( treatment naïve ) OR 
must have ended nucleos(t)ide therapy at least 6 months prior to the 
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
37 
 screening visit  
b. OR Currently receivi ng stable nucleos(t)ide analogue therapy population 
defined as no changes to their nucleos(t)ide regimen from at least 6 
months prior to screening and with no planned changes to the stable 
regimen over the duration of the study  
3. Plasma or serum HBsAg concen tration >100 IU/mL  
4. Plasma or serum HBV DNA concentration  
a. Participant s not currently on nucleos(t)ide analogue therapy , plasma or 
serum HBV DNA >2000 IU/mL  
b. Participants  who are receiving stable nucleos(t)ide analogue therapy must 
be adequately suppressed, defined as plasma or serum HBV DNA < 90 
IU/mL  
5. Alanine Transaminase (ALT)  
a. ALT for treatment naïve participant s and for participant s who are not 
currently receiving treatment  
i. ALT <3 X ULN will be included initially  
1. If agreed by the IDMC a fter review of safety data, the ALT 
inclusion criteria may be expanded to include  participant s 
with ALT <5 X ULN  
b. ALT ≤2 X ULN for participant s who are receiving stable 
nucleos(t)ide analogue therapy  
SEX  
6. Male and/or Female  
a. A male participant is eligible to participate if they agree to the following 
during the intervention period and for at least 90 days after the last dose of 
study treatment  
i. Refrain from donating sperm  
ii. AND be abstinent from heterosexual intercourse as their preferred 
and usual lifestyle (abstinent on a long term and persistent basis) 
and agree to remain abstinent OR Must agree to use 
contraception/barrier as detailed below  
1. Agree to use a male condom [and should  also be advised of 
the benefit for a female partner to use a highly effective 
method of contraception as a condom may break or leak] 
when having sexual intercourse with a woman of 
childbearing potential who is not currently pregnant  
b. A female participant i s eligible to participate:  
TMF-1395648 0 CONFIDENTIAL   
  209668  
  Protocol Amd 02 
38 
 i. If she is not pregnant or breastfeeding  
ii. AND at least one of the following conditions applies:  
1. Is not a woman of childbearing potential (WOCBP)  
2. OR is a WOCBP and using a contraceptive method that is 
highly effective (with a failu re rate of <1% per year), 
preferably with low user dependency during the 
intervention period and for at least 90 days after the last 
dose of study treatment  
iii.  A WOCBP must have both  
1. A confirmed menstrual period prior to the first dose of 
study intervention  [additional evaluation  (e.g., amenorrhea 
in athletes, birth control)  should also be considered ] 
2. AND a negative highly sensitive pregnancy test [urine or 
serum] within 24 hours before the first dose of study 
treatment  
Contraceptive use by men or women shou ld be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies.  
Additional requirements for pregnancy testing during and after study intervention 
are located in Appendix 2. 
The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pr egnancy  
INFORMED CONSENT  
7. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this 
protocol.  
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 39 
 5.2. Exclusion  Criteria  
MEDICAL CONDITIONS  
1. Clinically significant abnormalities, aside from chronic HBV infection in medical 
history (e.g., moderate -severe liver disease other than chronic HBV, acute coronary 
syndrome within 6 months of screening, major surgery within 3 months of screening, 
signifi cant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis or 
coagulopathy) or physical examination  
2. Co-infection with:  
a. Current or past history of Hepatitis C virus (HCV ) 
b. Human immunodeficiency virus (HIV)  
c. Hepatitis D virus (HDV)  
3. History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by  
a. both Aspartate aminotransferase (AST) -Platelet Index (APRI) >2 and 
FibroSure /FibroTest  result >0.7  
i. If only one parameter (APRI or FibroSure /FibroTest ) result is positive, 
a discussion with the Medical Monitor is required before inclusion in 
study is permitted  
b. Regardless of APRI  of Fibrosure /FibroTest  score, if the participant meets one 
of the following historical criteria, they will be excluded from the study  
i. Liver biopsy (i. e., Metavir Score F4)  
ii. Liver stiffness >12 kPa  
4. Diagnosed or suspected hepatocellular carcinoma as evidenced by the following  
a. Alpha -fetoprotein concentration ≥200 ng/mL  
b. If the screening alpha fetoprotein concentration is ≥50 ng/mL and <200 
ng/mL, the abse nce of liver mass must be documented by imaging within 6 
months before randomization  
5. History of malignancy within the past 5 years with the exception of specific cancers 
that are cured by surgical resection (e.g., skin cancer) . Participant s under evaluatio n 
for possible malignancy are not eligible.  
6. History of vasculitis or presence of symptoms and signs of potential vasculitis [e .g., 
vasculitic rash, skin ulceration, repeated blood detected in urine  without identified 
cause ] or history/presence of other diseases that may be associated with vasculitis 
condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing 
polychondritis, mononeuritis multiplex ) 
7. History of extrahepatic disorders possibly related to HBV i mmune conditions (e.g., 
nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa , 
cryoglobulinaemia , uncontrolled hypertension ) 
8. Positive (or borderline positive) ANCA at screening:  
a. Participants that meet this criteria may be considered for inclusion in the study 
following:  
i. Analysis of MPO -ANCA [pANCA] and PR3 -ANCA [cANCA] AND  
ii. A discussion with the Medical Monitor to review participant ’s complete 
medical history to ensure no past history or current manifestations of a 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 40 
 vasculitic/inflammatory/ auto-immune condition  
9. Low C3 at screening  AND evidence of  past history or current manifestations of 
vasculitic/inflammatory/auto -immune conditions  
a. All participants with low C3 at screening should have their medical history 
discussed with the Medical Monito r prior to enrolment  
10. History of alcohol or drug abuse/dependence  
a. Current alcohol use as judged by investigator to potentially interfere with 
participant compliance  
b. History of or current drug abuse/dependence as judged by the investigator to 
potentially int erfere with participant compliance  
i. Refers to illicit drugs and substances with abuse potential. Medications 
that are used by the participant  as directed, whether over -the-counter 
or through prescription, are acceptable and would not meet the 
exclusion criteria  
 
PRIOR/CONCOMITANT TH ERAPY  
11. Currently taking, or took within 3 months of screening, any immunosuppressing 
drugs (e.g., prednisone), other than a short course of therapy (≤2 weeks) or 
topical/inhaled steroid use .  
12. Participant s for whom immunosuppressive treatment is not advised, including 
therapeutic doses of steroids , will be excluded  
13. Currently taking, or took within 12 months of screening, any interferon -containing 
therapy.  
14. Participant s requiring anti -coagulation therapies (for example warfarin, Factor Xa 
inhibitors or anti -platelet agents like clopidogrel)  
 
PRIOR/CONCOMITANT TH ERAPY  
15. The participant  has participated in a clinical trial and has received an investigational 
product within the following time period prior to the first dosing day in the current 
study: 5 half -lives (if known) or twice the duration (if known) of the biological effect 
of the study treatment (whichever is longer) or 90 days (if half -life or duration is 
unknown).  
16. Prior treatment with any oligonucleotide or small interfering RNA (siRNA) within 12 
months prior to the first dosing day  
 
DIAGNOSTIC ASSESSMEN TS 
17. Fridericia’s QT corre ction formula (QTcF) ≥450  msec ( if single electrocardiogram  
[ECG] at screening shows QTcF  450 msec, a mean of triplicate measurements  
should be used to confirm that participant meets exclusion criterion ). 
18. Laboratory results as follows  
a. Serum albumin <3.5 g/dL  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 41 
 b. Glomerular filtration rate (GFR) <60 mL/min  /1.73m2 as calculated by the 
CKD -EPI formula (for Japan, JSN -CKDI equation).  
c. INR >1.25  
d. Platelet count <140 X 109/L 
e. Total bilirubin >1.25 x ULN  
i. For participants with benign unconjugated hyperbilirubinemia with 
total bilirubin >1.25 x ULN, discussion for inclusion to the study is 
required with the Medical Monitor  
f. Urine albumin to creatinine ratio (ACR) ≥0.03 mg/mg (or ≥30 mg/g). In the 
event of an ACR above this threshold, eligibility may be confirmed by a 
second measurement  
i. In cases where participant s have low urine albumin and low urine 
creatinine levels resulting in a urine ACR calculation ≥0.03 mg/mg (or 
≥30 mg/g), the investigator should confirm that the participant  does 
not have a history of diabetes, h ypertension or other risk factors that 
may affect renal function and discuss with the Medical Monitor, or 
designee  
 
OTHER EXCLUSIONS  
19. History of/sensitivity to GSK3228836 or components thereof or a history of drug or 
other allergy that, in the opinion of the investigator or Medical Monitor, 
contraindicates their participation  
 
5.3. Lifestyle Considerations  
5.3.1.  Alcohol  and Tobacco  
During each dosing session, participants will abstain from alcohol for 24 hours before the 
start of each scheduled clinic visit  until after they leave the clinic .  
Participants who use tobacco products will be instructed that use of nicotine -containing 
products (including nicotine patches and other delivery devices such as vaporizers)  will 
not be permitted while they are in the clinical unit.  
 
5.3.2.  Activity  
Participants will abstain from strenuous exercise for 48 hours before  each blood 
collection for clinical laboratory tests.   For the duration of the study, until final follow -up, 
participants  are encouraged to refrain from changing their activity beyond that which they 
normally perform.   Additionally, participants will abstain from taking  creatine -containing 
exercise  supplements  for all parts of the study.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomized. A minimal set of screen failure information is 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 42 
 required to en sure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes 
demography, screen failur e details, eligibility criteria, any protocol deviations and any 
serious adverse events (SAEs).  
Individuals who do not meet the criteria for participation in this study (screen failure) 
may not be rescreened  unless discussed and agreed with the Medical Mon itor. Individuals 
who fall out of the screening window, may be rescreened at the discretion of the 
investigator and site.  
5.5. Additional Participant Enrollment  
The planned number of participants will be approximately 440.  
In the case of a disruptive event (e.g ., COVID -19, natural disaster), sites and/or 
participants may be unable to conduct/attend dosing visits, conduct/attend follow -up 
visits, participants may be discontinued from study treatment, and/or participants may be 
withdrawn from the study.  
The study may enrol additional participants to within 10% of the planned 440 participants 
to support a sufficient safety database.   
6. STUDY INTERVENTION  
Study intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo , or medical devi ce(s) intended to be administered to a study participant according 
to the study protocol.  
6.1. Study Intervention (s) Administered  
Study Treatment  
Study Treatment  
Product Name:  GSK3228836  Placebo  
Formulation Description:  Clear colorless to slightly yellow solution  Clear colorless 
solution  
Dosage Form:  Solution for injection  Solution for injection  
Unit Dose Strength(s)/Dosage 
Level(s):  150mg/mL; 1.0mL nominal volume per vial  
(minimal overfill per vial)  Placebo  
Route/Administration/Duration:  SC, multiple  
(once weekly, up to 168 days , plus loading doses ) SC, multiple  
(once weekly, up to 
168 days , plus 
loading doses ) 
Dosing Instructions:  Administer two SC injections of GSK3228836 for 300 
mg dose, one SC injection of GSK3228836 for 150 mg 
dose  (plus one SC placebo dose for blinding purposes)  Administer two SC 
injections for placebo  
Manufacturer/Source of 
Procurement:  GSK GlaxoSmithKline Manufacturing SpA, Parma 
(Italy)  Locally sourced 
normal Saline  
Method for Individualizing 
Dosage  Dispensing  into syringes Dispensing into 
syringes  
SC=subcutaneous  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 43 
 The site of injection will be recorded for each participant  and dose(s).  Sites of injection 
are listed in order of preference and are a guide for the clinical staff.  
1. Abdominal quadrants  
2. Thighs  
3. Outer area of the upper arms  
4. Buttocks  
Injections should be rotated within each anatomical site or site(s) of injection should be 
changed administration -to-administration. Injection into areas with ongoing injection site 
reactions should be avoided.  
6.2. Preparation/Handling/Storage/Accountability  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of t he study intervention.  
Only participants enrolled in the study may receive study intervention and only 
authorized site staff may supply or administer study intervention.  All study interventions 
must be stored in a secure, environmentally controlled, and m onitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited to 
the investigator and authorized site staff.  
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible  for study intervention accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused study intervention 
are provided in the Study  Reference Manual .  
Under normal conditions of handling and administration, study intervention is not 
expected to pose significant safety risks to site staff .  Take adequate precautions to avoid 
direct eye or skin contact and the generation of aerosols or mists.  In the case of 
unintentional occupational exposure notify the monitor, Medical Monitor and/or GSK 
study contact.  
A Material Safety Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either wil l be provided to the 
investigator, where this is required by local laws, or is available upon request from GSK.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
All participants will be centrally randomized using an Interactive Voice/Web Response 
System (IVRS/IWRS).   Before the study is initiated, the telephone number and call -in 
directions for the IVRS and/or the log in information and directions for the IWRS will be 
provided to each site.  
Study intervention will be dispensed at the study visits summa rized in the SoA.  Returned 
study intervention should not be re -dispensed to the participants . 
In case of an emergency, the investigator has the sole responsibility for determining if 
unblinding the participant on their intervention assignment is warranted.  Participant 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 44 
 safety must always be the first consideration in making such a determination.  If the 
investigator decides that unblinding to the participant is warranted, the investigator 
should make every effort to cont act GSK prior to unblinding the participant to their 
intervention assignment unless this could delay emergency intervention of the participant.  
If a participant’s intervention assignment is unblinded , GSK must be notified within 24 
hours after breaking th e blind.  The date and reason that the blind was broken must be 
recorded in the source documentation and case report form, as applicable . 
Participants will be randomized in a 3:3:3:1 ratio to receive study intervention. 
Investigators will be unblinded to e ach participant’s assigned study intervention 
throughout the course of the study.  
Unblinded monitors and , in the event of a Quality Assurance audit, the auditor(s) will be 
allowed access to unblinded study intervention records at the site(s) to verify tha t 
randomization/dispensing has been done accurately.  
A participant may continue in the study if that participant’s intervention assignment is 
unblinded.  
GSK’s Clinical Safety Department  staff may unblind the intervention assignment for any 
participant with  an SAE.  If the SAE requires that an expedited regulatory report be sent 
to one or more regulatory agencies, a copy of the report, identifying the participant’s 
intervention assignment, may be sent to investigators in accordance with local regulations 
and/or GSK  policy.  
6.4. Study Intervention Compliance  
When participants are dosed at the site , they will receive study intervention directly from 
the investigator or designee, under medical supervision.  The date and time of each dose 
administered in the clinic wi ll be recorded in the source documents.  The dose of study 
intervention and study participant identification will be confirmed at the time of dosing 
by a member of the study site staff other than the person administering the study 
intervention.  
6.5. Concomitant  Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements or other specific categories of interest)  that the 
participant is receiving at the time of enrollment or receives during the study  must be 
recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency  
The Medical Monitor should be contacted if there are any questions regarding 
concomitant or prior therapy.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 45 
 Concomitant medications, including NAs (see Section 6.5.2  and Section 6.5.3 ), should be 
recorded.  
Traditional Chinese medicine (TCM) and/or acup uncture as it relates to CHB therapy 
should be avoided during the duration of the study.  If participants report use of TCM 
and/or acupuncture, then details must be recorded in the concomitant medication case 
report form (CRF).  
6.5.1.  Nucleos(t)ide Treatment duri ng and after the End of the Study  
The investigator is responsible for ensuring that consideration has been given to the care 
of the participant’s medical condition, and that participants are able to continue (for 
participants on NA therapy at Baseline, pa rticipants are expected to continue their NA 
therapy over the duration of the study) and/or start standard of care treatment during the 
study period.  
The investigator is responsible for ensuring that consideration has been given to the post -
study care of t he participant’s medical condition, whether or not GSK is providing 
specific post -study treatment.  
For participants who are not receiving NA therapy at baseline, initiate NA therapy if ALT 
≥3x ULN and bilirubin >1.5x ULN, as per Section  7.1.1  (Liver Chemistry Monitoring 
and Stopping Criteria ). NA therapy may be subsequently discontinued if other tests ( e.g., 
HBV DNA, HBsAg) rule out hepatitis B flare .  
6.5.2.  Initiation of N ucleos(t)Ides During GSK3228836 Treatment  
The barrier to development of GSK3228836 resistance is unknown.  Population 
sequencing of isolates from Study ISIS 505358 -CS3 did not detect the development of 
mutations in the GSK3228836 binding site following 4 w eeks of GSK3228836 
monotherapy.   
The risk of resistance development is expected to be lowest in participants receiving 
concomitant NA therapy due to the suppression of HBV viral replication.  Ongoing viral 
replication during GSK3228836 treatment ( e.g., due to virological breakthrough) may 
increase the risk of the development of resistance.  Investigators should therefore 
consider initiation of NAs for participant s not already receiving concomitant NA therapy 
and experience virological breakthrough whil st still receiving GSK3228836 (i.e. , haven’t 
completed treatment).  
Virological breakthrough is defined as one of the following confirmed (2 sequential 
visits) lab results : 
• ≥1 log increase from nadir of HBV DNA  
• HBV DNA becoming quantifiable after being bel ow the LLOQ  
Initiation of NA therapy  should also be considered for participants who are not receiving 
NA therapy at baseline,  but are having either no response or only a partial response to 
GSK3228836 treatment (i.e. Treatment Arms 1 to 3, but not Arm 4 in participants not 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 46 
 currently on NA therapy).  In Arm 4 of the participants not currently on NA therapy, NA 
will be withheld only during the initial 12 -week placebo period. During the la tter part of 
the study when the participants in Arm 4 are receiving activ e GSK3228836, NA therapy 
may be initiated as above if there is concern about developing resistance to GSK3228836 . 
No response to GSK3228836 treatment is defined as:  
• By Week 12, <1 log decline in HBV DNA level from baseline  
 
Partial response to GSK3228836 treatment is defined as:  
• >1 log decline in HBV DNA, but subsequent plateau of HBV DNA levels such 
that achievement of HBV DNA below the LLOQ is considered unlikely  
 
6.5.3.  Initiation of Nucleos(t)ide Therapy Post GSK3228836 Treatment  
Upon cessation of GSK3228836 treatment, participants, regardless of their baseline NA 
use or not, may experience virological relapse, DNA replication and an ALT flare.  
Investigators may, at their own discretion and in accordance with local guidelines, decide 
to initiate new or altern ative NA therapy in these participants. Any treatment should be 
recorded as a concomitant medication.  
6.5.4.  Prohibited Medications and Non -Drug Therapies  
The following concomitant medications are not permitted during the study.  
• PEG -interferon or other immunomodu lating therapies  
• Immunosuppressing drug (e.g., prednisone) use >2  weeks duration from 3  months 
prior to Screening through the final Follow -up visit (see  Section  5.2; unless required for 
safety see Section 7) 
• Prior treatment with any oligonucleotide or small interfering RNA (siRNA) within 12 
months prior to the first dosing  
• Creatine -containing gym supplements   
• Anti-coagulation therapies (e.g., warfarin, Factor Xa inhibitors or anti -platelet agents 
like clopidogrel).  
6.6. Dose Modification  
Dose modifications are not planned for this study.  
6.7. Intervention after the End of the Study  
No intervention is planned at the end of the study, although participants  may be asked to 
enrol in a long -term roll -over study.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 47 
 7. DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Intervention  
A participant may withdraw from the study treatment at any time at his/her own req uest 
or may be withdrawn at any time at the discretion of the Investigator for safety, 
behavioural or administrative reasons.  Participants that are discontinued from treatment 
will enter the post -treatment period unless consent is withdrawn.  Every effort  should be 
made to complete the early termination (ET) study procedures and observations if the 
participant does not enter post -treatment follow -up. 
Any laboratory parameter that meets the stopping criteria should be repeated to confirm 
the value prior to withdrawal  
In rare instances, it may be necessary for a participant to permanently discontinue 
(definitive discontinuation)  study intervention.  If study intervention is definitively 
discontinued, the participant may remain  in the study to be evaluated for  safety and 
efficacy assessments . For participants meeting the stopping criteria (Section 7.1.1 - 
Section  7.1.4 ), participants should be monitored until laboratory abnormalities resolve, 
stabilize, or return to within baseline values as indicated.  The participant must then 
attend the follow -up visi ts specified in the SoA.  See the SoA for data to be collected at 
the time of discontinuation of study interve ntion and follow -up and for any further 
evaluations that need to be completed.  
7.1.1.  Liver Chemistry Monitoring and Stopping Criteria  
Liver chemistry mo nitoring and stopping criteria have been designed to assure participant 
safety and to evaluate liver event etiology.  Study intervention will be discontinued for a 
participant if the liver stopping criteria are met. Restart/re -challenge guidelines are 
presented in Section 10.6. 
Discontinuation of study intervention for abnormal liver tests is required when:  
• a participant meets one of the discontinuation conditions outl ined in Table 6 
• when in the presence of abnormal liver chemistries not meeting protocol -specified 
stopping rules, the investigator believes study intervention discontin uation is in 
the best interest of the participant.  
Table 6 lists the criteria for withholding or discontinuing the study medication in a study 
participant with elevati on of ALT.   Additional testing will be performed  (see safety 
follow -up procedures for participants who meet increased monitoring or stopping criteria)  
and the participant  monitored until liver chemistr y abnormalities  resolve, stabilize, or 
return to within baseline values.  The participant  must then attend the follow -up visits 
specified in the SoA.  
Every attempt must be made to have the participant  evaluated (within 24 hours)  for repeat 
assessment of liver chemistries and additional testing and close monitoring (a specialist 
or hepatology consultation is recommended).  Participant s must be monitored twice 
weekly  until liver chemistr y abnormalities  (ALT, AST, alkaline phosphatase, bilirubin) 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 48 
 resolve, stabilize, or return to within baseline values.  Upon  completion of the safety 
follow -up procedures  (see below) , the participant  must attend the follow -up visits 
specified in the  SoA. 
Table 6 Liver Chemistry Monitoring and Stopping Criteria - 
ALT Level  Monitoring Plan  Discontinuation  
 
10x ULN ≤ ALT <12x ULN  
and 
Bilirubin ≤1.5x ULN  
and 
INR ≤1.5 (if available)  Monitor twice weekly  
Additional lab assessments  Permanently discontinue 
IMP if ALT >10x ULN 
>4 weeks  
 
 
ALT 12x ULN  
and 
Bilirubin ≤1.5x ULN  
and 
INR ≤1.5 (if available)  Hold dose  
Monitor twice weekly  
Additional lab assessments if not 
already done  
Take off hold:  150 mg SC weekly 
when ALT <10x ULN ; increasing dose 
to 300 mg (if applicable) should be 
agreed with Medical Monitor   
Permanently discontinue 
IMP if any of the following 
apply:  
• ALT 10x ULN 
>4 weeks  
• ALT 12x ULN recurs 
after IMP taken off hold  
ALT 3x ULN  
and 
1.5x ULN < bilirubin  ≤2x ULN 
(>35%  direct)  
and 
INR ≤1.5 (if available)  Hold dose  
Monitor twice weekly  
Additional lab assessments if not 
already done  
Take off hold:  150 mg SC weekly 
when bilirubin returns to <1.5x ULN; 
increasing dose to 300 mg (if 
applicable) should be agreed with 
Medical Monitor  
 
For participants not receiving NA 
therapy at baseline , initiate NA 
therapy1  
Permanently discontinue 
IMP if the followin g recurs 
after IMP taken off hold:  
1.5x ULN < bilirubin  ≤2x 
ULN (>35%  direct)  
And 
INR 1.5 (if available)  
ALT 3x ULN  and any of the 
following apply:  
• bilirubin >2x ULN 
(>35%  direct)  
• associated with the 
appearance  
or worsening of hepatitis 
symptoms  
• INR >1.5 (if available)    
Permanently discontinue 
IMP 
 
Monitor twice weekly until 
stable ALT  
 
Additional lab assessments 
if not already done   
For participants not 
receiving NA therapy at 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 49 
 ALT Level  Monitoring Plan  Discontinuation  
baseline , initiate NA 
therapy1 
ALT = alanine aminotransferase; IMP = investigational medicinal product; ULN = upper limit of normal  
1. NA therapy may be subsequently discontinued if other tests ( e.g., HBV DNA, HBsAg) rule out hepatitis B flare . 
 
*Notes:  
• Any abnormal laboratory parameters that meet the criteria for individua l treatment 
discontinuation  must be confirmed by retest of a new collection of blood samples 
as soon as possible.  
• Deterioration considered clinically significant from the baseline in the liver 
parameters must be confirmed by retesting ALT, total bilirubin, direct bilirubin , 
and INR (if available).   
• If one criterion in the list above is met and confirmed by retesting, further 
treatment may be discontinued  for this participant  after discussion with the 
Medical Monitor.  Results of retesting must be evaluated before the next dose is 
administered.  
• Monitor participant  until liver chemistr y abnormalities  resolve, stabilize, or return 
to within baseline values . 
• Cases such as Gilbert syndrome, where baseline bilirubin values are high, should 
be discussed w ith the Medical Monitor, to assess if it is a case of DILI or the 
participant may continue with dosing.  
 
The procedures listed below are to be followed if a participant meets any of the liver 
event  criteria defined in Table 6: 
• Notify the Medical Monitor within 24  hours of learning of the abnormality to 
confirm the participant ’s study treatment cessation and follow -up. 
• Complete the Liver Event CRF.  
• Complet e the “Safety Follow -up Procedures” listed below.  
 
Safety Follow -up Procedures for Participant s Who Meet Any of The Liver 
Monitoring and Stopping Criteria:  
Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing)  
o Hepatitis E IgM antibody  
o Hepatitis B virus DNA load  
o Hepatitis C virus RNA load  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 50 
 o Hepatitis D virus antibody  
Obtain a blood sample for pharmaco kinetic (PK) analysis as soon as possible following 
the occurrence of an event. Record the date/time of the PK blood sample collection and 
the date/time of the last dose of study treatment prior to blood sample collection on the 
CRF. If the date or time of  the last dose is unclear, provide the participant ’s best 
approximation. Instructions for sample handling and shipping are included in the Study 
Reference Manual (SRM).  
Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH).  
Review f ractionate d bilirubin  
Assess eosinophilia  
Record the appearance or worsening of clinical symptoms of hepatitis (fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash or eosinophilia) as relevant 
on the Adverse Event (AE) CRF.  
Record use of c oncomitant medications, acetaminophen, herbal remedies, other over the 
counter medications, or putative hepatotoxins on the Concomitant Medications CRF.  
Record alcohol use on the Liver Alcohol  CRF.  
 
The following are required for participant s who meet the ALT and bilirubin 
stopping  criteria but are optional for other abnormal liver chemistries . 
• Anti-nuclear antibody, anti -smooth muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies and quantitative total immunoglobulin G (IgG or 
gamma globulins).  
• Serum acetaminophen adduct high performance liquid chromatography 
(HPLC) assay (quantifies potential acetaminophen contribution to liver injury 
in participant s with definite or likely acetaminophen use in the preceding 
week [ James , 2009]) , if available.  
• Liver imaging (ultrasound, magnetic resonance, or computerized tomography) 
or Liver biopsy to evaluate liver disease.  
o The Liver Imaging and/or Liver Biopsy CRFs  are also to be completed if these 
tests are performed.  
7.1.2.  Drug Induced Vascular Injury and Complement Stopping Criteria  
If any of the following are observed, results should be confirmed with a repeat sample 
collection and analysis , and if confirmed, further evaluation for alternative causes should 
be pursued in consultation with the Medical Monitor.  
Repeat sample collection of C3, C4, Bb, C5a would be triggered by changes in the 
clinical signs and symptoms of complement activation  (≥2+ haematuria; increasing urine 
ACR; vasculitic or purpuric rash; peripheral neuropathy; jaundice) . Additional 
complement analyses for example CH50, Factor B level, Factor H level, sC5b -9 should 
also be considered in discussion with the Medical Monitor and Safety Panels.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 51 
 1. Persisting  & deteriorating longitudinal trends in change from baseline for 
C3 and/or C4 defined as:  
a. If participant ’s baseline C3 and/or C4 is within  the lab’s normal range at 
baseline: there is a sequential decline in C3 and/or C4 once levels have 
fallen below LLN f or ≥4 weeks OR  
b. If participant ’s baseline C3 and/or C4 is below  the lab’s LLN at baseline: 
there is further sequential decline in C3 and/or C4 for ≥4 weeks OR  
c. Regardless of baseline C3 and/or C4 level: there is a ≥80% reduction  in 
the participant ’s C3 and/o r C4 level at any point  
AND  
d. There is an associated ≥3-fold increase  in Bb and/or C5a from 
participant ’s baseline OR  
e. There are associated biochemical sequelae for example, a rising high 
sensitivity C -reactive protein  (hs-CRP ); rising monocyte chemoattractant 
protein -1 (MCP -1); new thrombocytopenia, new renal impairment with no 
other explanation such as intercurrent infection OR  
f. There are associated clinical sequelae, for example, ≥2+ haematuria; 
increasing urine ACR; vasculitic or purpuric rash ; peripheral neuropathy; 
jaundice OR  
g. There is new cANCA or pANCA positivity  
 
2. Persisting & deteriorating longitudinal trends in change from baseline for 
Bb and/or C5a where  
a. There is a ≥3 -fold increase in Bb and/or C5a over baseline  
AND  
b. This is persisting or  increasing week on week in sequential data plots OR  
c. There are associated biochemical sequelae for example, a rising hsCRP; 
rising MCP -1, new thrombocytopenia, new renal impairment with no 
other explanation such as intercurrent infection OR  
d. There are assoc iated clinical sequelae, for example, ≥2+ haematuria; 
increasing urine ACR, vasculitic or purpuric rash; peripheral neuropathy; 
jaundice or any combination of these OR  
e. There is new cANCA or pANCA positivity  
 
Treatment Hold/Treatment Discontinuation  
• Hold study treatment during evaluation of alternative causes for decreased C3 
and/or C4 associated with increased inflammatory markers including one or more 
of hs -CRP, MCP -1, Bb and C5a  
• Discontinue study treatment  permanently  if persistent change from baseline 
(≥4 weeks) in biomarker pattern ( decreased C3/C4 associated with increased 
inflammatory markers including one or more of hsCRP, MCP -1, Bb, C5a)  without 
clear alternative explanation.  
• Discontinue study treatment  permanently  if suspect clinical sequelae of  
complement activation, drug induced vascular injury, vasculitis or auto -immunity 
regardless of biomarkers changes or persistence.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 52 
 7.1.3.  Haematological Stopping Criteria  
If a participant  develops signs or symptoms of thrombocytopenia, obtain a platelet count 
(local lab)  as soon as possible and hold dosing until the platelet count is confirmed.  
 
If the platelet count is uninterpretable  or a decreasing trend is noted below LLN reference 
range, re -check the platelet counts as soon as possible (the investigator ma y, at their 
discretion, opt to have the participant come to their next scheduled visit OR ask the 
participant to come earlier than their scheduled visit, as they feel appropriate based on 
review of the participant’s clinical presentation and laboratory res ults). Samples showing 
platelet clumping should also be repeated.  
 
Participant s with  platelet  values below 75 x 109/L will undergo further assessment 
including, but not necessarily limited to, anti -platelet antibodies . If the participant  has a 
positive ant i-platelet antibody, study treatment should be discontinued  permanently . 
Monitor until platelet abnormalities resolve, stabilize, or return to within baseline values.  
 
Table 7 Haematological Stopping Criteria  
Platelet Count  Monitoring  Treatment  
75 X 109/L ≤ 
Platelets <100 X 
109/L Monitor weekly, results of local platelet count 
must be available prior to dosing  Hold treatment until platelets return to  100 
x109/L 
[if positive for anti -platelet antibodies, study 
treatment should be discontinued 
immediately]  50 X 109/L ≤ 
Platelets1 <75 X 
109/L Monitor every 2 -3 days until three successive 
measurements  75 x109/L, then weekly  
Assess anti -platelet antibodies  
<50 x 109/L Monitor daily until 25 x109/L, monitor every 2 -
3 days until three successive measurements 
75 x109/L, then weekly  until platelets ≥100 
x109/L 
Assess anti -platelet antibodies  Discontinue  treatment permanently  
Glucocorticoids recommended (unless the 
participant has a medical contraindication to 
receiving glucocorticoids), and 
discontinuation of any antiplatelet medicinal 
products/NSAIDs/anticoagulants  
 
7.1.4.  Drug Induced Kidney Injury (Renal) Stopping Criteria  
If any of the following are observed, results should be confirmed , and if confirmed, 
further evaluation for alternative causes should be pursued in consultation with the 
Medical Monitor:  
• Persistent ACR 0.03 mg/mg (30 mg/g)  
• Blood in urinalysis 5 RBC per high power field  (HPF) confirmed by urine 
microscopy  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 53 
 • Persistent elevation of serum creatinine (>26.52 mol/L or 0.3 mg/dL change 
from baseline)  
Following confirmation of the criteria above, further evaluation may include but not be 
limited to a 24 -hour urine analysis, consultation with a nephrology specialist, renal 
ultrasound, urine microscopy, serum urea and creatinine, platelet count, urgent serum 
vasculitis screen [including ANCA, ANA, dsDNA, cryoglobulins], serum protein 
electrophoresis (SPEP)/ urine protein electrophoresis (UPEP), and complement panel (C3, 
C4, C5a and Bb).  Further evaluation and actions should be determined by the 
investigator in consultation with the Medical Monitor.  
Treatment Hold/Treatment Discontinuation  
• Hold study treatmen t in participant s who develop ACR ≥0.5 mg/mg (500 mg/g), 
or eGFR >25% reduction from pre-dose range , pending consultation with the 
Medical Monitor and further evaluation of the cause.  
o If a dose is held, once eGFR increases to within baseline, ACR decreases 
to <0.5 mg/mg (500 mg/g), or the underlying cause of the decline in renal 
function is corrected, weekly dosing may be reinitiated after consultation 
with the Medical Monitor  
o Participa nts must be monitored weekly until ACR or eGFR resolve, 
stabilize, or return to within pre-dose range  
• Hold study treatment in participant s with ACR ≥2 mg/mg (2000 mg/g), perform 
further evaluation for acute glomerulonephritis, as clinically indicated.  If acute 
glomerulonephritis is confirmed or probable (i.e., meets clinical definition of 
rapidly progressive glomerulonephritis [RPGN] if biopsy not feasible), 
GSK3228836 should be permanently discontinued  
o Participant s must be monitored weekly until ACR resol ves, stabilize s, or 
return s to within baseline values  
• Delay in treatment of suspected RPGN should be avoided.  
7.1.5.  Study Intervention Restart or Rechallenge after stopping criteria 
met 
Study intervention rechallenge after stopping criteria are met  (i.e., study treatment 
discontinued)  by any participant in this study is not allowed.  Study intervention restart 
may be considered only for liver events as follows:  
Restart Following Transient Resolving Liver Stopping Events Not Related to Study 
Intervention  
Restart re fers to resuming study intervention following liver stopping events in which 
there is a clear underlying cause (other than drug -induced liver injury [DILI]) of the liver 
event (e.g. biliary obstruction, pancreatic events, hypotension, acute viral hepatitis ). 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 54 
 Furthermore, restart is not permitted following liver stopping event when the underlying 
cause was alcohol -related hepatitis.  
• Approval by GSK for study intervention restart can be considered where:  
o Investigator requests consideration for study intervent ion restart if liver 
chemistries have a clear underlying cause (e.g., biliary obstruction, hypotension 
and liver chemistries have improved to normal or are within 1.5 x baseline and 
ALT <3xULN).  
o Possible study intervention -induced liver injury has been exc luded by the 
investigator and the study team. This includes the absence of markers of 
hypersensitivity (otherwise unexplained fever, rash, eosinophilia). Where a study 
intervention has a confirmed genetic marker associated with liver injury, the 
presence o f the marker should be excluded. If study intervention -related liver 
injury cannot be excluded, the guidance on rechallenge will apply.  
o There is no evidence of alcohol -related hepatitis.  
o Institutional Review Boards (IRB)/Independent Ethics Committees (IEC)  
approval of study intervention restart has been obtained (if required).  
If restart of study intervention is approved by GSK Medical Governance in writing:  
• the participant must be provided with a clear description of the possible benefits and 
risks of study intervention administration including the possibility of recurrent, more 
severe liver injury or death.  
• The participant must also provide signed informed consent specifically for the restart 
of study intervention (refer to Section 10.1.3 ). Documentation of informed consent 
must be recorded in the study file.  
• Study int ervention must be administered at the dose specified by GSK  
• Participants approved by GSK for restart of study intervention must return to the 
clinic twice a week for liver function tests until stable liver function tests have been 
demonstrated and then sta ndard laboratory monitoring may resume as per protocol.  
• If the participant meets protocol -defined liver chemistry stopping criteria after study 
intervention restart, study intervention should be permanently discontinued.  
• The Medical Monitor, and the IRB/IE C, must be informed of the outcome for the 
participant following study intervention restart.  
• GSK must be notified of any adverse events.  
For treatment that has been placed on hold, please follow the guidelines above ( Section 
7.1.1  to Section 7.1.4 ). 
7.2. Participant Discontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at his/her own request or 
may be withdrawn at any time at the discretion of the investigator for safety, 
behavioral, compliance or administrative reasons.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 55 
 • The investigator may ask participants to withd raw from study treatment, but 
continue with post -treatment follow up visits instead of withdrawing completely 
from the study.  
• At the time of discontinuing from the study, if possible, an early termination 
visit should be conducted, as shown in the SoA. See  SoA for data to be collected 
at the time of study discontinuation and follow -up and for any further 
evaluations that need to be completed.  
• The participant will be permanently discontinued both from the study 
intervention and from the study at that time.  
• If the participant withdraws consent for disclosure of future information, the 
sponsor may retain and continue to use any data collected before such a 
withdrawal of consent.  
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site 
study records.  
7.3. Lost to Follow Up  
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted b y the study site.  
The following actions must be taken if a participant fails to return to the clinic for a 
required study visit:  
• The site must attempt to contact the participant and reschedule the missed visit 
as soon as possible and counsel the participa nt on the importance of maintaining 
the assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study.  
• Before a participant is deemed lost to follow up, the investigator or designee 
must make every effor t to regain contact with the participant (where possible, 3 
telephone calls and, if necessary, a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact attempts should be 
documented in the participant’s  medical record.  
• Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix 1 . 
8. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their timing are summarized in the SoA.  
• In selected sites/ countries, participant s will have the option to use a centralised home 
nursing pr ovider. Only selected visits will have the option to be performed as a home 
visit, these will include drug administration, blood draws, participant  assessments 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 56 
 and data collection. The full specifications of the home nursing services will be 
outlined in th e SRM  
• Protocol waivers or exemptions are not allowed . 
• Immediate safety concerns should be discussed with the sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or 
discontinue study intervention.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed  and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigato r will maintain a screening 
log to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (e.g., 
blood co unt) and obtained before signing of ICF may be utilized for screening or 
baseline purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA.  
• Repeat or unscheduled samples may be taken for  safety reasons or for technical 
issues with the samples.  
8.1. Efficacy Assessments  
The primary objective measurements for efficacy include:  
• HBsAg  
• HBV DNA  
HBsAg and HBV DNA are collected as per the SoA.  Details of sample collection can be 
found in the SRM.  
The primary efficacy endpoint is sustained virologic response, which is a composite 
endpoint defined as HBsAg <LLOQ and HBV DNA <LLOQ at the end of GSK3228836 
treatment which is sustained for 24 weeks post -GSK3228836 treatment.  Seroclearance 
refers to participant s with HBsAg and HBV DNA <LLOQ (with  or without the formation 
of HBs -antibody) .  Seroconversion refers to participant s with HBsAg and HBV DNA 
<LLOQ plus formation of HBs -antibody .  Both terms are used to evaluate efficacy.  For 
the purposes of this st udy, sustained response is defined as a continuous 24 weeks from 
end of GSK3228836 treatment during which levels of HBsAg in serum remain less than 
LLOQ  and HBV DNA less than LLOQ.  
Any HBsAg greater than LLOQ  or HBV DNA greater than LLOQ after achieving 
HBsAg seroclearance and HBV DNA suppression needs to be confirmed by re -test 
within 1 week of receiving the test result .  The re-test result will be used if the first test  is 
not confirmed . 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 57 
 8.2. Safety Assessments  
Planned time points for all safety assessments are provided in the SoA.  Additional time 
points for safety tests (such as vital signs, physical exams and laboratory safety tests) 
may be added during the course of the study based on newly available data to ensure 
appropriate safety monitoring.  
8.2.1.  Physical Examinations  
A complete physical exam will be conducted at the Screening visit.  Symptom -directed  
exams will be conducted at all other time points.  
• A complete physical exam will include, at a minimum, assessment of the 
dermatologic, cardiovascular, respi ratory, gastrointestinal, and neurological systems. 
Height and weight will also be measured and recorded (with participant wearing 
daytime clothing with no shoes).  
• A symptom -directed  exam will include, at a minimum , assessments of the 
dermatologic, cardio vascular, respiratory, and gastrointestinal systems.  
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
8.2.2.  Injection Site Reactions  
Injection Site Reactions  (ISRs)  are any experiences which occur at the site of  injection of 
the study treatment. Participants will be monitored closely for ISRs  and ISRs should be 
recorded as AEs   
Injection site reactions will be graded according to the criteria provided in the Division of 
AIDS ( DAIDS ) grading table (see Appendix  3). 
8.2.3.  Vital Signs  
• Temperature, pulse rate, respiratory rate, and blood pressure will be assessed.  
• Blood pressure and pulse measurements will be assessed  with a com pletely 
automated device. Manual techniques will be used only if an automated device 
is not available.  
• Blood pressure and pulse measurements should be preceded by at least 5 
minutes of rest for the participant in a quiet setting without distractions (e.g.,  
television, cell phones).  
• Vital signs will be measured in a semi -supine position (preferred, but not 
required) after 5 minutes rest and will include temperature, systolic and diastolic 
blood pressure, and pulse and respiratory rate.  
• If assessments are sc heduled for the same nominal time, then 12 -lead ECG and 
vital signs must be completed prior to blood collection. The order of conducting 
the 12 -lead ECG and vital sign measurements is flexible but should allow the 
blood collection to occur at the exact nom inal time.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 58 
 8.2.4.  Electrocardiograms  
The ECG is for screening purposes only . 
Single 12 -lead ECG will be obtained locally as outlined in the SoA (see Section 1.3) 
using an ECG machine that automatically calculates the heart rate and measures PR, 
QRS, QT, and QTc intervals . Manual calculation, if an automatic calculation is not 
available, is acceptable . 
 
8.2.5.  Clinical Safety Laboratory Assessments  
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and frequ ency.  
• The investigator must review the laboratory report, document this review, and 
record any clinically relevant  changes occurr ing during the study in the AE 
Section of the CRF. The laboratory reports must be filed with the source 
documents. Clinically significant abnormal laboratory findings are those which 
are not associated with the underlying disease, unless judged by the investigator 
to be more severe than expected for the participant's condition.  
• All laboratory tests with values considered clinical ly significantly abnormal 
during participation in the study should be repeated until the values return to 
normal or baseline or are no longer considered significantly abnormal by the 
investigator or Medical Monitor.  
• If such values do not return to normal/ baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified, and the sponsor 
notified.  
• If such values do not return to normal/baseline or are still considered 
significantly abnormal by the investigator by the p articipant’s last visit, 
additional follow -up should be discussed with the sponsor.  
• All protocol -required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the SoA.  
8.3. Adverse Events and Serious Adverse Events  
The definitions of an AE or SAE can be found in Appendix 3 . 
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, 
or the participant's legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, 
and reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study intervention or the 
study, or that caused the participant to discontinue the study intervention (see Sec tion 7).  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 59 
 8.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
• All AEs and SAEs will be collected from the signing of the informed consent  
until the final follow -up visit  at the time points specified in the SoA (Section 
1.3). However, AEs and SAEs that occur prior to the first a dministration of 
investigational medicinal product should be recorded only if assessed as related 
to study participation (e.g., protocol -mandated procedures or invasive tests).  
• Medical occurrences that begin before the start of study intervention but after  
obtaining informed consent will be recorded on the Medical History/Current 
Medical Conditions section of the CRF not the AE section.  
• All SAEs will be recorded and reported to the sponsor or designee immediately 
and under no circumstance should this exceed  24 hours,  as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor 
within 24  hours of it being available.  
• Investigators ar e not obligated to actively seek AEs or SAEs after the conclusion 
of the study participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been discharged from the 
study, and he/she considers the ev ent to be reasonably related to the study 
intervention or study participation, the investigator must promptly notify the 
sponsor.  
8.3.2.  Method of Detecting AEs and SAEs  
• The method of recording, evaluating, and assessing causality of AEs and SAEs 
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 3 . 
• Care will be tak en not to introduce bias when detecting AE and/or SAE.  Open -
ended and non -leading verbal questioning of the participant is the preferred 
method to inquire about AE  occurrence.  
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is  required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  will be followed until the event is 
resolved, stabilized, otherwise explained, or the participant is lost to follow -up (as 
defined in Section 7.3). Further information on follow -up procedures is given in 
Appendix 3 . 
8.3.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by the investigator to the sponsor of a SAE is essential so 
that legal obligations and ethical responsibilities towards the safety of 
participants and the safety of a study intervention under c linical investigation 
are met.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 60 
 • The sponsor has a legal responsibility to notify both the local regulatory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRB/IEC, and investigators.  
• For all studies except those utilizing medical devices investigator safety reports 
must be prepared for suspected unexpected serious adver se reactions (SUSAR) 
according to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary.  
• An investigator who receives an investigator safety report describing a SAE or 
other specific safety information e.g., summary o r listing of SAEs) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify the IRB/IEC, if appropriate according to local requirements.  
 
8.3.5.  Pregnancy  
• Details of all pregnancies in female will be collected after the  start of study 
intervention and until  no longer than 6 to 8 weeks following the estimated 
delivery date . 
• If a pregnancy is reported, the investigator should inform GSK within 24 hours 
of learning of the pregnancy and should follow the procedures outlined in 
Appendix  4. 
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE.  
8.3.6.  Cardiovascular and Death Events  
For any cardiovascular events and all deaths, whether or not they are considered SAEs, 
specific Cardiovascular (CV) and Death sections of the CRF will be required to be 
completed. These sections include questions regarding c ardiovascular (including sudden 
cardiac death) and non -cardiovascular death.  
The CV CRFs are presented as queries in response to reporting of certain CV medical 
dictionary for regulatory activities  (MedDRA ) terms.  The CV information should be 
recorded in  the specific cardiovascular section of the CRF within one week of receipt of a 
CV Event data query prompting its completion.  
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within  one 
week of when the death is reported.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 61 
 8.3.7.  Adverse Events of Special Interest  
8.3.7.1.  ALT Increases  
The liver is a site of accumulation of antisense oligonucleotides and this has been 
exploited in the treatment of liver relat ed diseases.  
Outside the setting of disease reactivation or rebound viremia, the aetiology of ALT 
increase (flares) in CHB patients is currently uncertain. It has been postulated that ALT 
flares are evidence of reactivation of the immune system in the liv er with accompanying 
clearance of infected hepatocytes, particularly when observed during immunotherapy or 
spontaneous loss of HBsAg. Therapeutic ALT flares have been shown to correlate with 
antiviral effect in blood (i.e. declines in HBV DNA, and/or HBsAg ). 
A monitoring strategy of ALT is presented in Section 7.1.1  
8.3.7.2.  Vascular Inflammation and Complement Activation  
Inflammatory and immune changes are recognized as a clas s effect of ASOs .  Despite the 
low risk for ASO -related vascular adverse events in patients, the nature of the toxicity 
demands a conservative approach to care and monitoring to ensure the safety of 
participants.  Because the complement -mediated mechanism of vascular inflammation in 
monkeys has been well established, a monitoring strategy has been proposed in 
participants that encompasses a multi -pronged approach for monitoring of this toxicity, 
from separate mechanistic, phenotypic and organ -specific persp ectives.  
Vascular inflammation will be monitored through various inflammatory markers (e.g., 
complement factors, hs -CRP, ANCA, MCP -1) and presence of clinical signs and 
symptoms.  
A monitoring strategy of vasculitis and complement activation is presented in  Section 
7.1.2  
8.3.7.3.  Thrombocytopenia  
Thrombocytopenia, decreased platelets, is a well -recognized toxicity associated with 
ASOs and is monitorable in the clinic.  Two types  of thrombocytopenia have been 
described by the FDA amongst the 2 -MOE ASOs.  One type is a rapid onset, 
unpredictable thrombocytopenia that may present with mild or moderate bleeding, 
however, catastrophic, fatal bleeding can occur.  The other more common type is 
characterised by a gradual decline in platelets leading to mild to severe thrombocytopenia 
and can be asymptomatic or associated with mild to severe bleeding.  
A monitoring strategy of platelet count is presented in Section 7.1.3  
8.3.7.4.  Renal Injury  
Glomerulonephritis, including rapidly progressing glomerulonephritis , has been reported 
with ASOs and is thought to be a result of the proinflammatory effect of ASOs.  
Accumulation of antisense oligonucleotides in proximal tubule cells of the kidney, is 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 62 
 thought to sometimes lead  to increased tubular proteinuria  (as d escribed in preclinical 
studies ).  Increases in urine protein have been described in the clinic.  
A monitoring  strategy of renal function (e.g., SCr, ACR) is presented in Section 7.1.4  
8.3.7.5.  Injection Site Reactions  
Injection site reactions were the most commonly reported treatmen t-related adverse event  
in previous studies with GSK3228836 . Injection site reactions included, but were not 
limited to, pain, erythema and pruritus. Injection site reactions will be assessed at all 
dosing visits and, if present, should be reported as AEs.  
8.4. Treatment  of Overdose  
For this study, any dose of GSK3228836  greater than 300 mg within a 24 -hour time 
period will be considered an overdose.  
GSK does not recommend specific treatment for an overdose.  
In the event of an overdose, the investigator should:  
1. Contact the Medical Monitor immediately.  
2. Closely monitor the participant for AE/SAE and laboratory abnormalities until 
GSK3228836 can no  longer be detected systemically (at least 105 days).  
3. Obtain a plasma sample for PK analysis within 1 day from the date of the last dose of 
study intervention if requested by the Medical Monitor ( determined on a case -by-
case basis).  
4. Document the quantity of the excess dose as well as the duration of the overdosing in 
the CRF.  
Decisions regarding dose interruptions or modifi cations will be made by the investigator 
in consultation with  the Medical Monitor based on the clinical evaluation of the 
participant.  
8.5. Pharmacokinetics  
Blood  samples will be collected for measurement of plasma concentrations of 
GSK3228836 and/or  nucleos (t)ide as specified in the SoA . 
• For standard PK sampling, one pre -dose PK sample at each visit during the treatment 
period (except for Day 4 and Day 11) and one PK sample at any time at each visit 
during the  off-treatment  period will be collected in participa nts from all 8 study arms.  
• For intensive PK sampling, a  maximum of 13 samples  in addition to the standard PK 
sampling  may be collected from 39 participants who were on stable NA therapy at 
baseline (13 in each region of Japan, China, and non -Asian country/ ies) at one 
additional time point during the study .  The intensive PK sampling will be collected  
at one visit between Week 14 (inclusive) and Week 24 (inclusive), chosen between 
the site and participant . See Table 8 for sample collection timings.  The timing of 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 63 
 sampling may be altered during the course of the study based on newly available data 
(e.g., to obtain data closer to the time of peak plasma conce ntrations) to ensure 
appropriate monitoring.  
• At the visit for intensive PK sampling, GSK3228836  and nucleos (t)ide will be 
administered as close together as possible, and t he date and time (24-hour clock time) 
of administration of both drugs will be recorde d. Instructions for drug administration 
at the visit for intensive PK sampling will be provided by the sponsor .  See SRM for 
details.  
• Instructions for the collection and handling of biological samples will be provided by 
the sponsor. The actual date and ti me (24 -hour clock time) of each sample will be 
recorded.  
• Standard PK s amples will be used to evaluate the PK of GSK3228836 , and explore 
PK-PD relationships . 
• For participants in the intensive PK sampling, samples will be used to evaluate the 
PK of GSK322883 6 and nucleos(t)ide therapy. See Table 8.  
• Samples collected for PK analyses may also be used to evaluate safety or efficacy 
aspects related to concerns arising during o r after the study.  
• Genetic analyses will not be performed on these plasma samples unless consent for 
this was included in the informed consent. Participant confidentiality will be 
maintained. At visits during which plasma samples for the determination of m ultiple 
aspects of GSK3228836 will be taken, one sample of sufficient volume can be used.  
• Drug concentration information and accompanied CRF information that would 
unblind the study will not be reported to blinded GSK personnel until the study has 
been unb linded.   See SRM for details.  
Table 8 Sample Collection Schedule for Intensive PK Sampling  
 Pre-
Dose  0.5 
hr 1 
hr 1.5 
hr 2 
hr 3 
hr 4 
hr 5 
hr 6 
hr 8 
hr 12 
hr 24 
hr 72 
hr 168 
hr1 
GSK3228836  X  X  X X X X X X X X X X 
Nucleos(t)ide  X X X X X X X X X X X X   
1. The 168 hr timepoint occurs approx. 7 days ( 24 hrs) after the dose. The site should align this PK timepoint 
collection with the next study visit as close to the nominal timepoint as possible ( 24 hrs), then the 168 hr PK can 
be collected as the next pre -dose PK sample (for example if the participant has their intensive PK visit at Week 16 
then the pre -dose PK at Week 17 would suffice and a separate 168 hr PK collection is not required, decreasing 
the participant’s scheduling burd en) 
8.6. Pharmacodynamics  
Pharmacodynamic parameters explored in  this study  will include but are not limited to : 
• Categorical: v irologic response, seroclearance (HBsAg), HBV DNA level below 
LLOQ, and seroconversion (HBsAb and HBeAb);  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 64 
 • Change from baseline: HBsAg, HBV DNA, HBeAg, and HBsAb levels.  
• Time to event: v irologic response, nadir of HBsAg and HBV DNA, seroclearance 
(HBsAg), HBV DNA level below LLOQ, seroconversion (HBsAb and HBeAb);  
peak of ALT flares ; 
• Safety assessments includ ing but not limited to vital signs, electrocardiograms, 
laboratory measurements and adverse events . 
8.7. Genetics  
A blood  sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analysis component of the study .  Participation is 
optional.  Participants who do not wish to participate in the genetic research may still 
participate in the study.  
In the event of DNA extraction failure, a replacement genetic blood sample may be 
requested from the participant.   Signed  informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.  
See Appendix  5 for information regarding genetic research.   Details on processes for 
collection and shipment and destruction of these samples can be found in the SRM.  
8.8. Biomarkers  
Collection of samples for other biomarker research is also part of this study. These 
exploratory biomarker samples will be collected to ev aluate the pathogenesis of CHB; the 
absorption, distribution, metabolism, or excretion of GSK3228836; or the participant’s 
response to GSK3228836.  In addition, continuing research may identify other proteins , 
transcripts or biomarkers related to  GSK3228836  treatment, the response to 
GSK3228836 or the pathogenesis of CHB , which will be evaluated in these samples.  
• Blood samples, including serum, plasma, PBMCs and PAXgene tubes, will be 
collected to evaluate virologic and immune biomarkers related to the path ogenesis 
of CHB and the participant’s response to GSK3228836. Samples will be collected 
according to the schedule described in the SoA and as detailed in the laboratory 
manual provided separately to sites . 
• GSK may store samples for up to 15 years after  the end of the study. The 
archived samples may be used for the purpose of follow -up exploration of 
laboratory findings and/or AEs (e.g., measurement of cytokine or chemokine 
levels, measurement of additional markers of kidney function, measurement of 
antibodies, etc.).  The archive samples may also be used for studying biomarkers 
that may be affected by treatment, such as HBcrAg, HBV RNA or indoleamine 
2,3 dioxygenase (IDO), or other immune -related responses.  Additionally, 
samples may be used for further research by GSK or others such as universities 
or other companies to contribute to the understanding of  chronic hepatitis B or 
other diseases, the development of related or new treatments or research 
methods.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 65 
 For China, see Appendix 7 on biomarkers.  
8.9. HBV Resistance Monitoring  
Samples collected for viral genotyping and phenotyping may be used for HBV resistance 
mutation analysis .  Viral DNA and/or viral RNA will be extracted fro m participant 
samples and t he viral genome will be DNA sequenced to determine whether mutations 
have occurred in the GSK3228836 binding region or elsewhere in the genome (and if 
applicable, whether any known nucleos(t)ide resistance mutations are present i n the 
polymerase coding region).  
Resistance monitoring will be conducted on all baseline isolates to identify pre -existing 
substitutions.  Sequencing of the viral RNA will be attempted in participants receiving 
stable NA therapy and having DNA <LLOQ.  Addi tional resistance monitoring will be 
conducted and will include, but not limited to, the analysis of isolates from participants 
experiencing virological failure during or post treatment as defined below.  C onfirmation 
of resistance should be done within 1 week after results are received . 
8.9.1.  Resistance Analysis based upon HBV DNA Criteria  
HBV DNA for each participant  will be measured throughout the study. HBV resistance 
monitoring will include analysis of isolates from participants experiencing virological 
failure. 
Virologic failure  is defined as the following confirmed (2 sequential ) lab results ; 
• ≥1 log increase from nadir of HBV DNA  OR 
• HBV DNA becoming quantifiable after being below the LLOQ  OR 
• Never achieved HBV DNA levels less than LLOQ  
8.9.2.  Resistance Analysis based upon HBsAg Criteria  
HBsAg levels for each participant  will be measured throughout the study.   In addition to 
the standard HBV DNA virological failure criteria defined above, HBV resistance 
monitoring will also include analysis of isolates from partic ipants experiencing HBsAg 
seroreversion in the absence of detectable HBV DNA.   
HBsAg seroreversion  is defined as the following confirmed (2 sequential ) lab results ; 
• ≥1 log increase from nadir of HBV HBsAg OR 
• HBV  HBsAg  becoming quantifiable after being bel ow the LLO Q OR 
• Never achieved HBsAg levels less than LLOQ  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 66 
 8.10.  Patient Reported Outcomes (PROs)  
8.10.1.  Hepatitis B Quality of Life (HBQOL)  
The HBQOL has been designed to assess quality of life in patients with Hepatitis B. It 
consists of 31 items and 6 domains: psycho logical well -being, anticipation anxiety, 
vitality, stigma, transmissibility and vulnerability. Response options range from 1 to 5 
with higher scores indicating more severe impact of Hepatitis B than lower scores.   
8.10.2.  EQ-5D-3L 
The EuroQOL (EQ -5D-3L) is a sta ndardized instrument for use as a measure of health 
status that is applicable to a wide range of health conditions and treatments.  It provides a 
simple descriptive profile and a single index value for health status that can be used in 
evaluation of health  care. The EQ -5D-3L is designed for self -completion by patients, and 
is cognitively undemanding, taking only a few minutes to complete.  Instructions to 
participant s are included in the questionnaire.  
The EQ -5D-3L consists of 2 parts: the EQ -5D descriptive  items and the EQ visual analog 
scale (EQ VAS).  The EQ -5D comprises 5 dimensions including mobility, self -care, 
usual activities, pain/discomfort and anxiety/depression.  Each dimension is ranked on 3 
levels.  The participant  is asked to indicate his/her health state by ticking in the box 
against the most appropriate statement for each of the 5 dimensions.  
The EQ VAS records the participan t’s self -rated health on a vertical VAS with endpoints 
labelled “the best health you can imagine” and “the worst health  you can imagine”.  The 
instructions ask the participant  to mark an X on the scale to indicate how your health is 
TODAY and then to write  the number marked on the scale in the box below the scale.  
8.11.  Survey Questionnaires  
Patient App  
Participants will be provided the option of downloading a patient app on their cellphone 
at the start of the study, which will be used primarily to assist in visit tracking and 
providing general information about the study .  
This app will contain an optional survey that partic ipants can complete and will ask 
questions about their experience participating in the study.  No formal analysis will be 
conducted on this data.  This data will be used to drive patient focus in future studies with 
GSK3228836 . 
Patient Feedback on Dosing R egiment  
Participants will be asked questions about their experience of the dosing regimen used in 
the study.   This data may be used to drive patient focus in future studies with 
GSK3228836 . 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 67 
 9. STATISTICAL CONSIDER ATIONS  
9.1. Statistical Hypotheses  
The primary objective of the study is to assess the efficacy of three dosing regimens 
(arms 1, 2, and 3) of GSK3228836 in participants with CHB as described in Section 4.1.  
Note that loading vs. no loading dose ( arm 3 vs. arm 4) is assessed in an exploratory 
objective. The primary endpoint is achieving a  sustained virologic response (HBsAg 
<LLOQ and HBV DNA <LLOQ) for 24 weeks after the planned end of GSK3228836 
treatment in the absence of rescue medication .  Rescue medication is defined as any 
medication initiated for the purpose of antiviral suppression . 
An estimation approach with no hypothesis testing will be used to address the primary 
objective.  The primary  assessments of interest are the point estimate of SVR rate and 
95% credible intervals;  in addition , posterior probabilities that the true SVR in each 
treatment arm is greater than a range of clinically meaningful response rates will be 
provided.  The poin t estimates for SVR will be calculated using a Bayesian probability 
approach.  Comparisons between treatment arms as defined in the key 
secondary/exploratory objectives will be assessed using probability inference approaches.  
9.2. Sample Size Determination  
Approximately 440 participants are planned to be  randomly assigned to study 
intervention.  
For each population, there will be approximately 66 participants assigned in each of the 
first three arms.  There will be approximately 22 participants assigned in the fo urth arm.  
It is assumed that the number of responders follows a Binomial distribution, with a 
weakly informative prior (Beta (0.5, 0.5)) for the true response rate .  The precision for a 
range of response rates with 95% credible intervals are shown in Table 9. 
Table 9 95% Credible Interval of Response Rate by Sample Size  
Sample size per arm  Number of responders  Response rate  95% credible interval*  
22 2 9% 1% – 23% 
3 14% 3% - 30% 
4 18% 5% - 36% 
5 23% 8% - 41% 
6 27% 11% - 46% 
66 6 9% 3% - 17% 
9 14% 6% - 23% 
12 18% 10% - 28% 
15 23% 13% - 33% 
18 27% 17% - 38% 
*95% highest posterior density interval  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 68 
 The lower bounds of 95% credible intervals will exclude the historical placebo response 
rate of 3% if observed response rate is greater than or equal to 14% in arms 1 -3 or 18% in 
arm 4.  
The posterior probabilities that the true sustained virologic respons e rate is greater than a 
range of response rates will be calculated from the implied Beta posterior, given the 
actual number of responders observed.  
The operating characteristics  based on at least 75% posterior confidence that the true rate 
exceeds a thre shold of interest, are shown in  Table 10, for various sample sizes, and true 
cure rates.  The operating characteristics shown are based on a Bayesian model without 
consi deration of baseline stratification factors and expected to be similar to operating 
characteristics from the hierarchical model defined in Section 9.4.3 .  
Table 10 End of Study Operating Characteristics by Sample Size  
Criterion  Sample size 
per arm  Minimum 
number (%) 
of 
responders 
required to 
meet 
Criterion  Probability of Meeting Criterion Under Various 
Assumptions  
True Resp 
Rate=5%  True Resp 
Rate=20%  True Resp 
Rate=25%  True Resp 
Rate=30%  
Probability (true 
response 
rate>15%)>75%  22 5 (23%)  0% 46% 68% 84% 
44 9 (20%)  0% 53% 81% 91% 
66 12 (18%)  0% 69% 93% 99% 
88 16 (18%)  0% 71% 95% 100%  
Probability (true 
response 
rate>20%)>75%  22 6 (27%)  0% 27% 48% 69% 
44 11 (25%)  0% 25% 56% 81% 
66 16 (24%)  0% 23% 60% 88% 
88 21 (24%)  0% 22% 64% 92% 
Probability (true 
response 
rate>25%)>75%  22 7 (32%)  0% 
 13% 30% 51% 
44 13 (30%)  0% 9% 29% 58% 
66 19 (29%)  0% 6% 28% 63% 
88 25 (28%)  0% 4% 27% 67% 
Note: If the true response rate is 0%, the probability of meeting each criterion is 0% for all sample sizes.  
 
Based on these operating characteristics, for a true response rate of 20%, the proposed 
sample -size of n=66 for arms 1 – 3 has ~70% probabil ity of confirming a true response of 
at least 15%, and if the true rate is 30%, there is an 88% chance of confirming a true 
response of at least 20%.  
There are no plans for sample size re -estimation.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 69 
 9.3. Populations for Analyses  
The following populations are defined:  
Population  Description  
Screened  All participants who were screened for eligibility  
Enrolled  • All participants who passed screening and entered the study  
• Note screening failures (who never passed screening even if rescreened) 
and participants screened but never enrolled into the study are excluded 
from the Enrolled population as they did not enter the study  
Intent -to-Treat (ITT)  • All randomized participants.  
• This population will be based on the treatment the participant was 
randomized to  
• Any pa rticipant who receives a treatment randomization number will be 
considered to have been randomized  
Safety  • All participants who were randomized and received  at least one dose of 
study treatment  
• This population will be based on the treatment the participant  received.  
•  Note: Participants who were not randomized but received at least one dose 
of study treatment will be listed   
Pharmacokinetic (PK)  • All participants in the Safety population who received an active study 
treatment and had at least 1 non -missing P K assessment (Non -quantifiable 
[NQ] values will be considered as non -missing values)  
• Note: PK samples that may be affected by protocol deviations will be 
reviewed by the study team to determine whether or not the sample will be 
excluded  
Pharmacodynamic (P D) All participants in the Safety population for whom a Pharmacodynamic sample 
was obtained and analysed.  
 
9.4. Statistical Analyses  
The statistical analysis plan will be finalized prior to unblinding and it will include a 
more technical and detailed description of the statistical analyses described  in this 
section.  This section is a summary of the planned statistical analyses of the most 
important endpoints including primary and key  secondary endpoints.  All summaries and 
analyses will be conducted separately for the 2 populations (on nucleos(t)ide  treatment 
and not currently on nucleos(t)ide  treatment).  No adjustments will be made for 
multiplicity.  
9.4.1.  General Considerations  
Unless  otherwise specified, baseline will be the last value/assessment before the first dose 
of study treatment (Day1 pre -dose).   If there are multiple assessments collected at the 
same scheduled time,  the average of these assessments will be used as the baseline . 
9.4.2.  Primary Endpoint(s)  
Analyses will be conducted separately for the on nucleos(t)ide treatment and not 
currently on nucleos(t)ide treatment populations . The primary analysis for the primary 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 70 
 endpoint will be conducted once the last participant has completed th e Week 48 visit and 
database lock has been achieved .  
The primary efficacy endpoint is achieving a  sustained virologic response for 24 weeks 
after the planned end of GSK3228836 treatment in the absence of rescue medication.  
Sustained virologic response is  defined as observing HBsAg <LLOQ and HBV DNA 
<LLOQ at each analysis window in the 24 weeks after the end of GSK3228836 
treatment.  Analysis windows for the post GSK3228836 treatment assessment s will be 
defined in the analysis plan.  
HBsAg and HBV DNA from Week 24 to Off -Treatment Week 24 will be used to assess 
the primary endpoint for arms 1 and 2, and the exploratory endpoint for arm 4. For dosing 
schedule of arms 1, 2, and 4, see Section 4.1. 
 
For arm 3, because of the shortened time on treatment (12 weeks instead of 24 weeks), 
post-treatment visit schedules will not match those of arms 1 and 2. To avoid risk of bias 
the following visits have been selected for arm 3 to match the number  and timing of visit 
windows for measuring off -treatment virologic responses in arms 1 and 2 to evaluate the 
primary endpoint  
o Week 12, 13, 14, 16, 20, 24,  off-treatment Week 4, 8, 12  
9.4.2.1.  Primary Estimands  
Primary Estimands supporting the pri mary objective are defined as:  
- Population : separate assessment for the following:  
• participants with CHB on stable nucleos(t)ide therapy   
• participants with CHB not currently on nucleos(t)ide therapy  
- Variable : Sustained virologic response (SVR) for 24 we eks after the planned end of 
GSK3228836 treatment in the absence of rescue medication.  
- Treatments : arms 1, 2, and 3.  Estimation of the within -arm response rate.  Note: arm 4 
is described in Section 9.4.2.2  
- Intercurrent events : use of rescue medication, and discontinuation of/interruption 
of/adherence to IP.  The use of rescue medication has been incorporated into the 
definition of variable (composite strategy).  Discontinuation of, interruption of, and 
adherence to IP wi ll be ignored (treatment policy). Wide disruptive events (such as 
COV ID-19 pandemic) leading to discontinuation of, interruption in, and non -adherence 
to GSK3228836 will be handled assuming they had not happened (hypothetical strategy).  
 
- Population summary : proportion of participants who achieve SVR for each treatment 
arm. 
 
The primary estimands for each sub -population is the proportion of participants in each 
treatment arm 1, 2, and 3 who achieve SVR for 24 weeks after the planned end of 
GSK3228836 treatment in the absence of rescue medication regardless of completing IP, 
interruptions in IP or adherence to IP had they not been affected by wide disruptive 
events.  
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 71 
 9.4.2.2.  Supplementary Estimands  
A supplementary estimand is defined to support the primary objective. The 
supplementary estimand is defined in the same way as the main esti mand, except the 
assessment time frame for participants achieving SVR will be 24 weeks after the actual 
end of treatment. Therefore, the strategy for intercurrent events of treatment 
discontinuation will be while -on-treatment. This supplementary estimand s upporting the 
primary objective in participants with CHB on stable nucloes(t)ide therapy and 
participants with CHB not currently on nucleos(t)ide therapy is the proportion of 
participants in each treatment arm 1, 2, and 3 who achieve SVR for 24 weeks after  the 
actual end of GSK3228836 treatment in the absence of rescue medication, regardless of 
completing IP, interruptions in IP or adherence to IP, had they not been affected by wide 
disruptive events.  
9.4.2.3.  Handling of Withdrawal from Study and Missing HBsAg and HBV DNA 
Data  
Two approaches will be used to determine a participant’s response when HBsAg and 
HBV DNA data are missing from visits required to derive the primary endpoint.  
1) For participants where wide disruptive events (such as COV ID-19 pandemic) 
preven t assessment of the primary outcome, SVR will be imputed using all available 
data for participants for whom SVR can be assessed. For other participants where 
SVR in the absence of rescue medication cannot be ascertained due to missing data 
(withdrawal from  the study or missing due to other reasons, but not due to a wide 
disruptive event), the participant wil l be assumed not to have achieved SVR (non -
responder imputation).  
2) For the primary estimands, a sensitivity analysis will be performed using the 
Bayes ian model described in Section 9.4.3  assuming missing at random whereby a 
participant’s response will be imputed using all available data (on and off treatment 
value s) for participants who completed the study.  
9.4.3.  Primary Analyses  
All analyses will be conducted separately for the 2 populations (on nucleos(t)ide  
treatment and not currently on nucleos(t)ide  treatment).  The participant population will 
not be included as a stratification factor in the analysis  model.  
The primary assessments of interest are the point estimate of sustained virologic response 
rate and 95% credible intervals; in addition , posterior probabilities that the true virologic 
response rate in each treatment arm is greater than a range  of values will be provided.  
A Bayesian hierarchical model will be used to estimate the posterior probability of 
sustained virologic response rate for each arm incorporating the baseline stratification 
factors [ Jones , 2011].  
Model for each arm:  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 72 
 
 
Priors:   
 
The four strata and representation of the two baseline stratification factors B 1 and B 2 in 
the model are shown in Table 11.  
Table 11 Baseline Stratification Factors for Four Stratum  
Stratum  B1: HBsAg  (
 ) B2: HBeAg  (
 ) 
1: HBsAg 3 log IU/mL and Negative HBeAg  B1-  (3 log IU/mL)  (0) B2- (Negative)  (0) 
2: HBsAg >3 log IU/mL and Negative HBeAg  B1+  (>3 log IU/mL)  (1) B2-  (Negative)  (0) 
3: HBsAg 3 log IU/mL and Positive HBeAg  B1-  (3 log IU/mL)  (0) B2+  (Positive)  (1) 
4: HBsAg >3 log IU/mL and Positive HBeAg  B1+  >3 log IU/mL)  (1) B2+  (Positive)  (1) 
For each arm, the posterior distribution of SVR rate P(p g|data), g=1,2,3,4 wil l be derived 
for each stratum usi ng the model specified above.  
The posterior distribution of the arm -level SVR rate will be derived using a mixture of 
the posterior distributions of SVR rate for each stratum in that arm. The weights are 
proportional to the sample size of each stratum.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 73 
 Posterior probability of sustained virologic response rate exceeding a range of clinically 
meaningful response rates  will be generated using the approach specified above for each 
arm. 
9.4.4.  Secondary Endpoint(s)  
9.4.4.1.  Estimands for Secondary Objectives:  
All analyses will be conducted separately for the 2 populations (on nucleos(t)ide  
treatment and not currently on nucleos(t)ide  treatment).  
Two groups of estimands are defined for the secondary efficacy objectives.  
Categorical definitions for secondary analyses will be  provided in the RAP.  
Estimands supporting secondary objective of assessing the efficacy of GSK3228836 on 
biomarkers and virus -specific antibody responses  are defined as follows:  
- Population : one subpopulation of participants with CHB on stable nucleos(t) ide 
therapy and a second subpopulation of participants with CHB not currently on 
nucleos(t)ide therapy .  
- Treatments : arms 1 -4. Estimation within  each arm. 
- Intercurrent events : use of rescue medication, and discontinuation of/interruption 
of/adherence t o IP. The use of rescue medication will be ignored (treatment policy 
strategy). Discontinuation of, interruption of, and adherence to IP will be ignored 
(treatment policy)  
1) Categorical Variables : 
- Achieving HBsAg <LLOQ and HBV DNA <LLOQ at the end of trea tment.  
- Categorical changes from baseline in HBsAg (e.g. <0.5, ≥0.5 , ≥1, ≥1.5, ≥3 log 10 
IU/mL)  and in HBV DNA  (e.g. <1, ≥ 1, ≥2, ≥3 log IU/mL) . Additional categories 
of changes from baseline may be added in the RAP.  
- ALT normalization (ALT≤ULN)  over time in absence of rescue medication  in 
participants with baseline ALT>ULN  
- HBe antibody (anti -HBeAg ) levels  
- Population summary:  proportion of participants in each category for each 
treatment arm.  
2) Continuous Variables : Actual values and change from baseline over time of HBsAg 
and HBV DNA and actual values and change from baseline  of HBeAg levels; HBs 
antibody (anti -HBsAg) levels .  
- Population summary : mean values and mean changes from baseline for each variable 
in each treatment arm  
3) Time to Event Variable : Time to ALT normalization in absence of rescue medication 
in participants with baseline ALT>ULN  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 74 
 - Population summary : Turnbull’s  estimat or for non-parametric estimation of Time to 
ALT normalization in each treatment arm  
The group of estiman ds supporting this objective for each sub -population are the 
population summary for each variable in each treatment arm 1 -4 regardless of completing 
IP, interruptions in IP or adherence to IP and regardless of rescue medication (except for 
ALT normalizatio n which can only be achieved in the absence of rescue medication) . 
Missing data for variables defined above (except for Time to ALT normalization) will be 
ignored, only available data will be summarized.  For participants who withdraw from the 
study or Par ticipants with ALT>ULN at the end of study, time to ALT normalization will 
be censored at the time of last visit. No sensitivity analysis is planned for the group of 
estimands supporting this objective. Further details will be provided in the RAP.  
• Estimands supporting secondary objective of comparing the efficacy between 12 
weeks, 12 weeks + 12 weeks step -down, and 24 weeks of GSK3228836 treatment are 
defined as follows:  
- Population : separate assessment for the following:  
• participants with CHB on s table nucleos(t)ide therapy   
• participants with CHB not currently on nucleos(t)ide therapy  
- Variable : Sustained virologic response (SVR) for 24 weeks after the 
planned end of GSK3228836 treatment in the absence of rescue medication.  
- Treatments : arms 1, 2 , and 3.  Three treatment comparisons between: arms 
1 and 2, arms 1 and 3, and arms 2 and 3. 
- Intercurrent events : use of rescue medication, and discontinuation 
of/interruption of/adherence to IP.  The use of rescue medication has been 
incorporated into t he definition of variable (composite strategy).  
Discontinuation of, interruption of, and adherence to IP will be ignored 
(treatment polic y). Wide disruptive events (such as COV ID-19 pandemic) 
leading to discontinuation of, interruption in, and non -adheren ce to 
GSK3228836 will be handled assuming they had not happened (hypothetical 
strategy).   
- Population summary : difference in proportion of participants who achieve 
SVR between treatment arms.  
The group of estimands supporting this objective for each sub -population are the 
difference in each treatment comparisons in the proportion of participants who achieve 
SVR for 24  weeks after the planned end of GSK3228836 treatment in the absence of 
rescue medication regardless of completing IP, interruptions in IP or  adherence to IP had 
they not been affected by wide disruptive events.  
The non -responder imputation described in Section 9.4.2.2  will be used when HBsAg and 
HBV DNA data are missing from visits required to derive the endpoint. Further details 
will be provided in the RAP.  
9.4.4.2.  Secondary Efficacy Analyses  
Secondary efficacy comparisons of interest include difference in sustained virologic 
response rate between following trea tment arms:  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 75 
 o Arm 1 vs. Arm 2  
o Arm 1 vs. Arm 3  
o Arm 2 vs. Arm 3  
  
Comparisons between the treatment arms will be conducted using a similar model 
specified in Section 9.4.3  but defining θ g as the log odds ratio of treatment effect 
comparing one treatment arm to another treatment arm.  The point estimates of 
differences in sustained virologic response rate with 95 % credible intervals will be 
calculated for the treatment comparisons described in the estimands.  Details of the model 
are included in the RAP.  
9.4.4.3.  Historical placebo:  
Summary -level historical placebo data over 48 weeks from publications may be included  
in a supplementary analysis .  A longitudinal model including historical response at 12, 24 
and 48 weeks of placebo treatment will be constructed.  For the first 12 -week period, the  
model will allow dynamic borrowing from historical placebo data to the concurre nt 
placebo in Weeks 1 -12 in arm 4. Furthermore, the model will provide longitudinal 
prediction of response at Week 24 and Week 48 for participants in arm 4 (had they 
continued on Placebo rather than switching to GSK3228836 treatment).  Descriptive 
comparis ons will be included in summary tables and figures as appropriate.  Further 
details will be provided in the RAP.  
9.4.5.  Safety Endpoints  
Safety  analyses  
All analyses will be conducted separately for the 2 populations (on nucleos(t)ide  
treatment and not currently on nucleos(t)ide  treatment).  
All safety analyses will be based on the Safety Population .  
Exposure to study medication, measured by the number of injections and proportion of 
planned number of injections of  study drug, will be summarized by treatment arm.  
The proportion of participant s reporting adverse events (AEs) will be tabulated for each 
treatment arm.  The following summaries of AEs will be provided:  
• Incidence and severity of All AEs;  
• Incidence and severity of treatment related AEs;  
• Incidence and severity of AEs leading to withdrawal from study;  
• Incidence of serious AEs  (SAEs).  
Laboratory data, vital signs and ECG data (absolute values and change from Baseline) 
will be summarized by visit and treatment group.   In addition, the  maximum post -
baseline  toxicity grade (based on DAIDS categories) will be tabulated by treatment arm .  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 76 
 Detail s of exploratory analyses for exploratory efficacy, virology, and biomarker will be 
provided in the RAP.  The results of HBcrAg, HBV RNA, virology and biomarker 
investig ations may be reported separately from the main clinical study report.  All 
endpoints of interest from all comparisons will be descriptively and/or graphically 
summarized as appropriate to the data . 
9.4.6.  Exploratory Objectives  
9.4.6.1.  Estimand for Exploratory Objectives  
• Estimands supporting exploratory objective of comparing the efficacy between 
12 weeks of GSK3228836 treatment with a loading dose or without a loading dose 
are defined as follows:  
- Population : separate assessment for the following:  
• participants  with CHB on stable nucleos(t)ide therapy   
• participants with CHB not currently on nucleos(t)ide therapy  
- Variable : Sustained virologic response (SVR) for 24 weeks after the 
planned end of GSK3228836 treatment in the absence of rescue medication.  
- Treatments : arm 3 and 4. Treatment comparison between arms 3  and 4. 
- Intercurrent events : use of rescue medication, and discontinuation 
of/interruption of/adherence to IP.  The use of rescue medication has been 
incorporated into the definition of variable  (composite strategy).  
Discontinuation of, interruption of, and adherence to IP will be ignored 
(treatment policy). Wide disruptive events (such as COV ID-19 pandemic) 
leading to discontinuation of, interruption in, and non -adherence to  
GSK3228836 will be  handled assuming they had not happened (hypothetical 
strategy).  
- Population summary : difference in proportion of participants who achieve 
SVR between treatment arms 3 and 4. 
 
The group of estimands supporting this objective for each sub -population are th e 
differences between arms 3 and 4 in the proportion of participants  who achieve SVR for 
24 weeks after the planned end of GSK3228836 treatment in the absence of rescue 
medication regardless of completing IP, interruptions in IP or adherence to IP had they  
not been affected by wide disruptive events.  
 
The non -responder imputation described in Section 9.4.2.2 will be used when HBsAg and 
HBV DNA data are missing from vis its required to derive the endpoint. Further details 
will be provided in the RAP.  
 
Comparisons between the treatment arms 3  and 4 will be conducted using the same 
model specified in Section 9.4.2.2  but defining θ g as the log odds ratio of treatment effect 
comparing one treatment arm to another treatment arm, further details will be included in 
the RAP.  
9.4.6.2.  Participant Population Analyses  
Participant disposition, treatment status, demographics, baseline characteristics (that 
include year of birth, sex, race, and ethnicity), medical history, prior and concomitant 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 77 
 medications, study treatment exposure will be summarized descriptively and list ed by 
participant. The participant’s baseline characteristics may be used to derive differences (if 
any) between the pharmacokinetic parameters of different racial groups (e.g., Chinese, 
Japanese vs non -Asian) as per the request of regulatory bodies.  
9.4.6.3.  PK and PK -PD Analyses  
Pharmacokinetics (PK)  of GSK3228836 and nucleos(t)ide will be characterize d. In all 
participants , C and terminal half -life (t½)  will be estimated . In participants with 
intensive PK sampling , GSK3228836 and nucleos(t)ide plasma PK parame ters will be 
derived , including but not limited to AUC, C , Cmax, and tmax.  
Population PK model: A Population PK model will be developed to describe the time -
course of plasma PK of GSK3228836 in HBV patients. The data will be analyzed using 
nonlinear mixed  effect modeling to estimate the PK parameters of GSK3228836 and the 
associated between -subject variabilities in addition to the residual variability. Covariate 
modeling and model qualification will be conducted. Additional details on the modeling 
process will be detailed in the population PK -PD analysis plan and the results will be 
reported separately.   
PK-PD model: Various PK -PD relationships including PK -efficacy and PK -safety 
relationships will initially be explored graphically; if a relationship betwee n exposure and 
efficacy and/or safety endpoints is present, population PK -PD modeling will be 
conducted using nonlinear mixed effect methods. These models will characterize the 
exposure -response relationships and will define the factors (covariates) that m ay be 
predictors of efficacy and safety. Additional details of PK -PD analyses will be provided 
in the population PK -PD analysis plan and the results will be reported separately.  
9.5. Interim Analyses  
Three interim analyses are planned for the study in addition to regular IDMC safety 
reviews (See Section 9.6).   
All interim analyses will be conduc ted separately for participants on stable nucleos(t)ide 
treatment and participants not currently on nucleos(t)ide therapy .  Where possible, the 
interim analyses will be scheduled  such that both populations are assessed at the same 
time. All interim analysi s will be based on the ITT population.  
The approximate timing, endpoint and criteria for each interim analysis are summarized 
in Table 12. The IDMC will  review and approve the timing, endpoint and decision 
criteria for the planned interim analyses and the final approved framework will be 
included in the IDMC charter.  
Additional interim analyses may be conducted after the third interim ( at which time all 
participants  will have completed treatment  and sponsor  staff [as specified  in the blinding 
plan]  will be unblinded ), to support development planning and decision making.  If 
conducted, these analyses will be unblinded to the sponsor staff (as specified in the 
blinding plan ) and referenced in the clinical study report.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 78 
 Table 12 Interim analysis timing, endpoint and decision rule  
Interim  Timing  Endpoint  Decision Rule  Note  
1 ~ 30% participants 
complete Week 12  Week 12 response rate  
(≥0.5 log10 decline in 
HBsAg at Week 12)  Stop sub -population if all 
participants’ Week 12 
response rate is predicted to 
be very low  Arms 1 -3 
combined  
2 ~ 50% participants 
complete Week 24  Week 24 response rate  
(HBsAg <LLOQ and 
HBV DNA <LLOQ at 
Week 24)  Stop sub -population if all 
participants’ Week 24 
response rate is predicted to 
be very low  Arms 1 &2 
combined  
3 All participants 
complete Week 24  Sustained v irologic 
response rate  
(Primary endpoint)  The predicted end -of-study 
sustained virologic response 
rate will be modelled to 
support development plan 
decision making. No option 
to stop the trial at this point 
as all participants will have 
completed  treatment.   
9.6. Independent Data Monitoring Committee (IDMC)  
An independent data monitoring committee (IDMC) will review ongoing unblinded 
safety data in this study and the planned interim analysis described in Section 9.5.  The 
IDMC will meet on a regular basis as outlined in the charter.  The IDMC/Review Board 
charter will describe the procedures related to IDMC operations in greater detail.  For 
details on the  IDMC, refer to Section 10.1.5 . 
The first data review meeting will be held approximately 18 weeks post first -subject -first-
dose (the initial dry run will be blinded with a data cut at approximately 12 weeks post -
first subject first dose [FSFD]).  Thereafter, the frequency of scheduled  meetings depends 
on subject enrolment, information accumulated and safety event rates but will occur 
approximately every 3 months.  At the first meeting the IDMC may consider if the 
benefit risk assessment is acceptable to expand the ALT inclusion criterion threshold 
(from ALT<3xULN to <5xULN) for participants not receiving nucleos(t)ide therapy.  
Review of the ALT threshold will continue  at each meeting as required.  
9.7. Internal Safety Review Team (SRT)  
A separate  internal safety review team will meet to review all participants’ blinded safety 
data on a regular basis . 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 79 
 10. SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived from international guidelines 
including the Declaratio n of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations  
• The protocol, protocol amendments, ICF, Investigat or Brochure, and other 
relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by 
the investigator and reviewed and approved by the IRB/IEC before the study is 
initiated.  
• Any amendments to the protocol will require IEC/IRB approval befor e 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
• Providing written summaries of the status of the study to th e IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by the IRB/EC  
• Notifying the IRB/IEC of SAE or other significant safety findings as 
required by IRB/IEC procedures  
• Providing oversight of the con duct of the study at the site and adherence 
to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations  
10.1.2.  Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 80 
 10.1.3.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally authorized representative and answer all 
questions regarding the study.  
• Participants must be informed that their participation is volunta ry. Participants 
or their legally authorized representative will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) 
requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The autho rized person obtaining the informed consent 
must also sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the partic ipant’s 
legally authorized representative.  
A participant who is rescreened is not required to sign another ICF if the rescreening 
occurs within 45 days from the previous ICF signature date.  
GSK (alone or working with others) may use participant’s coded st udy data and samples 
and other information to carry out this study; understand the results of this study; learn 
more about GSK3228836 or about the study  disease; publish the results of these research 
efforts; work with government agencies or insurers to ha ve GSK3228836  approved for 
medical use or approved for payment coverage.   
The ICF contains a separate section that addresses the use of participant data and 
remaining samples for optional further research. The investigator or authorised designee 
will infor m each participant of the possibility of further research not related to the 
study/disease. Participants will be told that they are free to refuse to participate and may 
withdraw their consent at any time and for any reason during the storage period. A 
separate tick box will be required to document a participant's agreement to allow any 
participant data and/or remaining leftover samples to be used for further research not 
related to the study/disease. Participants who decline further research will tick the 
corresponding “No” box.  
10.1.4.  Data Protection  
• Participants will be assigned a unique identifier by the sponsor. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any information which w ould make the participant 
identifiable will not be transferred.  
• The participant must be informed that his/her personal study -related data will be 
used by the sponsor in accordance with local data protection law. The level of 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 81 
 disclosure must also be explai ned to the participant who will be required to give 
consent for their data to be used as described in the informed consent.  
• The participant must be informed that his/her medical records may be examined 
by Clinical Quality Assurance auditors or other autho rized personnel appointed 
by the sponsor, by appropriate IRB/IEC members, and by inspectors from 
regulatory authorities.  
 
10.1.5.  Committees Structure  
The overall responsibility of the IDMC, which consists of at least 2 physicians and 1 
statistician, is to protect  the ethical and safety interests of participants recruited into 
clinical  studies while ensuring the scientific validity of the studies. The IDMC will meet 
at predefined times for each study , as well as ad hoc (as deemed appropriate), to evaluate 
the risk versus benefit of GSK3228836 . 
Specific responsibilities of the IDMC include:   
1. Reviewing the IDMC Charter supplied by GSK and making any recommendations for 
changes to GSK; all IDMC members mu st approve and sign the Charter prior to 
enrolling the first participant  into the study . 
2. Determining the type of information needed for review of efficacy/safety data, as 
required, in the context of benefit/risk.  
3. Recommending the format for the presentatio n of this information.  
4. Reviewing data collection methods, safety/efficacy monitoring procedures and 
making recommendations for additions or adjustments to the trial design following 
interim analyses (IA).  
GSK is responsible for the selectio n of IDMC memb ers.  The IDMC Chairperson may 
assist in selecting IDMC members.  The skills and experiences necessary to properly 
fulfil the role of the IDMC ( e.g., relevant medical specialties) require careful 
consideration and have been pre -specified by GSK.  In the even t that a member is unable 
to continue participation on the IDMC, GSK, in conjunction with the IDMC Chairperson, 
will recommend a replacement.  GSK has the final decision on the replacement.  No 
substitution of members is permissible for individual meetings . 
10.1.6.  Dissemination of Clinical Study Data  
• Where required by applicable regulatory requirements, an investigator signatory 
will be identified for the approval of the clinical study report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity to review the complete study results at a 
GSK site or other mutually -agreeable location.  
• GSK will also provide the investigator with the full summary of the study 
results.  The investigato r is encouraged to share the summary results with the 
study participants, as appropriate.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 82 
 • The procedures and timing for public disclosure of the protocol and results 
summary and for development of a manuscript for publication for this study will 
be in acco rdance with GSK Policy.  
• GSK intends to make anonymized participant -level data from this trial available 
to external researchers for scientific analyses or to conduct further research that 
can help advance medical science or improve patient care. This helps  ensure the 
data provided by trial participants are used to maximum effect in the creation of 
knowledge and understanding  
10.1.7.  Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically (e.g., 
laboratory data). The investigator is responsible for verifying that data entries 
are accurate and correct by physically or electronically signing the CRF.  
• The investigator must maintain accurate documentation  (source data) that 
supports the information entered in the CRF.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents.  
• Monitoring details descr ibing strategy (e.g., risk -based initiatives in operations 
and quality such as Risk Management and Mitigation Strategies and Analytical 
Risk-Based Monitoring), methods, responsibilities and requirements, including 
handling of noncompliance issues and monit oring techniques (central, remote, 
or on -site monitoring) are provided in the Monitoring Plan.  
• The sponsor or designee is responsible for the data management of this study 
including quality checking of the data.  
• The sponsor assumes accountability for acti ons delegated to other individuals 
(e.g., Contract Research Organizations).  
• Study monitors will perform ongoing source data verification to confirm that 
data entered into the CRF by authorized site personnel are accurate, complete, 
and verifiable from sour ce documents; that the safety and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
• Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by the investigator for 25 years from the issue of the final 
Clinical Study Report (CSR)/ equivalent summary unless local regulations or 
institutional polici es require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or party without 
written notification to the sponsor.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 83 
 • Quality tole rance limits (QTLs) will be pre -defined in the trial master file  to 
identify systematic issues that can impact participant safety and/or reliability of 
study results. These pre -defined parameters will be monitored during and at the 
end of the study and all  deviations from the QTLs and remedial actions taken 
will be summarized in the clinical study report.  
10.1.8.  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source docum ents are filed at the 
investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may need to request previous 
medical records or transfer records, depending on the study. Also, current 
medical records must be available.  
• Definition of what constitutes source data can be found in the RAP . 
10.1.9.  Study and Site Start and Closure  
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The first act of recruitment is the first site open  and will be the study start date.  
GSK or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of GSK. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The inve stigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include 
but are  not limited to:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by the investigator  
• Discontinuation of  further study intervention development  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform 
the Investigators, the IECs/IRBs, the regulatory authorities, and any contract research 
organization(s) used in the study of the reason for termination or suspension, as specified 
by the applicable regulatory requirements. The Investigator shall promptly inform the 
participant  and should assure appropriate participant  therapy and/or follow -up. 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 84 
 10.1.10.  Publication Policy  
• The results of this study may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary 
information  and to provide comments.  
• The sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the sponsor will generally 
support publication of multicenter studies only in their entir ety and not as 
individual site data. In this case, a coordinating investigator will be designated by 
mutual agreement.  
• Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirem ents. 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 85 
 10.2.  Appendix 2: Clinical Laboratory Tests  
• The tests detailed in Table 13 will be performed by the central laboratory.  Local 
laboratory samples may sti ll be collected as needed by the site.  
• Local laboratory results are required for analysis of platelets during the dosing 
period, and be available for the investigator’s review prior to dosing. A  sample 
for central analysis is obtained at the same time  
• Othe rwise, l ocal laboratory results are only required in the event that the central 
laboratory results are not available in time for either study intervention 
administration and/or response evaluation. If a local sample is required, it is 
important that the sa mple for central analysis is obtained at the same time.  
• Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations.  
• Pregnancy Testing  
• Refer to Section 5.1 Inclusion Criteria for screening pregnancy criteria.  
• Additional serum or urine pregnancy tests may be performed, as determined 
necessary by the investigator or required by local regulation, t o establish the 
absence of pregnancy at any time during the participant's participation in the 
study.  
Table 13 Protocol -Required Safety Laboratory Assessments  
Laboratory 
Assessments  Parameters  
Hematology  Platelet Count1  RBC Indices:  
MCV  
MCH  
 WBC count (with 
Differential  if WBC 
abnormal) : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  RBC Count  
Hemoglobin  
Hematocrit  
Clinical 
Chemistry  Blood Urea 
Nitrogen  (BUN ) Potassium  Aspartate 
Aminotransferase  
(AST)/  Serum 
Glutamic -
Oxaloacetic 
Transaminase  
(SGOT)  Total , indirect,  
and direct 
bilirubin  
 Creatinine  Sodium  Alanine 
Aminotransferase  
 (ALT)/  Serum Total Protein  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 86 
 Laboratory 
Assessments  Parameters  
Glutamic -Pyruvic 
Transaminase  
(SGPT)  
 Glucose  Calcium  Alkaline 
phosphatase  Albumin  
Routine 
Urinalysis  • By dipstick  
• Microscopic examination (if blood or protein is abnormal)  
Other Tests  • Follicle -stimulating hormone and estradiol (as needed only)  
• Highly sensitive urine or serum human chorionic gonadotropin (hCG) 
pregnancy test (as needed for women  of childbearing potential)2 
• Total bile acid  
• Serology (HIV antibody, hepatitis C virus antibody, and hepatitis D virus 
antibody)  
• Hepatitis B serology ( hepatitis B surface antigen [HBsAg], hepatitis B 
surface antibody [anti -HBsAg], hepatitis B e antigen  [HBeAg], hepatitis B e 
antibody [anti -HBeAg] , Hepatitis B virus DNA [HBV DNA], Hepatitis B virus 
RNA [HBV RNA], Hepatitis B core related antigen [HBcrAg])  
• Other laboratory: PT, INR, activated partial thromboplastin time  (aPTT), 
Alpha -fetoprotein, ANCA  (MPO -ANCA, PR3 -ANCA) , APRI/Fibrosure, 
Complement factors C3, C4, and Bb, hs -CRP , MCP -1, angiopoetin II, 
PBMC, soluble protein, PAX Gene  
• Urine ACR  
• Optional collections: genetic sample  
• Viral Sequencing: HBV Genotype /phenotype , HBV DNA, HBV RNA  
All study -required la boratory assessments will be performed by a central 
laboratory, with the exception:  
• Platelet counts for investigator decisions may be drawn at local laboratory  
Additional tests 
listed under 
safety follow -up 
processes  Liver Chemistry Stopping Criteria3 
• Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovirus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if 
unavailable, obtain heterophile antibody or monospot testing);  
o Hepatitis E IgM antibody  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 87 
 Laboratory 
Assessments  Parameters  
o Hepatitis B virus DN A load  
o Hepatitis C virus RNA load  
o Hepatitis D virus antibody  
• PK sample  
• Serum creatine phosphokinase (CPK) and lactate dehydrogenase 
(LDH).  
• Fractionate bilirubin , Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney microsomal antibo dies and 
quantitative total immunoglobulin G (IgG or gamma globulins).  
• Serum acetaminophen adduct high performance liquid chromatography 
(HPLC) assay  
Drug Induced Vascular Injury and Complement Stopping Criteria  
• CH50  
• Factor B level  
• Factor H level  
• sC5b -9 
Hematological Stopping Criteria  
• anti-platelet antibodies  
Drug Induced Kidney Injury Stopping Criteria  
• 24-hour urine analysis  
• renal ultrasound  
• urine microscopy  
• serum urea and creatinine  
• platelets  
• urgent serum vasculitis screen [including ANCA, ANA, dsDNA, 
cryoglobulins  
•  serum protein electrophoresis (SPEP)/urine protein electrophoresis 
(UPEP)  
• complement panel (C3, C4, C5a and Bb ) 
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 88 
 NOTES :  
1. Platelets will require local/central lab collection while participants are on -treatment; local lab will be optional for 
sites during the post -treatment period  
2. Urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC or if 
urine testing is unavailable  
3. Details of liver chemistry stopping criteria and require d actions and follow -up assessments after liver stopping or 
monitoring event are given in Section 7.1 and Appendix 7.  All events of ALT 3 × upper limit of normal (ULN) and 
bilirubin >2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalized ratio (INR) >1.5, if INR 
measured, w hich may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis).  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 89 
 10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
10.3.1.  Defini tion of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, 
temporally associated with the use of a study intervention, whether or not 
considered related to the study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a study intervention.  
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or 
urinalysis) or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of th e investigator (i.e., not 
related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either 
an increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed afte r study intervention administration 
even though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of eit her study 
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of effic acy will be reported as AE or SAE if they fulfill the definition of an AE 
or SAE.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlyin g disease, unless judged by 
the investigator to be more severe than expected for the participant’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 90 
 of the disease/disorder being studied, unless more severe than expe cted for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition 
that leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
 
10.3.2.  Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE eve n if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, 
death due to progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
o Results in death  
o Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
Requires  inpatient hospitalization or prolongation of existing hospitalization  
• In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are AE. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious.  When in doubt as to whether 
“hospitalization” occurred or was necessary, the AE should be considered serious.  
• Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
Results in persist ent or significant disability /incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as unco mplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. sprained ankle) which may interfere with 
or prevent everyday life functions but do not constitute a substantial disruption.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 91 
 Is a congenital anomaly/birth defect  
Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life -threatening or result in death or hospitalization but 
may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually be considered serious.  
• Examples of such events include invasive or malignant cancers , intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse.  
 
10.3.3.  Definition of Cardiovascular Events  
Cardiovascular Ev ents (CV) Definition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revascularization  
 
10.3.4.  Recording and Follow -Up of AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) 
related to the event.  
• The investigator will then record all relevant AE/SAE information in the CRF.  
• It is not acceptable for the investigator to send photocopies of the participant’s 
T M F -1 3 9 5 6 4 8 0 C O N FI D E N TI A L  
  2 0 9 6 6 8  
 Pr ot o c ol A m d 0 2  
 9 2  
 me dical rec or ds t o G S K i n lie u of c o m pleti o n of t he G S K / A E/ S A E C R F pa ge.  
• T here ma y b e i nsta nces w he n c o pies of m e dical r ec or ds f or certai n cas es are 
re q ueste d b y G S K. I n t his case, all partici pa nt i de ntifiers, wit h t he e x ce pti o n of 
t he partici pa nt n u m ber, will be re dact e d o n t he c o pies of t he me dical r ec or ds 
bef ore s u b missi o n t o G S K.  
• T he i n vesti gat or will atte m pt t o esta blis h a dia g n osis of t he e ve nt base d o n si g ns, 
s y m pt o ms, a n d/ or ot her cli nical i nf or mati o n. W he ne ver p ossi ble, t he dia g n osis 
( n ot t he i n di vi d ual si g ns/s y m pt o ms) will be d oc u me nte d as t he A E/ S A E.  
A s s e ss m e nt of I nt e n sit y  
T he i n vesti gat or will assess i nte nsit y f or eac h A E a n d S A E re p ort e d d uri n g t he st u d y a n d 
assi g n it t o 1 of t he f oll o wi n g cate g ories:  
• Mil d: A n e ve nt t hat is easil y t olerate d b y t h e parti ci pa nt, ca usi n g mi ni mal 
disc o mf ort a n d n ot i nterferi n g wit h e ver y d a y a cti vities.  
• M o derate: A n e ve nt t hat ca uses s ufficie nt disc o mf ort a n d i nterferes wit h n or mal 
e ver y da y acti vities.  
• Se vere: A n e v e nt t hat pre ve nts n or mal e ver y d a y acti vities. A n A E t hat is 
assesse d as se v ere s h o ul d n ot be c o nf use d wit h a n S A E. Se vere is a cate g or y 
utilize d f or rati n g t he i nte nsit y of a n e ve nt; a n d b ot h A E a n d S A E ca n b e 
assesse d as se v ere.  
A n e ve nt is defi ne d as ‘s eri o us’ w he n it meets at least 1 of t he pre defi n e d o utc o mes 
as descri be d i n t he d efi niti o n of a n S A E, N O T w h e n it is rate d as se v ere . 
1 0. 3. 5.  Di vi si o n of AI D S ( D AI D S) T a bl e f or Gr a di n g S e v erit y of A d ult a n d 
P e di atri c A d v er s e E v e nt s  
T he D AI D S T a ble [ D AI D S , 2 0 1 7 ] will be use d t o gra de t he s e verit y o f a n A E t hat is n ot 
s pecificall y i de ntifie d i n t he gra di n g ta ble. I n a d diti o n, are t o 
be classifie d as gra de 5.   
T he D AI D S T a ble is a vaila ble at t he f oll o wi n g li n k:  
htt ps://rsc. niai d. ni h. g o v/cli nical -researc h -sites/ gra di n g -se v erit y -a d ult -p e diatric -a d verse -
e ve nts -c orrecte d -versi o n -t w o -o ne   
A s s e ss m e nt of C a u s alit y  
• T he i n vesti gat or is o bli gate d t o assess t he relati o ns hi p bet wee n st u d y i nter ve nti o n 
a n d eac h occ urre n ce of  eac h A E/ S A E.  
• A "reas o na bl e p ossi bilit y" of a relati o ns hi p c o n ve ys t hat t here are facts, e vi de nce, 
a n d/ or ar g u me nts t o s u g gest a ca us al relati o ns hi p, rat her t ha n a rel ati o ns hi p 
ca n n ot be r ule d o ut.  
• T he i n vesti gat or will use cli nical j u d g me nt t o deter mi ne t he relati o ns hi p.  C CI 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 93 
 • Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator wi ll also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that 
he/she has reviewed the AE/SAE and has provided an assessme nt of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK. However, it is very 
important that the investigator always make an assessment of causality for 
every  event before the initial transmission of the SAE data to GSK . 
• The investigator may change his/her opinion of causality in light of follow -up 
information and send an SAE follow -up report with the updated causality 
assessment.  
• The causality assessment is on e of the criteria used when determining regulatory 
reporting requirements.  
 
10.3.6.  Reporting of SAE to GSK  
SAE Reporting to GSK  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to GSK will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next Section) in order to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• The investigator or medically -qualified sub -investigator must show evidence 
within the eCRF of review and verification of the relationship of each SAE to 
IP/study participation (causality) within 72 hours of SAE entry into the eCRF.  
• After the study is com pleted at a given site, the electronic data collection tool 
will be taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives 
updated data on a previously repo rted SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next Section ) or to the Medical Monitor  by telephone.  
• Contacts for SAE reporting can be found in the SRM . 
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 94 
 SAE Reporting to GSK via Paper CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Medical Monitor . 
• In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptabl e with a copy of the SAE data co llection tool sent by 
overnight mail or courier service.  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time 
frames.  
• Contacts for SAE reporting can be  found in the SRM . 
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 95 
 10.4.  Appendix  4: Contraceptive Guidance and Collection of 
Pregnancy Information  
10.4.1.  Definitions:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below).  
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation should 
be considered.  
Wom en in the following categories are not considered WOCBP  
• Premenarchal  
• Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
For individuals with permanent infertility due t o an alternate medical cause other 
than the above, (e.g., Mullerian agenesis, androgen insensitivity), investigator 
discretion should be applied to determining study entry.  
Note: Documentation can come from the site personnel’s: review of the 
participant’s  medical records, medical examination, or medical history interview.  
• Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopa usal 
range may be used to confirm a postmenopausal state in women not 
using hormonal contraception or hormonal replacement therapy (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required.  
• Fema les on HRT and whose menopausal status is in doubt will be required to 
use one of the non -estrogen hormonal highly effective contraception methods 
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmati on of postmenopausal status before 
study enrollment.  
 
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 96 
 10.4.2.  Contraception Guidance:  
• CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
• Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per 
year when used consistently and correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of 
ovulationb 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS) b 
• Bilateral tubal occlusion  
• Vasectomized partner  
Note: Vasectomized partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the absence 
of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatog enesis cycle is approximately 90 days.  
• Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year 
when used consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated 
with inhibition of ovulationc 
• oral 
• intravaginal  
• transdermal  
• injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
• oral 
• injectable  
• Sexual abstinence  
• Note: Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of t he 
participant.  
• ACCEPTABLE METHODSd 
• Progestogen -only oral hormonal contraception where inhibition of ovulation is not the 
primary mode of action  
• Male or female condom with or without spermicidee 
• Cervical cap, diaphragm, or sponge with spermicide  
• A combination of male condom with either cervical cap, diaphragm, or sponge with 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 97 
 spermicide (double -barrier methods)c 
a. Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for those partic ipating in clinical studies.  
b. Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those when 
used consistently and correctly.  
c. If locally required, in accordance with Clinical Trial Facilitation Group (CTF G) guidelines, acceptable contraceptive 
methods are limited to those which inhibit ovulation as the primary mode of action.  
d. Considered effective, but not highly effective - failure rate of ≥1% per year.  Periodic abstinence (calendar, 
sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational 
amenorrhoea method (LAM) are not acceptable methods of contraception.  
e. Male condom and female condom should not be used together (due to risk of failure with friction).  
 
10.4.3.  Collection of Pregnancy Information:  
Female Participants who become pregnant  
• Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study.  
• The initial information will be recorded on the appropriate form and submitted to 
GSK  within 24 hours of learning of a  participant's pregnancy.  
• Participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on participant and neonate, whi ch 
will be forwarded to GSK  Generally, follow -up will not be required for longer 
than 6 to 8 weeks beyond the estimated delivery date.   
• Any termination of pregnancy will be reported, regardless of fetal status 
(presence or absence of anomalies) or indicat ion for procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 weeks gestati onal age) or still birth 
(occurring at >22 weeks gestational age) is always considered to be an SAE and 
will be reported as such.  
• Any SAE occurring as a result of a post -study pregnancy  which is considered 
reasonably related to the study intervention by t he investigator, will be reported 
to GSK  as described in Appendix 3 . While the investigator is not obligated to 
actively seek this information in former study participants, he  or she may learn of 
an SAE through spontaneous reporting.  
Any female participant who becomes pregnant while participating   
• will discontinue study intervention or be withdrawn from the study  
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 98 
 10.5.  Appendix  5: Genetics  
USE/ANALYSIS OF DNA  
• Genetic variation may  impact a participant’s response to study intervention, 
susceptibility, severity and progression of disease. Variable response to study 
intervention may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; me chanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will  be collected for DNA 
analysis  
• DNA samples will be used for research related to  GSK3228836 or CHB and 
related  diseases. They may also be used to develop tests/assays including 
diagnostic tests related to GSK3228836 or other 2’ -MOE ASOs, and CHB. 
Genetic  research may consist of the analysis of one or more candidate genes or 
the analys is of genetic markers throughout the genome or analysis of the entire 
genome (as  appropriate)  
• Additional analyses of DNA samples may be conducted if it is hypothesized that 
this may help further understand the clinical data.  
• The samples may be analyzed as  part of a multi -study assessment of genetic 
factors involved in the response to GSK3228836 or study  interventions of this 
class. The results of genetic analyses may be reported in the clinical study report 
or in a separate study summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained while research on GSK3228836 (or study 
interventions of this class) or CHB continues but no longer than 15 years after 
the last  participant  last visit or other period as  per local requirements.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 99 
 10.6.  Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments and Study Intervention Restart/Rechallenge 
Guidelines  
Phase 2 liver chemistry stopping and increased monitoring criteria  have been 
designed to assure participant safety and evaluate liver event etiology .  
The procedures listed below are to be followed if a participant meets any of the liver 
chemistry stopping criteria defined in Section  7.1.1 . 
• Immediately withdraw the participant  from study treatment.  
• Notify the Medical Monitor within 24  hours of learning of the abnormality to 
confirm the participant ’s study treatment cessation and follow -up. 
• Complete the Liver Event CRF.  
• Complete the “Safety Follow -up Procedures” listed below.  
Safety Follow -up Procedures for Participant s Who Meet Any of The 
Stopping Criteria:  
Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Cytomegalovi rus IgM antibody;  
o Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  
o Hepatitis E IgM antibody.  
o Hepatitis C virus RNA load  
o Hepatitis D virus antibody  
• Obtain a blood sample for pharmacokinet ic (PK) analysis as soon as possible 
following the occurrence of an event. Record the date/time of the PK blood sample 
collection and the date/time of the last dose of study treatment prior to blood sample 
collection on the CRF. If the date or time of the last dose is unclear, provide the 
participant ’s best approximation. Instructions for sample handling and shipping are 
included in the Study Reference Manual (SRM).  
• Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH).  
• Fractionate bilirubin, if total bilirubin  1.5 X upper limit of normal (ULN)  
• Assess eosinophilia  
• Record the appearance or worsening of clinical symptoms of hepatitis 
(fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash 
or eosin ophilia) as relevant on the Adverse Event (AE) CRF.  
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 100 
 • Record use of concomitant medications, acetaminophen, herbal remedies, 
other over the counter medications, or putative hepatotoxins on the 
Concomitant Medications CRF.  
• Record alcohol use on the Liver Even ts CRF.  
The following are required for participant s who meet the ALT and bilirubin 
stopping  criteria but are optional for other abnormal liver chemistries . 
• Anti-nuclear antibody, anti -smooth muscle antibody, Type 1 anti -liver kidney 
microsomal antibodies a nd quantitative total immunoglobulin G (IgG or  
gamma globulins).  
• Serum acetaminophen adduct high performance liquid chromatography 
(HPLC) assay (quantifies potential acetaminophen contribution to liver injury 
in participant s with definite or likely acetam inophen use in the preceding 
week [James , 2009]) , if available.  
• Liver imaging (ultrasound, magnetic resonance, or computerized tomography) 
or Liver biopsy to evaluate liver disease.  
o The Liver Imaging and/or Liver Biopsy CRFs are also to be completed if these 
tests are performed.  
Restart Following Transient Resolving Liver Stopping Events Not Related to Study 
Intervention  
Restart refers to resuming study interve ntion following liver stopping events in which 
there is a clear underlying cause (other than drug -induced liver injury [DILI]) of the liver 
event (e.g. biliary obstruction, pancreatic events, hypotension, acute viral hepatitis). 
Furthermore, restart is not  permitted following liver stopping event when the underlying 
cause was alcohol -related hepatitis.  
• Approval by GSK for study intervention restart can be considered where:  
• Investigator requests consideration for study intervention restart if liver 
chemistri es have a clear underlying cause (e.g., biliary obstruction, hypotension 
and liver chemistries have improved to normal or are within 1.5 x baseline and 
ALT <3xULN).  
• Possible study intervention -induced liver injury has been excluded by the 
investigator and the study team. This includes the absence of markers of 
hypersensitivity (otherwise unexplained fever, rash, eosinophilia). Where a 
study intervention has a confirmed genetic marker associated with liver injury, 
the presence of the marker should be exclude d. If study intervention -related 
liver injury cannot be excluded, the guidance on rechallenge will apply.  
• There is no evidence of alcohol -related hepatitis.  
• Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) 
approval of study interventio n restart (as required) has been obtained.  
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 101 
 If restart of study intervention is approved by GSK Medical Governance in writing:  
• The participant must be provided with a clear description of the possible benefits 
and risks of study intervention administration  including the possibility of recurrent, 
more severe liver injury or death.  
• The participant must also provide signed informed consent specifically for the 
restart of study intervention. Documentation of informed consent must be recorded 
in the study file.   
• Study intervention must be administered at the dose specified by GSK  
• Participants approved by GSK for restart of study intervention must return to the 
clinic twice a week for liver function tests until stable liver function tests have 
been demonstrated a nd then standard laboratory monitoring may resume as per 
protocol.  
• If the participant meets protocol -defined liver chemistry stopping criteria after 
study intervention restart, study intervention should be permanently discontinued.  
• The Medical Monitor, and  the IRB/IEC, must be informed of the outcome for the 
participant following study intervention restart.  
• GSK must be notified of any adverse events.  
 
TMF-1395648 0 CONFIDENTIAL  
  209668  
 Protocol Amd 02  
 102 
 10.7.  Appendix 7: Country -specific requirements  
10.7.1.  China  
The following sections outline China -specific changes from the main protocol.  
In China, collection of exploratory/biomarker labs will be contingent on agreements with 
China regulatory (HGRAC) , otherwise the SoA should be the same as the main study 
protoco l. 
10.7.1.1.  China Schedule of Activities  
Table 14 Screening  
ASSESSMENTS   
Informed Consent  X 
Inclusion and exclusion criteria  X 
Demography  X 
Medical history (includes substance usage) and current medical conditions  X 
Medication history and concomitant medication review  X 
Full physical exam including height and weight  X 
Vital signs  X 
12-lead ECG  X 
LABORATORY  
Serum hCG pregnancy test (women of child -bearing potential)  X 
FSH/Estradiol (to confirm status of women of non -child-bearing potential)1 X 
Hematology/Chemistry/Urinalysis  X 
Urine ACR  X 
PT, INR, aPTT  X 
HIV, hepatitis D, and hepatitis C screen  X 
Hepatitis B profile (HBsAg, HBV DNA, HBeAg)  X 
Alpha -fetoprotein  X 
APRI/Fibrosure  X 
ANCA2  X 
Total bile acid profile (as available)  X 
Complement C3, C4, C5a, hsCRP, MCP -1, complement Bb, Ang -2 X 
1. As appropriate to confirm menopause  
2. With MPO -ANCA, PR3 -ANCA if results are positive or border -line positive  
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 103 
 Table 15 On Treatment Day 1 to Day 50  
ASSESSMENTS1 Day 1  
 D4 D8 D11 D15 D22 D29 D36 D43 D50 
Window   1 day  3 days  
 Week 1  W1 W2 W2 W3 W4 W5 W6 W7 W8 
Randomization  X          
Study treatment dosing  X X X X X X X X X X 
Safety Assessments   
AE/SAE review  X X X X X X X X X X 
Concomitant medication review  X X X X X X X X X X 
Symptom directed exam  X      X    
Vital signs X X X X X X X X X X 
Injection site reactions X X X X X X X X X X 
Questionnaire (cell phone app, 
optional)  X          
Questionnaire (patient feedback on 
dosing regimen)  X          
Patient Reported Outcomes 
Questionnaires: HBQoL, EQ -5D X          
Laboratory   
Pregnancy test (women of child 
bearing potential)2 X2      X    
Hematology3 [includes platelet count  
and WBC] X  X  X X X X X X 
PT, INR, aPTT  X      X    
Chemistry  X  X  X X X X X X 
Urinalysis  X  X  X X X X X X 
Urine ACR X    X  X  X  
HBsAg and HBV DNA  X  X  X X X X X X 
Anti- HBsAg  X      X    
Anti-HBeAg  X      X    
HBeAg (only for participant s HBeAg 
positive at screening)  X  X  X X X X X X 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 104 
 ASSESSMENTS1 Day 1  
 D4 D8 D11 D15 D22 D29 D36 D43 D50 
Window   1 day  3 days  
 Week 1  W1 W2 W2 W3 W4 W5 W6 W7 W8 
HBV RNA , HBcrAg  and Sequencing 
(HBV Genotype /phenotype ; HBV 
DNA and/or RNA)  X     X    X 
Complement C3, Complement C4, 
hs-CRP, MCP -1 X    X  X  X  
Complement C5a, Complement 
factor Bb  X    X  X  X  
ANCA, Ang II  X      X    
PK X  X  X X X X X X 
PBMC Collection for 
immunophenotyping4 X          
Soluble  Protein (immunology) 4 X     X    X 
PAXGene RNA for expression 
analysis in whole blood4 X          
OPTIONAL: Genetics4 X          
Archived Samples  [serum; plasma]  X    X  X  X  
1. In selected countries /sites , participant s will have the option to use a centralised home nursing provider. Only selected visits will have the option to be performed as a home 
visit, these will include drug administration, blood draws, participant  assessments and data collection. The full specifi cations of the home nursing services will be outlined in 
the SRM  
2. A WOCBP must have both:  
a. A confirmed menstrual period prior to the first dose of study intervention; additional evaluation (e.g., amenorrhea in athlet es, birth control) should also be 
consider ed 
b. AND a negative highly sensitive pregnancy test [urine or serum] within 24 hours before the first dose of study treatment  
3. Hematology - platelet count to be analyzed at local laboratory  prior to dose ; hematology samples to be collected for central laborat ory assessments in parallel  
4. In China, collection of these labs will be contingent on agreements with China regulatory (HGRAC), and will be optional for C hinese participants  
 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 105 
 Table 16 On-Treatment: Day 57 to Day 162  
Assessments1 D57 D64 D71 D78 D85 D92 D99 D106  D113  D120  D127  D134  D141  D148  D155  D162  
Window  3 days  
 W9 W10 W11 W12 W13 W14 W15 W16 W17 W18 W19 W20 W21 W22 W23 W24 
Study treatment dosing  X X X X X X X X X X X X X X X X 
Safety Assessments   
AE/SAE review  X X X X X X X X X X X X X X X X 
Concomitant 
medication review  X X X X X X X X X X X X X X X X 
Symptom directed 
exam  X    X    X    X    
Vital signs  X X X X X X X X X X X X X X X X 
Injection site reactions  X X X X X X X X X X X X X X X X 
Questionnaire (cell 
phone app; optional)                 X 
Questionnaire (patient 
feedback on dosing 
regimen)                 X 
Laboratory   
Pregnancy test (women 
of child bearing 
potential)  X    X    X    X    
Hematology2 [includes 
platelet count, and 
WBC]  X X X X X X X X X X X X X X X X 
PT, INR, aPTT  X X X X X X X X X X X X X X X X 
Chemistry  X X X X X X X X X X X X X X X X 
Urinalysis  X X X X X X X X X X X X X X X X 
Urine ACR  X  X  X  X  X  X  X  X  
HBsAg and HBV DNA  X X X X X X X X X X X X X X X X 
Anti- HBsAg  X    X    X    X    
Anti- HBeAg  X    X    X    X    
HBeAg  (only for 
participants HBeAg 
positive at screening)  X X X X X X X X X X X X X X X X 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 106 
 Assessments1 D57 D64 D71 D78 D85 D92 D99 D106  D113  D120  D127  D134  D141  D148  D155  D162  
Window  3 days  
 W9 W10 W11 W12 W13 W14 W15 W16 W17 W18 W19 W20 W21 W22 W23 W24 
HBV RNA , HBcrAg  and 
Sequencing (HBV 
Genotype /phenotype ; 
HBV DNA and/or RNA)     X    X    X    X 
Complement C3, 
Complement C4, hs -
CRP, MCP -1 X  X  X  X  X  X  X  X  
Complement C5a, 
Complement factor Bb  X  X  X  X  X  X  X  X  
ANCA, Ang II  X    X    X    X    
PK3 X X X X X X X X X X X X X X X X 
PBMC Collection for 
immunophenotyping4    X            X 
Soluble protein 
(immunology) 4    X    X    X    X 
PAXGene RNA for 
expression analysis in 
whole blood4     X            
Archived Samples  
[serum; plasma]  X  X  X  X  X  X  X  X  
1. In selected countries /sites , participant s will have the option to use a centralised home nursing provider. Only selected visits will have the option to be performed as a home 
visit, these will include drug administration, blood draws, participant  assessments and data collection. The full specifi cations of the home nursing services will be outlined in the 
SRM  
2. Hematology - platelet count to be analyzed at local laboratory  prior to dose ; hematology samples to be collected for central laboratory assessments in parallel  
3. In addition to the pre -dose samp le Intensive PK collection may be collected  for China, Japan, and country(ies) with participants of non -Asian heritage (TBD) See Table 8 for 
details of intensive PK sample collection  
Intensive PK  (GSK3228836 and nucleos[t]ide) will be collected at one visit between Week 14 (inclusive)  and Week 24  (inclusive)  chosen between the site and participant : 
post dose at 0.5 hr, 1 hr, 1.5 hr,  2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 12 hr, 24 hr, 72 hr, and 168 hr  [the site should make all attempts to align the 168 hr post -dose PK with the 
next scheduled visit’s pre-dose PK, see Table 8 for more details]  
4. For China, collection of these labs will be contingent on agreements with China regulatory (HGRAC), and will be optional for Chinese participants  
 
 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 107 
 Table 17 Off-Treatment Follow -Up  
Assessments1  OT-Day 1  OT-Day 8  OT-Day 22  OT-Day 50  OT-Day 78  OT-Day 106   OT-Day 134  OT-Day 162  Early 
Termination  
Window    3 days   10 days   
  OT- W1 OT-W2 OT-W4 OT-W8 OT-W12 OT-W16 OT-W20 OT-W24  
Safety Assessments   
AE/SAE review  X X X X X X X X X 
Concomitant medication review  X X X X X X X X X 
Symptom directed  exam  X X  X X X X X X 
Vital signs X X X X X X X X X 
Patient Reported Outcomes 
Questionnaire : HBQOL, EQ -5D        X  
Laboratory   
Pregnancy test (women of  child bearing 
potential)  X  X X X X X X X 
Hematology2 [includes platelet count, 
and WBC] X X X X X X X X X 
PT, INR, aPTT  X  X  X X X X X 
Chemistry  X X X X X X X X X 
Urinalysis  X X X X X X X X X 
Urine ACR X X X X X X X X X 
HBsAg and HBV DNA  X X X X X X X X X 
Anti- HBsAg  X X X X X X X X X 
Anti- HBeAg  X X X X X X X X X 
HBeAg (only for participant s HBeAg 
positive at screening)  X X X X X X X X X 
HBV RNA , HBcrAg  and Sequencing 
(HBV Genotype /phenotype ; HBV DNA 
and/or RNA)  X  X  X  X X X 
Complement C3,  Complement C4, hs -
CRP, MCP -1  X X X X X X X X 
Complement C5a, Complement factor  X X X X X X X X 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 108 
 Assessments1  OT-Day 1  OT-Day 8  OT-Day 22  OT-Day 50  OT-Day 78  OT-Day 106   OT-Day 134  OT-Day 162  Early 
Termination  
Window    3 days   10 days   
  OT- W1 OT-W2 OT-W4 OT-W8 OT-W12 OT-W16 OT-W20 OT-W24  
Bb 
ANCA, Ang II  X  X X X X X X X 
PK X X X X X X X X X 
PBMC Collection for 
immunophenotyping3 X    X   X X 
Soluble  Protein (immunology)3 X  X  X  X X X 
PAXGene RNA for expression analysis 
in whole blood3 X    X   X X 
APRI/Fibrosure         X X 
Archived Samples [serum; plasma]  X X X X X X X X X 
1. In selected countries /sites , participant s will have the option to use a centralised home nursing provider. Only selected visits will have the option to be performed as a 
home visit, these will include drug administration, blood draws, participant  assessments and data collection. The full specifi cations of the home nursing services will be 
outlined in the SRM  
2. Hematology - platelet count analyzed  at local laboratory  is optional during the off -treatment period ; hematology samples to be collected for central laboratory 
assessments  (required; if local lab is being drawn, in parallel with local lab sample)  
3. For China, collection of these labs will be contingent on agreements with China regulatory (HGRAC), and will be optional for Chinese participants  
 
OT: off -treatment; the first off -treatment visit occurs 7 days after the last study treatment dose received, whether planned or last dose given after 
participant is withdrawn from study treatment (e.g., the planned first off -treatment visit occurs on Day 169, 7 days after the Day 162 visit; if participan t is 
withdrawn from study treatment on Day 50, the first off -treatment visit occurs on Day 57)  
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 109 
 10.7.1.2.  China Biomarkers and Archived Samples  
For China, collection of PBMCs, plasma protein, PAXgene RNA, and genetic samples 
will be contingent on agreements with China regulatory (HGRAC) and will be optional 
for Chinese participants. Depending on the agreements with China regulatory and ethics 
committees, all  or some of these biomarkers will be made optional for Chinese 
participants.  
 
Collection of samples for other biomarker research is part of this study. These 
exploratory biomarker samples will be collected to evaluate the pathogenesis of CHB; the 
absorptio n, distribution, metabolism, or excretion of GSK3228836; or the participant’s 
response to GSK3228836. In addition, continuing research may identify other proteins, 
transcripts or biomarkers related to GSK3228836 treatment, the response to 
GSK3228836 or the  pathogenesis of CHB, which will be evaluated in these samples.  
• Blood samples, including serum, plasma, PBMCs and PAX gene tubes, will be 
collected to evaluate virologic and immune biomarkers related to the pathogenesis 
of CHB and the participant’s respons e to GSK3228836. Samples will be collected 
according to the schedule described in the SoA and as detailed in the laboratory 
manual provided separately to sites.  
• For China - stored samples (e.g., archived samples) may be used for the purposes 
of follow -up ex ploration of laboratory findings and/or AEs (e.g., see Section 7 
for additional analyses in case of an AE or SAE).  
 
 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 110 
 10.8.  Appendix 8: Abbreviations and Trademarks  
ACR  albumin to creatinine ratio  
AE adverse event  
ALT alanine aminotransferase  
APRI  aspartate aminotransferase -platelet index  
aPTT  activated partial thromboplastin time  
ASO  antisense oligonucleotide  
AST aspartate aminotransferase  
AUC  area under the concentration -time curve  
BUN  blood urea nitrogen  
CHB  chronic hepatitis B  
CL/F  apparent subcutaneous plasma clearance  
CKD -EPI Chronic Kidney Disease Epidemiologic Collaboration  
Cmax maximum observed concentration  
Ct concentration  
CONSORT  consolidated standards of reporting trials 
CRF case report form  
CRO  contract research organization  
CV cardiovascular  
DAIDS  Division of Acquired Immune Deficiency Syndrome  
dL deciliters  
DNA  deoxyribonucleic acid  
ECG  electrocardiogram  
ET early termination  
FSH follicle stimulating hormone  
GCP  good clinical practice  
GFR  glomerular filtration rate  
GSK  GlaxoSmithKline  
H hours  
HBcrAg  hepatitis B core -related antigen  
HBeAg  hepatitis B virus e -antigen  
Anti- HBsA g hepatitis B virus surface antibody  
HBsAg  hepatitis B virus surface antigen  
HBV hepatitis B virus  
HCC  hepatocellular carcinoma  
hCG human chorionic gonadotropin  
HCV  hepatitis C virus  
HDV  hepatitis D virus  
HIV human immunodeficiency virus  
HPLC  High performance liquid chromatography  
HPF high-power field  
hs-CRP  high sensitivity C -reactive protein  
IB investigator’s brochure  
ICH international conference on harmonisation  
IDMC  Independent Data Monitoring Committee  
IDO indoleamine 2,3 dioxygenase  
IEC independent ethics committee  
IND investigational new drug 
INR international normalized ratio  
ISR injection site reaction  
ITT intent -to-treat 
IU international units  
Kg kilograms  
kPa kilopascals  
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 111 
 L liters  
LDH lactate dehydrogenase  
LLOQ  lower limit of quantification  
m2 square meters  
MedDRA  medical dictionary for regulatory activities  
Mg milligrams  
Min minutes  
mL milliliters  
mm3 cubic millimeters  
MOE  methoxyethyl  
Msec  milliseconds  
MSDS  material safety data sheet 
NA nucleos(t)ide  analog  
Ng nanograms  
Nucleos(t)ide  nucleoside or nucleotide  
PBMC  peripheral blood mononuclear cells  
PD pharmacodynamics(s)  
PEG  pegylated  
PK pharmacokinetic(s)  
PT prothrombin time  
QTcF  Fridericia’s QT correction formula  
RAP reporting and analysis plan 
RBC  red blood cell  
RNA  ribonucleic acid  
RR response rate  
SAE serious adverse event  
SC subcutaneous(ly)  
siRNA  small interfering ribonucleic acid  
SOP  standard operating procedure  
SPEP  serum protein electrophoresis  
SRM  study reference manual  
SVR sustained virologic response  
t½ terminal half -life 
TCM  traditional Chinese medicine  
tmax time of maximum observed concentration  
U units  
UA urinalysis  
g micrograms  
ULN upper limit of normal  
UPEP  urine protein electrophoresis  
mol micromole  
WBC  white blood cell 
 
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by the 
GlaxoSmithKline group of companies  
NONE   None  
 
 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 112 
 10.9.  Appendix 9: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is 
located directly before the Table of Contents (TOC).  
Amendment 01:  10-MAY -2021  
This amendment is considered to be non -substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and t he Council of the 
Europe because it neither significantly impacts the safety or physical/mental integrity of 
participants nor the scientific value of the study.  
Overall Rationale for the Amendment:   
The primary drivers for this amendment were non -substanti al changes, mostly for 
clarification and further directives due to the COVID -19 pandemic.  
In addition, minor typographical errors and inconsistencies have been corrected and 
minor editorial changes have been made. Changes made to the text body have been ma de 
concurrently in the synopsis.  
Section # and 
Name  Description of Change  Brief Rationale  
Throughout, as 
appropriate  Changed the primary estimand text from: "sustained 
virologic response for 24 weeks after the end of 
GSK3228836 treatment in the absence of  rescue 
medication.", to:  
“sustained virologic response for 24 weeks after the 
planned  end of GSK3228836 treatment in the absence 
of rescue medication."  Some participants may withdraw from 
treatment early, the word “ planned ” 
has been added to clarify that for the 
primary estimand, SVR is assessed 
24 weeks after the planned end of 
treatment, not the actual end of 
treatment.  
Throughout, as 
appropriate  Changed subject to participant.  Current guidelines.  
Schedule of 
Activities 
tables, all and 
Section 8.2.1 
Physical 
Examinations  Changed brief physical exam to symptom directed 
exam.  Updated to reflect risk reduction 
practices in limiting physical contact 
due to COVID -19 and to align with 
assessment covered by home 
nursing licenses.  
Schedule of 
Activities  
table s, as 
required and 
applicable text 
throughout  Added phenotype  for HBV RNA, HBcrAg, and 
Sequencing (HBV Genotype/ phenotype ; HBV DNA 
and/or RNA) . To provide clarity that sequencing will 
also be used to understand HBV 
phenotype . 
Schedule of 
Activities  
tables, as 
required  Added footnote (o nly for selected sites able to transport 
to the analysis lab within the timeframe  specified in the 
SRM ) to entry for PBMC collection for 
immunophenotyping . To allow flexibility for sites that are 
not equipped to transpo rt the PBMC 
samples in a timely fashion.  
Schedule of 
Activities,  
Table 4 and  
Table  17 
(China)  Remove optional genetics sample from the Off -
treatment follow -up visits in the Schedule of Activities .  Genetics sampl ing is only required at 
Day 1. The off-treatment follow -up 
sample was included in error.  
Section 2.3.1.1  Added section titled Regarding COVID -19. To inform of (no known additional) 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 113 
 Section # and 
Name  Description of Change  Brief Rationale  
risk of COVID -19 for HBV 
participants.  
Section 3  
Key Objectives 
and 
Estimand/Endp
oints table and 
Section  9.4.2.2  A supplementary estimand for the primary endpoint was 
added.  Some participants may withdraw from 
treatment early, a supplementary 
estimand that assesses SVR 24 
weeks after the actual end of 
treatment is included to support the 
primary objective.  
Section 3  
Key Objectives 
and 
Estimand/Endp
oints table and 
Section  9.4.4.1 
Estimands for 
Secondary 
Objective  Secondary Efficacy Endpoints:  
moved HBe -antibody (anti -HBeAg) levels from a 
continuous variable to a categorical variable.  Correction.  
Section 3  
Key Objectives 
and 
Estimand/Endp
oints table  and 
Section  9.4.4.1 
Estimands for 
Secondary 
Objective  Secondary Efficacy Endpoints; Population summary:  
changed statistical estimator from Kaplan -Meier to 
Turnbull.  Given the data will be interval -
censored, Turnb ull’s method is more 
appropriate than Kaplan -Meier 
method . 
Section 3  
Key Objectives 
and 
Estimand/Endp
oints table  Secondary Efficacy Endpoints ; Pharmacokinetics:  
removed PK derivations for apparent plasma clearance 
and apparent subcutaneous plasma clearan ce for 
GSK3228836 and apparent oral plasma clearance for 
nucleos(t)ide.  Apparent plasma clearance  = 
Dose/AUC, with DOSE being 
constant, “apparent plasma 
clearance” reflects the same PK 
characteristics as AUC, thus 
redundant and can be removed.  
Section 3  
Estimand/Endp
oints 
corresponding 
to Exploratory 
PK-PD 
relationships  Exploratory PK -PD endpoints changed from descriptive 
statistical summaries to PK -PD model dependent 
parameter outputs as endpoints.  Correction.  
Section 5.2  
Exclusion 
Criteria  Medical Condi tions Number 3:  
provide clarity that liver biopsy and stiffness are 
historical measurements.  Provide clarity to investigators that 
these are for historical 
measurements , if available, not to be 
performed for assess ment.  
Section 5.2  
Exclusion 
Criteria  Medical Conditions Number 8: 
ANCA  Updated to provide clear parameters 
for exclusion . 
Section 5.2  
Exclusion 
Criteria  Medical Conditions Number 9: 
C3 Updated to provide clear parameters 
for exclusion . 
Section 6.5.2 
Initiation of 
Nucleos(t)ides 
During 
GSK32 28836 
Treatment  Allowing for use of NA therapy in Arm 4 of the study 
(after the NA -restriction period, while on active 
GSK3228836), if there is concern about developing 
resistance to GSK3228836.  Updated to provide clarity as 
participants in Arm 4 do not st art 
GSK3228836 until after Week 12.  
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 114 
 Section # and 
Name  Description of Change  Brief Rationale  
Section 6.5.4 
Prohibited 
Medications 
and Non -Drug 
Therapies  Addition of anticoagulation therapies.  To make clear that anti -coagulation 
therapy is a prohibited medication as 
per the exclusion criteria.  
Table 6  
Liver 
Monitoring and 
Stopping 
Criteria  Updated to include discussions with Medical Monitor 
and clarification for taking patients off hold, as the 
terminology of “restart” should be used for the re -start 
criteria after a patient is permanently discontinued from 
treatment.  Clarification.  
Section 7.1.1  
Liver 
Chemistry 
Monitoring and 
Stopping 
Criteria  Added twice (in bold): Participants must be monitored 
twice  weekly until liver chemistry abnormalities (ALT, 
AST, alkaline phosphatase, bilirubin) resolve,  
stabilize, or  return to within baseline values.  Corrected to align with the monitoring 
plan in Table 6.  
Section 7.1.1  
Liver 
Chemistry 
Monitoring and 
Stopping 
Criteria  Added text:  
Cases such as Gilbert syndrome, where baseline 
bilirubin values are high, should be discussed with the 
Medical Monitor, to assess if it is a case of DILI or the 
participant may continue with dosing.  To clarify and identify instance where 
medical monitor should be consulted.  
Section 7.1.1  
Liver 
Chemistry 
Monitoring and 
Stopping 
Criteria  Updated to include clarification that clinically significant 
lab changes should be confirmed, to correct Liver 
Events CRF to Liver Alcohol CRF.  Clarification/correction.  
Section 7.1.1  
Liver 
Chemistry 
Monitoring and 
Stopping 
Criteria  Clarify that the seru m acetaminophen adduct high 
performance liquid chromatography (HPLC) assay 
(quantifies potential acetaminophen contribution to liver 
injury in participants with definite or likely 
acetaminophen use in the preceding week) should be 
conducted if available.  Serum acetaminophen adduct high 
performance liquid chromatography 
assay may not be available in all 
countries.  
Section 7.1.3 
Haematological 
Stopping 
Criteria  Added text (in bold):  
If the platelet count is uninterpretable or a decreasing 
trend is noted below LLN reference range, re -check the 
platelet counts as soon as possible (the investigator 
may, at their discretion, opt to have the participant 
come to their next scheduled visit OR ask the 
participant to come earlier than their scheduled 
visit, as they f eel appropriate based on review of the 
participant’s clinical presentation and laboratory 
results).  Clarification and to provide guidance 
to investigator.  
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 115 
 Section # and 
Name  Description of Change  Brief Rationale  
Section 7.1.4  
Drug Induced 
Kidney Injury 
(Renal) 
Stopping 
Criteria  Treatment Hold/Treatment Discontinuation  
changed baseline to pre -dose range for ACR and eGFR 
changes.  Clarification. The investigator may 
take into account natural fluctuations, 
as may be seen in the pre -dose 
screening or Day 1 values, in 
assessing changes in these 
parameters for the hold/stopping 
criteria.  
Section 8.3.1  
Time Period 
and Frequency 
for Collecting 
AE and SAE 
Information  Updated timing for recording AE/SAE as related to 
informed consent/dose administration.  Clarification.  
9.4 Statistical 
Analysis  Updated all section s to provide clarity that statistical 
summaries and analyses will be conducted separately 
for the 2 population (on nucleos(t)ide treatment and not 
currently on nucleos(t)ide treatment).  Clarification.  
Section 9.4.3  
Primary 
Analyses  Amended specification of Bayesian model.  Model specification was amended to 
improve clarity and avoid repetition.  
Table 11  Updates to clarify stratification factors for the 4 stratum.  Clarification/Correction.  
Table 13  Changed SAE reporting bilirubin <2X ULN to >2X ULN.  Correction, due to typo.  
Section 9.4.6.3 
PK and PK -PD 
Analyses  Added description of Population PK model, removed 
efficacy and safety assessments (described in 
Objective/Endpoints).  Correction. Exploratory graphical 
analyses will be initially performed for 
efficacy and safety endpoints.  
Only If a relationship (exposure and 
efficacy and/or safety endpoints) is 
present will further modeling be 
conducted.  
Section 9.6  
Independent 
Data 
Monitoring 
Committee 
(IDMC)  Additional text added around IDMC safety reviews and 
IDMC review of ALT criteria.  Updated to describe the planned 
safety reviews and to provide clarity 
around when IDMC would review 
safety data to expand ALT inclusion 
criteria for treatment naïve 
participants and for participants who 
are not currently receiving treatment.  
Section 10.3. 5 
Division of 
AIDS (DAIDS) 
Table for 
Grading 
Severity of 
Adult and 
Pediatric 
Adverse 
Events  Removed criteria that are contained within the DAIDs 
table.  Correction.  
Section 10.6  
Appendix 6  Added re -start guidelines.  Re-start guidelines were presented in 
Section 7.1.5 but were not included in 
the appendices.  
Section 10.7.1  Corrected China Schedule of Activities, previously 
addressed in China -specific amendment.  To align with global Schedule of 
Activities.  
 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 116 
 11. REFERENCES  
Baraclude (Entecavir) [package insert] . Bristol -Myers Squibb Company. Princeton (NJ); 
2015.  
Bennett CF and Swayze EE. RNA targeting therapeutics: molecular mechanisms of 
antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 
50: 259 -293.  
Bertoletti  A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus 
infections: towards restoration of immune control of viral infection. Postgrad Med J  
2013;89:294 -304. 
Boettler T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Cornberg M, Be rg T. 
Care of patients with liver disease during the COVID -19 pandemic: EASL -ESCMID 
position paper. JHEP Rep. 2020;2(3):100113.  
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. 
Characterization of hepatitis B virus (HBV) -specifi c T-cell dysfunction in chronic HBV 
infection. J Virol  2007;81:4215 -25. 
Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored 
function of HBV -specific T cells after long -term effective therapy with nucleos(t)ide 
analogues. Gastroenterology  2012;143:963 -73. 
Bristol -Myers Squibb Company. Baraclude prescribing information (USA). 12/2018 
revision.  
Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg 
seroclearance in patients with inactive chronic hepatitis  B virus infection. Clin 
Gastroenterol Hepatol 2012; 10: 297 -302. 
Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA -based 
therapeutics, Drug Discovery Today,( 2017 )  22 (5): 823 -833, ISSN 1359 -6446, 
https://doi.org/10.1016/j.drudis.20 17.01.013 . 
Cihlar T, Bleasby K, Roy A, Prichard J. Abstr. 44th Intersci. Conf. Antimicrob. Agents 
Chemother., abstr. A448, 2004.  
Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its 
role in the nephrotoxicity of antiviral  nucleotide analogs. Nucleosides Nucleotides 
Nucleic Acids 2001; 20: 641 -648.  
Crooke ST, Baker BF, Wiztum JL, Kwoh TJ, Pham NC, Salgado et al.  The effects of 2’ -
O-Methoxyethyl containgin antisense oligonucleotides on platelets in human clinical 
trials.  Nucleic Acid Ther 2017; 27(3):121 -129.  
Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult 
and Pediatric Adverse Events Version 2.0. National Institutes of Health; Institute of 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 117 
 Allergy and Infectious Diseases, Bethesda, MD; 2017. Available at: http://rsc.tech -
res.com/Document/safetyandpharmacovigilance/DAIDS_AE_Grading_Table_v 2.1_201 7
.pdf  
Epivir (Lamivudine) [package insert]. GlaxoSmithKline. Research Triangle Park (NC); 
2002.  
European Association for the Study of the Liver (EASL). 2017 Clinical Practice 
Guidelines on the management of hepatitis B virus infection. Electronic address: 
easloffice@easloffice.eu ; J Hepatol . 2017 Aug;67(2):370 -398. doi: 
10.1016/j.jhep.2017.03.021.  
European Association for the Study of the Liver (E ASL). EASL clinical practice 
guidelines: Management of chronic hepatitis B virus infection. J Hepatol 
2012;57:167 -85. 
Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. 
Hepatology  2009;49(5 Suppl):S96 -S102.  
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC,  et al.  Clinical 
Best Practice Advice for Hepatology and Liver Transplant Providers During the 
COVID -19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 
2020;72(1):287 -304.  
Geary RS,  Yu RZ, Siwkowski A, Levin AA. Pharmacokinetic/pharmacodynamics 
properties of phosphorothioate 2ʹ -O-(2-methoxyethyl) -modified antisense 
oligonucleotides in animals and man. In Crooke ST, editor. Antisense Drug Technology: 
Principles, Strategies and Applica tions, 2nd Edition. Boca Raton, FL. Taylor & Francis 
Group 2008; 305 -326.  
Gilead Sciences Inc. Viread prescribing information (USA). 12/2018 revision.  
Hepsera (Adefovir dipivoxil) [package insert]. Gilead Sciences, Inc. Foster City (CA); 
2012.  
Höner Zu S iederdissen C, Cornberg M. The role of HBsAg levels in the current 
management of chronic HBV infection. Ann Gastroenterol 2014;27(2):105 -112. 
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA et al. 
Pharmacokinetics of Acetaminophen -Adduc t in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos  2009;37:1779 -84. 
Jaroszewicz J, Ho H, Markova A, Deterding K, Schlue K, Raupach R, et al. Hepatitis B 
surface antigen (HBsAg) decrease and serum interferon -inducible protein -10 levels as 
predictive markers for HBsAg loss during treatment with nucleoside/nucleotide 
analogues. Antivir Ther 2011; 16(6): 915 -924. 
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 118 
 Jones  HE, Ohlssen  DI, Neuenschwander  B, Racine A, Branson M.  Bayesian models for 
subgroup analysis in clinical trials. Clin Trials. 2011 Apr; 8(2): 129 –143. Published online 
2011 Jan 31. doi: 10.1177/1740774510396933  
Kearney B, Flaherty J, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and 
pharmacokinetics. Clin Pharmacokinet 2004;439:595‐612  
Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, et al .  Incidence of hepatocellular 
carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for 
surveillance.  J Hepatol . 2014; 62(5), 1092 –99. https://doi.org/10.1016/j.jhep.2014.11.031   
Liaw  YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Cirrhosis Asian 
Lamivudine Multicenter Study Group. Lamivudine for patients with chronic hepatitis B 
and advanced liver disease. N Engl J Med  2004;351:1521 -31. 
Lok AS, Zoulim F, Dusheiko G, Ghany MG.  Hepatitis B cure: From discovery to 
regulatory approval. Hepatol.  2017 Oct;66(4):1296 -1313. doi: 10.1002/hep.29323. Epub 
2017 Aug 1.  
Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. AASLD practice guidelines. 
Hepatol  2009;50:1 -36. 
Maruyama  T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR, et al. The 
serology of chronic hepatitis B infection revisited. J Clin Invest  1993; 91:2586 -95. 
Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can 
modulate the immu ne response to the nucleocapsid: a mechanism for persistence. J 
Immunol  1998;160:2013 -21. 
Minuesa G, Volk C, Molina -Arcas M, Gorboulev V, Erkizia I, Arndt P, et al. Transport 
of lamivudine [( -)-beta-L-2’,3’ -dideoxy -3’-thiacytidine] and high -affinity intera ction of 
nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, 
and 3. J Pharmacol Exp Ther 2009;329:252 –61. 
Op den Brouw M L, Binda RS, van Roosmalen MH, Protzer U, Janssen HLA, van de 
Molen RG, et al. Hepatitis B virus s urface antigen impairs myeloid dendritic cell 
function: a possible immune escape mechanism of hepatitis B virus. Immunol  
2009;126:280 -89. 
Servais A, Lechat P, Zahr N, Urien S, Aymard G, Jaudon MC, et al. Tubular transporters 
and clearance of adefovir. Eur J Pharmacol 2006;540:168 -74. 
Shemesh CS, Yu RZ, Warren MS, Liu M, Jahic M, Nichols B, et al. Assessment of the 
drug interaction potential of unconjugated and galNAc3 -conjugated 2′ -MOE ASOs. Mol 
Therapy: Nuc Acids 2017; 9: 34 -47. 
Tyzeka (Telbivudine) [packa ge insert]. Novartis Pharmaceuticals Corporation. East 
Hanover (NJ); 2013.  
TMF-13956480  CONFIDENTIAL   
  209668  
 Protocol Amd 02  
 119 
 Uwai Y, Ida H, Tsuji Y, Toshiya K, Kenichi I. Renal transport of adefovir, cidofovir, and 
tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res 2007; 
24: 811 -815. 
Vanlandschoot P, Leroux -Roels G. Viral apoptotic mimicry: an immune evasion strategy 
developed by the hepatitis B virus? Trends  Immunol  2003;24:144 -47. 
Vanlandschoot P, Van Houtte F, Roobrouck A, Farhoudi A, Leroux -Roels G. Hepatitis B 
virus surface antig en suppresses the activation of monocytes through interaction with a 
serum protein and a monocyte -specific receptor. J Gen Virol  2002;83:1281 -89. 
Walsh R, Locarnini S. Hepatitis B precore protein: pathogenic potential and therapeutic 
promise. Yonsei Med J  2012;53:875 -85. 
World Health Organization (WHO). Guidelines for the prevention, care and treatment of 
persons with chronic hepatitis B infection. March 2015.  
Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R et al. Hepatitis B virus suppresses 
toll-like receptor -mediated innate immune responses in murine parenchymal and 
nonparenchymal liver cells. Hepatology  2009;49:1132 -40. 
Wursthorn  K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline 
during 3 years of telbivudine treatment in hepatitis B e antigen -positive patients. Hepatol 
2010; 52(5): 1611 -1620.  
Xu Q, Wang C, Meng Q. OAT1 and OAT3: targets of drug -drug interac tion between 
entecavir and JBP485. Eur J Pharm Sci 2013; 48: 650 -657.  
Yanxiao C, Ruijuan X, Jin Y, Lei C, Qian W, Xuefen Y, et al. Organic anion and cation 
transporters are possibly involved in renal excretion of entecavir in rats. Life Sci 
2011;89:1 –6. 
Yip VSK, Cheung TT, Poon RTP. Does hepatitis B seroconversion affect survival 
outcome in patients with hepatitis B related hepatocellular carcinoma?  Transl 
Gastroenterol  Hepatol ; 2016. 1:51. 
Yu RZ, Warren MS, Watanabe T, et al. Lack of interactions between a n antisense 
oligonucleotide with 2' -O-(2- methoxyethyl) modifications and major drug transporters. 
Nucleic Acid Ther 2016; 26: 111 -117.  
 